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Biological impact of Quantum Dots in ro-
dents
 ABSTRACT 
 Quantum Dots (QDs) are fluorescent semiconductor nanocrystals that have a narrow 
and tunable emission wavelengths across the visible and infrared spectrum. This makes 
them a promising tool for in vivo, in vitro and ex vivo imaging (Smith et al., 2000). How-
ever, the assessment of biocompatibility and biosafety  of QDs is a critical issue for further 
applications as diagnostic and imaging tools on humans. The work of this thesis focuses on 
non modified QTracker® 800 QDs, which are a commercial type of QDs with a heavy met-
als core of CdSeTe, specifically designed for in vivo vascular and tumour imaging, for their 
emission wavelength in the near infrared spectrum (800nm).  
 The biodistribution of QTracker QDs is assessed in Balb-c mice (40pM, 10µl/g) during 
3 weeks following an i.v. injection.  Accumulation is monitored using inductively coupled 
plasma mass spectroscopy, optical imaging, confocal microscopy and electron microscopy, 
and revealed a major accumulation of QDs in liver and spleen, specifically in the mononu-
clear phagocytic system. The accumulation in the brain is observed over 3 weeks, suggest-
ing a long biological half-life, in the scale of weeks or months. It is in particularly observed 
around blood vessels, in different brain areas. QDs are found in neurons, glia and epithelial 
cells,  both in cytosol and nucleus.
 Animal’s behaviour is investigated and novel object recognition test shows that QDs can 
significantly impair recognition memory at 3 weeks after treatment (with no locomotory 
and coordination alterations observed). Such impairment is possibly due to the alteration of 
physiological conditions in the anatomical regions that encode for recognition memory, 
such as enthorinal and perirhinal cortices, dentate gyrus and areas CA1-CA3 of hippocam-
pus.
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Therefore, an increased inflammatory response in terms of microglia and astrocytes activa-
tion is observed in all these regions. However, it do not have an effect on hippocampal 
plasticity, which is investigated by measuring long term potentiation (LTP) at 1 and 3 
weeks after treatment. 
 Taken together, the data presented in this thesis suggest that due to long term accumula-
tion, induction of neuroinflammation and behavioural changes, the application of QDs in 
human should be cautious.
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 ABSTRACT 
I Quantum Dots (QDs) sono nanoparticelle fluorescenti largamente impiegate nell’imaging 
in vivo, ex vivo ed in vitro, grazie alle loro straordinarie proprietà ottiche. In particolare, i 
QTracker® 800 (Invitrogen) sono una tipologia commerciale di QDs con emissione nel 
Near-Infra-Red (800nm), disegnati appositamente per l’esecuzione di studi in vivo di dia-
gnosi nell’uomo o drug delivery in piccoli animali da laboratorio. Uno dei principali pro-
blemi relativi a queste nanoparticelle è la presenza di metalli pesanti, fondamentali per le 
proprietà ottiche, che, nel caso dei QTracker®, sono CdSeTe.
Gli studi della possibile tossicità dei QDs che si trovano in letteratura sono stati effettuati 
principalmente in vitro e potrebbero non corrispondere in modo soddisfacente alla risposta 
scatenata  in vivo dalle nanoparticelle.
Lo scopo di questa tesi è quindi lo studio di biodistribuzione e potenziali effetti dannosi dei 
QDs in sistemi viventi, con particolare attenzione al sistema nervoso centrale, prima di po-
ter utilizzare tali nanocomposti in campo clinico.
In seguito al trattamento di topi Balb-c con QDs (con iniezione intravenosa di 10µl/g, 
40pM) è stato eseguito uno studio di biodistribuzione, tramite visualizzazione in vivo con 
la tecnica di Optical Imaging, seguita dalla conferma con microscopia elettronica e micro-
scopia confocale e quantificazione dei metalli pesanti mediante ICP-MS a 24h, 1, 2 e 3 set-
timane dopo l’iniezione. 
Si è constatato che i QDs sono in grado di penetrare attraverso i vasi nei tessuti animali e di 
accumularsi, in particolare, nel reticolo endoteliale di fegato e milza. Inoltre i QDs sono in 
grado di attraversare la barriera ematoencefalica e di accumularsi intorno ai vasi sanguigni 
e nel parenchima in diverse aree cerebrali, soprattutto nella corteccia. L’ICP-MS ha rivela-
to un accumulo di metalli pesanti nel cervello immediatamente dopo l’iniezione, e signifi-
cativamente elevato per tutte le 3 settimane dello studio. Nel cervello, ad una settimana dal 
trattamento, si trovano aggregati di alcune decine di nanoparticelle, distribuiti in neuroni, 
cellule epiteliali e cellule della glia, sia nel citosol che nel nucleo, talora anche a livello di 
sinapsi, sulle guaine mieliniche che ricoprono gli assoni neuronali e nei mitocondri.
Abbiamo quindi valutato se la presenza sporadica delle nanoparticelle possa causare ano-
malie comportamentali, ad esempio anomalie nell’attività locomotoria, nell’attività cogni-
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tiva ecc. Dati recenti indicano che tutte le cellule cerebrali dialogano fra loro, e che l'attivi-
tà dei neuroni è profondamente influenzata dall'intera orchestra cellulare. L’ipotesi di base 
è che se i nanocomposti, presenti a livello del parenchima, innescano una risposta infiam-
matoria prolungata, questo può riverberarsi in una modificazione dell’eccitabilità del neu-
rone e conseguentemente in una modificazione del comportamento dell’animale.
La presenza di tali nanoparticelle a livello del sistema nervoso centrale ha indotto un’alte-
razione della memoria di riconoscimento a 3 settimane dopo il trattamento, valutata con il 
test del Novel Object Recognition (senza alterazioni delle capacità locomotorie).
La presenza di tali nanoparticelle induce una risposta infiammatoria che rimane elevata per 
le 3 settimane, caratterizzata da un aumento di microglia e astrociti a livello della corteccia 
entorinale e dell’ippocampo (giro dentato, aree CA1, CA2, CA3), che corrispondono alle 
aree associate alla codifica dei processi mnesici. 
La Long Term Potentiation, un modello di plasticità sinaptica d’altra parte non ha eviden-
ziato nessuna alterazione delle funzioni ippocampali ad 1 e 3 settimane dal trattamento.
Abbiamo valutato poi se la presenza nel parenchima cerebrale di NPs possa portare ad alte-
razioni del ciclo sonno/veglia e dell’attività dell’animale nell’home cage. 
I dati ottenuti indicano che occorre una valutazione accurata degli effetti dei nanocomposti 
sulla salute umana, ed occorrono molti studi approfonditi sia in vitro che in vivo prima del 
loro utilizzo in biomedicina.
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LIST OF ABBREVIATIONS
BBB = blood brain barrier
BCSF = blood cerebrospinal fluid barrier
BRET = bioluminescence resonance energy transfer
CA1/CA2/ CA3 = Cornu Ammonis 1/2/3
Cd = cadmium
CdSe = cadmium selenide
CdTe = cadmium telluride
CNS = central nervous system
CTR = controls
DG = dentate gyrus
GFAP = glial fibrillary acidic protein
HFS = high frequency stimulus
IBA-1 = ionised calcium-binding adaptor molecule 1
IL = interleukin
In = Indium
i.v. = intravenous 
LPS = lipopolysaccharide
LTP = long term potentiation
MRI = magnetic resonance imaging
NIR = near-infra-red
NOR = novel object recognition test
NPs = nanoparticles
PEG = polyethylene glycol
PET = positron emission tomography 
PL = photoluminescence 
p.o. = per os
QDs = Quantum Dots
ROS = reactive oxygen species
s.c. = subcutaneous
Se = selenium
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SPECT = single photon emission computed tomography 
Te = tellurium
TEM = transmission electron microscopy
TNF-α = tumour necrosis factor alpha 
TJ = tight junction
Zn = zinc
ZnS = zinc sulphide
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AIM of the thesis
The aim of this thesis is to study and better understand the effects of Quantum Dots nano-
particles in an animal model of rodent. 
Fig. I. Thesis organisation
First we follow the biodistribution of Quantum Dots (QDs) nanoparticles on different or-
gans, at different time points, after a systemic administration. The systemic administration 
was chosen to mimic the human way of exposure. Different imaging techniques allow the 
study of the biodistribution both in in vivo and ex vivo. In liver, spleen and brain the accu-
mulation is measured in terms of fluorescence emission during time, heavy metals content 
and ultrastructural analysis which confirms the localisation of nanoparticles inside the 
cells. The detection of the external coating of the nanoparticle is evaluated in order to un-
derstand their integrity of the QDs over time.
Since QDs accumulate in the brain, we study their effects on nervous system functions. 
Cognitive and locomotor abilities, induction of an inflammatory response and neuronal 
plasticity are assessed in order to understand the possible effects of QDs on central nervous 
system.
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We also hypothesise a possible impairment on circadian rhythm after QDs treatment, and a 
possible development of sickness behavioural syndrome.
Moreover, during the first year of the PhD I followed some studies on silica nanoparticles 
toxicity, after intratracheal instillation. This part was performed in prof. Oberdorster lab, 
University of Rochester, NY.
Part of the experiments on Quantum Dots toxicity  were performed during the third year of 
the PhD, in Prof. Balleine lab, Brain and Mind Research Institute, University  of Sydney, 
NSW.
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CHAPTER 1
Quantum Dots nanoparticles 
The new field of nanotechnology
 The prefix “nano” derives from the Greek “nanos” signifying “dwarf” and is becoming 
increasingly  common in scientific literature. Nano is now a popular label for much of 
modern science, and many “nano” words recently appeared in dictionaries. Nanotechnol-
ogy field in the last 20 years is receiving increasing attention as one of the leading tech-
nologies of the twenty-first century. Nanotechnology  is the study of manipulating matter 
on atomic and molecular scale, developing materials called nanomaterials, possessing at 
least one dimension sized from 1 to 100 nanometers (Terminology  for nanomaterials; Sci-
entific Committee on Emerging and Newly Identified Health Risks, SCENIHR). Although 
nanotechnology  is a relatively recent field in scientific research, the development of its 
central concepts born quite long time ago. It  was the invention of the scanning tunnelling 
microscope in 1981, combined with the discovery of fullerenes few years later, that created 
the emergence of nanotechnology. The elucidation and popularisation of the concept of 
nanotechnology  was introduced in 1986 in the publication of the book Engines of Creation 
(Drexler, 1986). 
 Engineered nanomaterials have been widely  and increasingly  used in different fields. 
The activities and the functions of nanoparticles depends on structure, shape (which affects 
the particle properties and functions), surface chemistry, and self-assembly. The small size 
of nanomaterials results in large surface area, giving them more reactive capacity that has 
generated enormous excitement and expectation regarding their application.
The journal Nature Nanotechnology in 2006 published a discussion about what is exactly 
nanotechnology.
While Thomas Theis (director of physical sciences at the IBM Watson Research Center) 
regards at nanotechnology with enthusiasm seeing it  as a sparkling field that  can trans-
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forms medical diagnostics, energy conversion, and structural materials, and is sparking 
new fields such as quantum information processing and nanobiotechnology, Doug Parr 
(chief scientist for Greenpeace in the UK) sees the new field as an “upcoming economic, 
business and social phenomenon” that needs to be controlled (Theis et al., 2006).
 I n 2 0 0 8 , t h e P r o j e c t o n E m e r g i n g N a n o t e c h n o l o g i e s 
(http://www.nanotechproject.org/about/mission/) estimates over 800 manufacturer nano-
tech products are available on the market.
 The most used nanomaterials are titanium dioxide (TiO2) and zinc oxide (ZnO2) ap-
plied in sunscreen, cosmetics, surface coatings, and some food products (Kurtoglu et al., 
2011), silver nanoparticles are used in food packaging, clothing, disinfectants and house-
hold appliances (http://www.americanelements.com/nanotech.htm).
Nanotechnology has an impact in cars, for fewer metals and less fuel to operate 
(http://www.nanoandme.org/nano-products/transport/) and computers for being faster and 
c o n t a i n m o r e m e m o r y 
(http://www.nanoandme.org/nano-products/computing-and-electronics/).
Many kinds of manufactured nanomaterials show promising application in biomedicine 
(refer to the following paragraphs). For biomedical uses, especially in in vivo applications, 
for disease diagnose and therapy, the NPs are designed to ensure that they can easily enter 
the cells (Yan et al., 2011). It follows that the other major concerns, regarding nanotech-
nology applications, is the potential risks (e.g., toxic effects) and the fate of NPs after en-
tering normal cells.
Some internalised NPs, in fact, can interact with cellular structures and produce effects ad-
verse to human health (Li et al., 2008; Giljohann et al., 2007; Decuzzi and Ferrari,  2007). 
The concern about their toxicity  is due to the high ratio area/volume that provides to the 
NP much more area that  can interact with the cell. Moreover, the small size allow easier 
penetration into cells of different  organs  and facilitate the spreading of the NPs in the body 
even far away from the portal of entry (Lai et  al., 2007; Zhao et al., 2008; Wang et al., 
2009; Nishikawa et al., 2009).
 Understanding the biological fate of NPs, the mechanism of cellular uptake and accu-
mulation is important in order to understand and prevent their toxicity. 
Results in literature are mixed due to variable methods, the great variety in the types of 
particles studied, the different cell lines, different incubation conditions, surface function-
alisations, protein adsorptions, agglomerations, and aggregations, different doses etc. (Nel 
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et al., 2009; Soenen and Cuyper, 2010). The great diversity  and complexity of the various 
nanomaterials also increase the difficulty of future challenges. 
In nanotechnology there are two main approaches for building engineered nanomaterials. 
The top-down approach starts from a bulk material and breaks it  into smaller pieces using 
mechanical, chemical or other form of energy. The bottom-up approach synthesised mate-
rials from atomic or molecular species controlling chemical reactions and allowing for the 
precursor particles to grow in size. Both approaches can be done in either gas, liquid, su-
percritical fluids, solid states, or in vacuum. The most important part of the building engi-
neered material is the control of the particle size, the particle shape, the size distribution, 
the particle composition and the degree of particle agglomeration (Rodgers, 2006). 
The reaction of formation of nanoparticles are controlled by the amount of reactants (its 
exhaustion will terminate the reaction) or by the introduction of a chemical that block the 
reaction. Another method is the physical restriction of the volume available for the growth 
of the single nanoparticle by using templates.
Quantum Dots nanoparticles : Characteristics and syn-
thesis
Quantum Dots composition 
 One of the fastest developing and most exciting fields of nanotechnology is the use of 
quantum dots (QDs) in biology. QDs nanoparticles were discovered at the beginning of 
the1980s by Luis Brus and Alexei Ekimov (Rossetti et al.,1983). 
QDs are fluorescent semiconductor nanocrystals that, thanks to their narrow and tunable 
emission wavelengths across the visible and infrared, are a promising tool for in vivo, in 
vitro and ex vivo imaging (Smith et al., 2000). The biological targets of QDs include tu-
mours (Akerman et al., 2002; Gao et al., 2004), vasculature in normal tissues (Larson et al., 
2003), and different intracellular or extracellular targets depending on the functionalisation 
(Ballou et al., 2004).
QDs are colloidal nanocrystals (2–15 nm diameter) whose size and shape can be precisely 
controlled by the duration, temperature, and ligand molecules used in the synthesis (Alivi-
sator, 1996). They  are characterised by broad absorption band with narrow and symmetric 
emission band  in the visible to near-infra-red (NIR) spectral range (Medintz et al., 2005; 
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Michalet et al., 2005; Gao et al., 2005), making them excellent probes for two-photon con-
focal microscopy (Larson et al., 2005).
 QDs consist of a core made of heavy metal, responsible for fluorescence properties, sur-
rounded by  an external coating, generally an amphiphilic polymer, that increases solubility 
in a biologically compatible medium. The core/shell QDs have a layer (or “shell”) of zinc 
sulphide (ZnS) between the core and the coating, that reduces the leaching of metals from 
the core, improving photo-stability (Fig. 1) (Brus et al., 2007). The most utilised materials 
for QDs applications are semiconducting materials: CdSe (cadmium selenide), CdTe (cad-
mium telluride) and CdSeTe. III/V group or ternary  semiconductors such as InP and InGaP, 
which lack cytotoxic cadmium ions, are possible alternatives (Tab. 1). The semiconducting 
materials differ from a metallic conductor because the current  is carried by the flow of 
electrons or by the flow of positively charged  called “holes” in the electron structure of the 
material. 
At present, commercial products made of CdSe or CdSeTe (from Sigma-Aldrich, Invitro-
gen, Evident and Plasmachem), CdTe (from Plasmachem) and InP or InGaP (from Evident) 
are available.
Depending on the application, the external layer can be functionalised with therapeutic and 
diagnostic macromolecules, receptor ligands or antibodies (Michalet et al., 2005). 
Their properties depend on particle synthesis and surface modifications. Addition of the 
passivation shell often results in a slight red shift in absorption and emission as compared 
to the core alone because of tunneling of charge carriers into the shell (Daboussi et al., 
1997).
Fig. 1. On the left a schematic representation of the CdSe QDs described by Bawendi and colleagues in 1989, 
with ZnS shell  and TOPO coating (Bawendi et al., 1989).  The core of CdSe is the primary source of an opti-
cal signal. Organic molecules or “cap” are surrounding the core, preventing aggregation, oxidation and stabi-
lising NPs in solution. They also electronically isolate the particles and passivate the surface states (Rossetti 
et al., 1983). 
On the right image the indirect relationship between the size and the area and the chemical potential of a 
molecule. 
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Quantum Dots optical properties 
 One of the most attractive characteristics of QDs are their optical properties and the 
photostability over time. 
The QDs fluorescence is associated with the transition of an electron from the conducting 
band to the valence band. The difference between the two energy state depends on the size 
of the QDs: the smaller is the QDs the higher is the energy that it requires to be excited and 
the higher is the energy emitted when the crystal returns to the resting state. The size de-
pends on the core composition (Fig. 2).
Fig. 
2. Size and composition tune the optical emission of QDs.  Electrons can move between energy levels in re-
sponse to an external energy source. Although they move from the ground to the excited state,  electrons even-
tually return to the ground state and emit fluorescence, the wavelength (colour) of which is determined by the 
distance between the two energy levels (indicated by the double arrows), which in turn is determined by the 
size of the nanostructure.  Increasing the size of the QDs (diameter of the core) and keeping the composition 
constant, results in different emission wavelength in the visible region. Changing the composition of the core 
while the size stays constant, results in a shift of the emission wavelength.  All CdSe/ZnS or CdSeTe/Zn QDs 
can be excited at 350nm (Kim et al., 2010).
 The property  of a semiconductor material was described by Pauli exclusion principle, 
according to which two nearby electrons can’t share the same energy  level.  The absorption 
is associated with the promotion of electrons from the conduction band to the valence 
band. When the excitation energy exceeds that band gap energy between the two electronic 
bands (semiconductor band gap), the result is the formation of an electron–hole pair, called 
exciton. Since the QD is smaller than the Bohr exciton radius (which is a few nanometers), 
the energy  levels are quantised, with values directly  related to the QDs size (an effect 
called quantum confinement, hence the name “quantum dots”) (Alivisatos, 1996). QDs 
emission is due to a radiative recombination of an exciton, which is characterised by  a long 
lifetime (>10 ns) (Efros et al., 2000), leading to the emission of a photon in a narrow and 
symmetric energy band. These spectral characteristics of QD materials are different from a 
typical organic fluorescent molecule with red-tailed broad emission band and short fluores-
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cence life-times (Resch-Genger et al., 2008). In comparison to traditional fluorescent 
molecules (fluorophores) or fluorescent proteins (e.g., GFP), QDs have several attractive 
optical features that are desirable for long-term, multi-target and highly  sensitive bio-
imaging applications. Some of the major optical features of QDs are: 
1. Large molar extinction coefficient: QDs are highly sensitive fluorescent agents for 
labelling cells and tissues (Leatherdale et al., 2002), the absorption rate is approxi-
mately  10-50x faster than organic dyes and approximately  10-20x brighter than or-
ganic dyes (Dabbousi et al., 1997; Bruchez et al., 1998; Chan et al., 2008).
2. QDs are several thousand times more photostable than organic dyes (Resch-Genger 
et al., 2008).
3. QDs are excitable without  excitation of the biological matrix and detectable with 
conventional instruments (So et al., 2006).
4. QDs are suitable for time-correlated lifetime imaging spectroscopy thanks to the 
longer excited state lifetime of QDs (Pepperkok et al., 1999; Jakobs et al., 2000).
5. Unlike in organic dyes, the excitation and emission spectra of QDs are well sepa-
rated, improving the sensitivity (Gao, et al., 2004).
6. The wavelength of QD emission is size dependent  allowing multiple targeting capa-
bility. This feature is particularly  important in tracking a panel of disease-specific 
molecular biomarkers simultaneously (Gao, and Nie, 2003). 
Tab. 1. Core composition,  size range 
and emission wavelength ranges of 
QDs.
External coatings
 Since QDs are insoluble in water, which limits their biological applications, a number 
of surface functionalisation studies have been developed to make QDs water-soluble (Kim 
and Bawendi, 2003).
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A common approach to increase water solubility is to replace or attach to the original hy-
drophobic coatings water-soluble functional molecules (e.g., dithiothreitol, mercaptocar-
bonic acids, 2-aminoethanethiol, dihydrolipoic acid, oligomeric phosphines, peptides, and 
cross-linked dendrons) through the ligand exchange reactions or through the encapsulation.
Because the optical properties of the inorganic core are often very  sensitive to the surface, 
the ligand exchange process results in poorer performance, particularly in the case of QDs 
(Rogach et al., 2000). Other studies utilised the combinations of layers of different mole-
cules that lead to the required colloidal stability  (Matoussi et al., 2000) or developed water-
based synthesis methods (Gaponik et al., 2002).
 The encapsulation of QDs in an amphiphilic coating consists in attaching amphiphilic 
diblock copolymers, silica or polymer shells, phospolipid micelles or amphiphilic polysac-
charides to the QDs core/shell structure (Chan and Nie, 1998; Bruchez et al., 1998; Duber-
tret et al., 2002; Kim and Bawendi, 2003; Guo et  al., 2003; Pinaud et al., 2004; Osaki et al., 
2004; Wu et al., 2005). 
These amphiphilic molecules bind with hydrophobic ends the organic shell,  protecting the 
core/shell structure and maintaining the original photo-physics of QDs, increases water-
solubility and provides a biological interface and multiple functions (Michalet et al., 2005). 
The hydrophilic end groups, made of biocompatible surfactants, may  not protect nanocrys-
tals from nonspecific biomolecular interactions (Wu et al., 2009). For this reason single 
polymer amphiphilic chains can containing multiple hydrophobic units, are preferred. They 
establish numerous interactions with the organic shell on QDs, encapsulating it strongly 
than conventional surfactants. The range of amphiphilic polymers for creating stable and 
non-aggregating QDs in biological settings is relatively limited. Up to now, most of the 
amphiphilic polymers used are commercial and their hydrophobic/hydrophilic ratios are 
fixed, hence the cost is high and it is difficult to control the process of forming water-
soluble QDs and optimise the forming conditions (Wu et al., 2009). 
 Moreover, the surfaces of QDs then can be modified with bioinert, hydrophilic mole-
cules such as polyethylene glycol (PEG), that eliminate possible nonspecific binding, and 
decrease the rate of clearance from the bloodstream following intravenous injection (Fig. 
3).
Water-soluble QDs also can be cross-linked to biomolecules such antibodies, oligonucleo-
tides, or small molecule ligands that functionalise them to recognise specific biological tar-
gets (Fig. 3 Bottom). The reactivity  of biomolecules generally remains stable after conju-
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gation to NPs surfaces, although a decreased binding strength can occur. The optimisation 
of surface immobilisation of biomolecules is currently  an active area of research (Lieleg et 
al., 2007; Pathak et al., 2007).
Fig. 3.  Top: Schematic diagram of generation of antibody/protein-QDs conjugate (Barroso, 2011). Bottom: 
different coatings on non functionalised QDs for imaging and sensing applications (Smith et al., 2008).
Quantum Dots applications in biomedicine 
 Thanks to their photophysical properties and the tunable emission at  different wave-
lengths QDs are becoming an useful tool in many biological applications. 
The Tab. 2 gives an example of all the application of QDs in biology and biomedicine. The 
large-surface area of QDs is beneficial to covalently link to target molecules, such as pep-
tides, antibodies, nucleic acids or small-molecule ligands for further application as fluores-
cent probes. 
In 1998, the potential of these nanocrystals for applications involving biological labelling 
was first reported (Bruchez et al., 1998). Current and future applications of QDs include 
using fluorescent labels for cellular labelling (Bruchez et  al., 1998; Kim et al., 2004), intra-
cellular sensors (Gao et al., 2004; Liu et al., 2007), deep-tissue and tumour targeting and 
imaging agents (Michalet et al., 2005), nanoparticles for photodynamic therapy (Juzenas et 
al., 2008; Rhyner et al., 2006), vectors for gene therapy (Jiang et al., 2007; Woodle and Lu, 
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2005), magnetic resonance imaging (MRI) contrast agents (Nabiev et al., 2007; Lewin et 
al., 2000), in situ hybridisation and as live cell markers (Alivisator et al., 2005; Bruchez, 
2005) etc. 
Tab. 2. Schematic representation of QDs ap-
plications in biomedicine.
QDs for FRET- and BRET-based sensors
 QDs are emerging as a new class of sensor, where beyond their application as passive 
labels, they transfer the electronic excitation energy  to a nearby acceptor specie such as an 
organic fluorophore in a process called fluorescence resonance energy transfer, FRET 
(Tran et al., 2002; Medintz et al., 2003; Zhang et al., 2005). The rate of energy transfer de-
pends on the distance between the donor of energy  (the QDs) and the acceptor of the en-
ergy (fluorophore), their relative orientation and spectral overlap. This method allow to 
follow specific interactions between molecules or cleavage events (Williard et al., 2006). 
The first application of QDs in FRET was done in 2001 by Williard  (Williard et al., 2001). 
For applications of QDs in FRET refer to Gill et al. (2005) and Menditz et al. (2007). 
Fig. 4. Schematic representation of QD as  FRET-
based, BRET-based sensors
QDs can be applied also in Biolumines-
cence Resonance Energy Transfer (BRET) 
where a light emitting protein (donor) 
transfers energy  to QDs (acceptor). With 
this technique QDs can emit fluorescence 
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without an external source of excitation, but with an enzyme is in close proximity  that ca-
talyses bioluminescent reactions  (Fig. 4) (So et al., 2006). 
QDs in immunohystochemistry and immunoassays
 Several applications of QDs for in vitro bioassays (Smith and Nie, 2004; Smith et al., 
2006) have been proposed e.g. labelling fixed cells (Wu et  al., 2003) or tissue (Fountaines 
et al., 2006; Ferrara et al., 2006). The utility of QDs in immunohistochemical applications 
was demonstrated by Ness and colleagues (2003) who developed an immunohistochemical 
protocol for detection of intracellular antigens in mouse and rat brain tissue sections, show-
ing that QDs labelling had superior sensitivity than conventional dyes (Ness et al., 2003).
 The QDs staining gives molecular and morphological information at the same time 
(Matzumo et al., 2011). One of the earliest experiments where QDs were used to locate 
molecules in cells was performed by Bruchez and coworkers (1998) to stain F-actin in 
fixed cells with antibodies labeled with CdSe/ZnS QDs. In another experiment QD immu-
noconjugates showed that  mortalin (heat shock protein-70) could be a reliable marker for 
distinguishing between normal and cancer cells (Kaul et al. 2003). For this application the 
possible toxic effect of QDs are less important and their multiplexing capabilities are use-
ful in a high-throughput or multiplexed detection of biomolecules for ex vivo diagnosis 
(Fournier-Bidoz et al., 2008; Zhu et al., 2008). The use of multiple QD labels is suitable for 
optical bar coding of targets (Jain, 2003).   The multiplexing potential of QDs can enable 
obtaining information on the location, abundance, and distribution of multiple proteins in 
living cells. It would also allow multicolour encoding of cells or beads and thus obtaining 
data on differential response of cell types to common stimuli. This multiplexing potential 
would be particularly significant for cancer diagnostics and research, where multiple can-
cer biomarkers can be simultaneously  detected, which would help  untangle the associated 
complex gene expression patterns (Smith et al., 2006).
QDs in Western Blot and Proteomics
 QDs can be employed for detection of multiple proteins on Western blots (Bruchez et 
al., 2005), this would constitute a significant empowerment to the field of proteomics. Cur-
rently, kits employing QD-conjugated anti-rabbit and anti-mouse antibodies are available 
for use in Western blotting.
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QDs in Fluorescent In Situ Hybridisation 
 QDs can also be used as labels for detection of multiple mRNA targets using fluores-
cence in situ hybridisation (FISH) (Chan et al., 2005). Oligonucleotide probes can be la-
beled with QDs or biotinylated oligonucleotide probes may be coupled to QDs coated with 
streptavidin.  
QDs can be used for profiling of microRNA (miRNA, single-stranded RNA molecules and 
play  a role in gene expression). In one such study, miRNAs are labeled with biotin and hy-
bridised with complementary oligo-DNA probes immobilised on glass slides,and detected 
by measuring fluorescence of streptavidin-labeled QDs bound to miRNAs (Liang et al., 
2005).
QDs for imaging living cells
 The QDs cell internalisation has attracted many interests for diagnosis or treatment.
The applications of QDs for imaging inside the cell is limited cause the difficulties in de-
livering QDs into the cytoplasm of living cells, since they tend to aggregate inside cells, 
and are often trapped in endocytotic vesicles such as endosomes and lysosomes (Lidke et 
al., 2004; Dahan et al., 2003 Brandenberger et al., 2010).
 Nevertheless there are different pathways for delivering QDs into a cell: transfection, 
peptide-mediated delivery or passive uptake. It has been reported that the peptide mediated 
approach employed the amphiphilic peptide Pep-1, while in the transfection approach the 
PolyFect has been used.  The QDs maintain their fluorescence, they distribute in the cyto-
plasm, they are passed during the mitosis to the daughter cell, escape lysosome degradation 
and do not inhibit cell growth (Mattheakis et al., 2004; Morris et al., 2001). 
 The passive uptake, on the other hand, is used to deliver non functionalised QDs into 
the cells through endocytosis, and depends on surface coatings. In general, the positive 
charge (like polyethylenimine, PEI) allows the interaction with the membrane, inducing the 
endocytosis. It  has been shown that PEI-QDs, with the addition of the external coating 
PEG, show a high degree of endocytosis with reduced harmful effects. 
 It has been found that the efficiency  of the QDs internalisation is enhanced by conju-
gation of the QDs to membrane receptors. For example, QDs coupled to Shiga toxin, ricin, 
and Tfn are all endocytosed specifically  via binding to their receptors in a clathrin-
mediated manner (Tekle et al. 2008).  Clathrin-mediated endocytosis is the most important 
pathway for the intracellular delivery of peptide-conjugated QDs (Anas et al. 2009). 
19
 A new class of cell-penetrating quantum dots is based on the use of multivalent and 
endosome-disrupting (endosomolytic) surface coatings. The copolymer ligands PEG-
grafted polyethylenimine (PEI-g-PEG), thanks to the cationic charges associated with mul-
tivalent amine groups, these QDs can penetrate cell membranes and disrupt endosomal or-
ganelles in living cells (Boussif et al., 1995; Neu et al., 2005; Pack et al., 2005; Duna and 
Nie, 2007). 
Another positive charged QDs (2.2 nm) coated with small molecule ligands (cysteamine) 
spontaneously  translocated to the nuclei of murine microglial cells following cellular up-
take through passive endocytosis. In contrast, larger QDs (5.5 nm) and small QDs bound to 
albumin remained in the cytosol (Lovric et al., 2005). 
QDs for single molecules tracking
 The tracking of single proteins represents an important tool in many field. QD biocon-
jugates have been found to be powerful imaging agents for specific recognition and track-
ing of molecules, like plasma membrane antigens, allowing to follow the movement of 
single molecules in live cells for milliseconds to hours. As compared to normal fluoro-
phores QDs are more resistant to photobleaching. 
Real-time detection of single molecules antibodies is performed conjugating to different 
QDs that would bind to different sites of the target biomolecule. A signal is detected only if 
both QD-labeled antibodies bind to the target at the same time (Agrawal et al., 2006). 
Some example of applications in neuroscience fields are in the study of dynamics for vari-
ous receptors, like GABA, AMPA and NMDA, acetyl coline and cannabinoids receptors. 
One of the first experiments in this field was done in 2003, and QDs was conjugated to an 
antibody for detecting glycine receptor (Dahn et al., 2003). After this publication many 
others studies followed using QDs to monitor membrane proteins like integrins (Lieleg et 
al., 2007), G-protein coupled receptors (Young and Rozengurt, 2006) and for exploring the 
processes of synaptic vesicle fusions during neuronal stimulation.
 The single molecule tracking with QDs has been also investigated for labelling mole-
cules inside the cell.  The main problem in this process is avoiding the internalisation of 
QDs in the cells through endocytosis, that is the most probable way  of QDs uptake (Hanaki 
et al., 2003). By  passive uptake, QDs are internalised in vesicle as aggregates and they 
can’t reach specific intracellular targets. This is a good method to label endocytosis or cells 
but not single molecules. Moreover, internalised QDs it is difficult to distinguish between 
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bound and unbound QDs in the cells. QDs size and charge become important in order to 
predict the QDs behaviour inside the cell. Researchers are exploring the use of fusion tags 
but this application is still developing.  
In vivo vascular imaging
 The main applications described in literature for in vivo imaging of mice after QDs 
injection encompass imaging of blood vessels, lymph nodes, tumours and cell tracking. 
In vivo vascular imaging
 One of the most important and successful applications of QDs is the in vivo imaging. 
They  are used as contrast  agents for circulatory  system of mammals, the cardiovascular 
system and the lymphatic system. 
In 2003, Larson and colleagues demonstrated that red-light emitting QDs remained fluo-
rescent and they are detectable in capillaries of adipose tissue and skin of a living mouse 
following intravenous injection (Larson et al., 2003). 
From 2003 to nowadays, near infrared QDs have had a great application for in vivo imag-
ing. They have been used to image the coronary vasculature of a rat heart (Lim et al., 
2003), or blood vessels of chicken embryos (Smith et al., 2007). The conjugation of the 
QDs to cell adhesion molecules (CAMs) can en-light inflammation cells behaviour, like 
leukocytes rolling and extravasation from blood vessels (Jayagopal et  al., 2007). As we re-
ported in the previous paragraph, the advantage of QDs is that they can be detected with 
higher sensitivity than traditional dyes (e.g. fluorescein–dextran conjugates), and resulted 
in a higher uniformity in image contrast across vessel lumen.
 Applications involving in vivo imaging must consider that haemoglobin strongly ab-
sorbs in the visible region (300–600 nm), water and lipids that are transparent in the visible 
region but absorb strongly in the infrared (1400–2000 nm); and autofluorescence of, for 
example, endogenous skin fluorophores. The latter include nicotinamide adenine 
dinucleotide/nicotinamide adeninine dinucleotide phosphate (em. 425 nm), flavin adenine 
dinucleotide (em. 520 nm), and porphyrins (em. 625 nm), with relative contributions of 
approximately 75%, 25%, and 2%, respectively (Nah et al., 2000).
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Fig. 5. The first NIR window is ideally 
suited for in vivo imaging because of 
minimal light absorption by haemoglobin 
(<650 nm) and water (>900 nm). It is 
called also transparency window for this 
reason.
The second window is also very conven-
ient for in vivo imaging, but lack of ade-
quate detection systems (from Smith et 
al., 2009).
Near infra-red light (700-2500 nm) 
can penetrate biological tissues 
such as skin and blood more effi-
ciently  than visible light (Smith et al., 2009). The clearer window for optical imaging in 
vivo is between 650 and 950 nm (Weissleder, 2001) (Fig. 5). At this wavelength the tissue 
penetration is about 1-2 cm (Smith et al., 2009) and biological components do not substan-
tially interfere.
A different type of QDs for in vivo imaging have 1320 nm emission wavelength, instead of 
850 (second window emission), that improves of 100 times the fluorescence of QDs (Lim 
et al., 2003) (Fig. 5). Other types of NPs with a second window emission have been pro-
duces for in vivo imaging: fluorescent single-walled carbon nanotubes, with an emission 
wavelength of 950-1,400 nm and plasmonic NPs, such as gold nanorods (Smith et al., 
2009). The problem associated with the second window emitting NPs is the lack of the 
adequate system of detection, like enough sensible CCD cameras (Smith et al., 2009).
Near infra-red QDs have been used also for imaging the lymphatic system. It has been 
shown  that intradermally  injected ~ 16–19 nm near-infrared QD translocate to sentinel 
lymph nodes, likely due to a combination of passive flow in lymphatic vessels, and active 
migration of dendritic cells that engulfed the NPs (Kim et al., 2004). Only  QDs with an 
hydrodynamic diameter smaller then 9 nm can migrate in the lymphatic system (Roberts et 
al., 2002). This technique could have great clinical impact due to the quick speed of lym-
phatic drainage and the ease of identification of lymph nodes, enabling surgeons to fluo-
rescently identify and excise nodes draining from primary metastatic tumours (Ballou et 
al., 2007).
 Another type of QDs designed for in vivo imaging are the self-illuminating QDs. Self-
illuminating QDs fluorescence is based on bioluminescence resonance energy transfer, that 
is the conversion of chemical energy  into photons energy, and has several advantages like 
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increased fluorescence emission and decreased autofluorescence (So et al., 2006). QDs are 
covalently attached  to Renilla reniformis luciferase, which, in presence of its substrate 
coelenterazine, emits at 480 nm (blue light). The blue light is absorbed by  QDs, giving an 
efficient fluorophore excitation.
This system decreases the autofluorescence since there is no excitation light but the exist-
ing formulation of QDs contains semiconductor or heavy metals with associated toxicity. 
Moreover, external coating, like amphiphilic molecules, are added to improve the solubility 
in biological fluids and secondary  coating, like PEG, are added to have longer blood circu-
lation. These external modifications increase the hydrodynamic diameter of the QDs, de-
creasing the possible clearance from the body (Frangioni, 2006).  
 
In vivo tumour imaging
 Imaging of tumours presents a unique challenge not only  because of the urgent need 
for sensitive and specific imaging agents of cancer, but also because of the unique biologi-
cal attributes inherent to cancerous tissue. 
Recently, Doxil® (PEGylated liposomal form of doxorubicin) and Abraxane (albumin-
bound Paclitaxel nanoparticle) have been approved by  Food and Drug Administration for 
solid tumours-therapy. These NPs have a big size (about 100-130 nm) that allow to prefer-
entially enter tumours tissues, thus reducing normal tissue toxicity. In tumours blood ves-
sels are abnormally formed with wide endothelial pores. These pores are large enough to 
allow the extravasation of large macromolecules up to ~ 400 nm in size, which accumulate 
in the tumour microenvironment due to a lack of effective lymphatic drainage (Jain, 2001). 
This tumours characteristic has been called “enhanced permeability and retention” effect 
(EPR effect) and has inspired the development of a variety of nanotherapeutics and nano-
particulates for the treatment and imaging of cancer (Fig. 6) (Perrault et al., 2009).
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Fig. 6. Use of nanomaterials for tumour diagnosis. (Kim et al., 2010)
Cancerous cells have different surface receptors as compared to normal cells and the expo-
sure to the bloodstream make them a good target for functionalised NPs. For this reason, 
active targeting of cancer antigens has become an area of tremendous interest to the field of 
medicine because of the potential to detect early stage cancers and their metastases. 
QDs are great promise for these applications, due to their intense in vivo fluorescent sig-
nals and multiplexing capabilities, which could allow a high degree of sensitivity and se-
lectivity in cancer imaging with multiple antigens.
One of the first approach for in vivo tumour imaging has been done in 2002 by  Akerman 
and colleagues that conjugated QDs to peptides with affinity for various tumour cells and 
their vasculatures (Akerman et al., 2002). Few years later tumour targeting with QDs could 
generate tumour contrast in the whole-animal imaging (Gao et al., 2004). The  active tu-
mour recognition by means of QDs functionalisation with antibodies or molecules that 
specifically recognise tumour epitopes, results as a better tool in tumour imaging as com-
pared to nonconjugated QDs, that by contrast, passively accumulate though the EPR effect.
Conjugation with different tumoural epitopes (e.g. alpha-fetoprotein) created different type 
of QDs that target specifically  a certain type of tumours (Yu et  al., 2007). Human cancer 
evolves over a long time course and shows a multitude of molecular and cellular heteroge-
neity (Heppner and Miller, 1983). The heterogeneity  is in the genetic mutations and pheno-
types and in the multitude of different cells that compose the tumours (malignant cells, be-
nign cells, fibroblasts, vascular cells, inflammatory cells etc.).  At this purpose the use of 
multiplexed QDs-antibody conjugate with different wavelength for molecular mapping of 
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tumour heterogeneity on human prostate cancer tissue is an example of high throughput 
mapping of all the tumours variations on prostate tumours (Liu et al., 2010).
 QDs can be applied for intravital microscopy techniques as a contrast agent for the im-
aging of tumour microenvironment (Stroh et al., 2005) or blood vessels using two-photon 
excitation. 
Using intravital fluorescence microscopy of the tumour following systemic QD administra-
tion, it  is possible to distinguish individual QDs as they circulated in the bloodstream, ex-
travasated into the tumour, diffused in extracellular matrix, bound to their receptors on tu-
mour cells, and then translocated into the perinuclear region of the cells (Tada et al., 2007). 
The development of clinically relevant QD contrast agents for in vivo imaging is certain to 
encounter many roadblocks in the near future, however QDs can currently  be used as pow-
erful imaging agents for the study of the complex anatomy and pathophysiology of cancer 
in animal models.
The Tab. 3 summarises the most relevant studies using QDs for medical applications.
Tab. 3. QDs-based medical approaches
Multimodal Quantum Dots
 The applications of QDs described above for in vivo imaging, with Optical Imaging or 
others techniques are limited by  tissue penetration depth, quantification problems, and a 
lack of anatomic resolution and spatial information. To overpass these limitations, it is pos-
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sible to couple QD-based optical imaging with other imaging modalities (e.g. magnetic 
resonance imaging (MRI), positron emission tomography  (PET) and single photon emis-
sion computed tomography (SPECT)) (Cai et al., 2008). 
The incorporation of paramagnetic gadolinium complexes in the lipid coating layer of 
QDs, for example, gives the possibility  of follow QDs imaging with both optical imaging 
and MRI (Mulder et al., 2006). In vitro experiments showed that labelling of cultured cells 
with these QDs led to significant T1 contrast enhancement with a brightening effect in 
MRI, as well as an easily detectable fluorescence signal from QDs. 
However, the in vivo imaging potential of this specific dual-modality  contrast agent is un-
certain due to the unstable nature of the lipid coating that was used. 
 Another approach attaches PET-detectable radionuclide 64Cu to the polymeric coating 
of QDs through a covalently bound chelation compound (Cai et al., 2007). This probe is 
used to target a subcutaneous mouse tumour model in an in vivo system, functionalising the 
QDs surface with αvβ3 integrin-binding RGD peptides (Cai et al., 2007). 
The majority of these probes are still at  an early stage of development. The clinical rele-
vance of these nanoplatforms still needs further improvement in sensitivity  and better inte-
gration of different imaging modalities, as well as validation of their biocompatibility and 
safety.
Moreover, it is possible to detect  all type of QDs with TEM thanks to their electron dense 
core.
The synthesis of QDs containing paramagnetic dopants, such as manganese, have led to a 
new class of QDs that are intrinsically fluorescent and magnetic  (Santra et al., 2005; wang 
et al., 2007). However the utility of these new probes for bioimaging application is unclear 
because they are currently  limited to the ultraviolet and visible emission windows, they 
increase the amount of heavy metals and possibly the toxicity and their possibly limit  the 
QDs stability (e.g., photochemical and colloidal) (Pradhan and Peng, 2007). All these  pa-
rameters have to be investigated .
Integration of imaging and therapy
 Peptide-functionalised QDs are internalised after binding to cell surface, and may  thus 
be of value for drug delivery (Rozenzhak et al., 2005).
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QDs can be utilised for controlled drug delivery via their surface modification (Alivisator 
et al., 2005). Surface-modified CdS QDs retain drug molecules and neurotransmitters in-
side mesoporous silica nanospheres. The CdS cap ensures the drug is inside the system un-
til released by disulphide bond-reducing reagents (Lai et al., 2003).
Quantum Dots quantification techniques
 Various methods are used to detect QDs in vivo such as fluorescent (Optical Imaging) or 
nuclear imaging systems (SPECT and PET). These different techniques make possible to 
follow QDs in a whole body  over several days but  give only a semi-quantitative aspect of 
QDs concentration in vivo. QD tracking methods in ex vivo systems are numerous and in-
clude confocal microscopy, total internal reflection microscopy, wide-field epifluorescence 
microscopy, and fluorometry  (Bruchez et  al., 1998; Chan et al., 1998; Jain, 2005; Michalet 
et al., 2005). The most significant techniques for measuring QDs concentration are those 
which detect QDs at the elementary level (Cd, Te, Se), such as Inductively Coupled Plasma 
- Mass Spectroscopy (ICP-MS) and Inductively  Coupled Plasma - Atomic Emission Spec-
troscopy (ICP-AES), followed by fluorescent and radioactivity measurements which allow 
to quantify directly QDs. The sensitivity of ICP-MS is an enormous asset to identify trace 
levels that are undetectable by optical methods. However, these four last techniques can 
only be used ex vivo after resection and specific preparations of biological samples. Never-
theless, despite numerous techniques for the detection of QDs, biodistribution studies in 
vivo are sparse.  
ICP-MS
 The ICP-MS is one of the most utilised technique in nanotoxicology because of its 
sensitivity. The instrument employs a plasma (ICP) as the ionisation source and a mass 
spectrometer (MS) analyser to detect the ions produced (Fig. 7). It can simultaneously 
measure most elements in the periodic table and determine analyte concentration down to 
the sub nanogram-per-liter (ng/l) or part-per trillion (ppt) level. It can perform qualitative, 
semiquantitative, and quantitative analysis, and since it employs a mass analyser, it  can 
also measure isotopic ratios.
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Fig. 7. ICP-MS schematic 
representation.
In general, samples are 
introduced by a peristal-
tic pump, to the nebu-
liser where the sample 
aerosol is formed. Argon (Ar) gas is introduced through a series of concentric quartz tubes 
which form the ICP. The torch is located in the centre of an radio frequency  coil, through 
which radio frequency  energy is passed. A radio frequency potential applied to the coil 
produces an electromagnetic field that causes collisions between the Ar atoms, generating a 
high-energy plasma. The sample aerosol is instantaneously  decomposed in the plasma 
(plasma temperature is in the order of 6000 - 10000 K) to form analyte atoms which are 
simultaneously  ionised. The ions produced are extracted from the plasma into the mass 
spectrometer region which is held at high vacuum (typically 10-4 Pa). The vacuum is 
maintained by differential pumping: the analyte ions are extracted through a pair of ori-
fices, known as the sampling and skimmer cones. 
The analyte ions are then focused by  a series of ion lenses into a quadrupole mass analyser, 
which separates the ions based on their mass/charge ratio. The term quadrupole is used 
since the mass analyser is essentially consists of four parallel stainless steel rods to which a 
combination of radio frequency and DC voltages are applied. The combination of these 
voltages allows the analyser to transmit only ions of a specific mass/charge ratio. Finally, 
the ions are measured using an electron multiplier, and are collected by a counter for each 
mass number.
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CHAPTER 2
Biodistribution of Quantum Dots after i.v. 
administration
INTRODUCTION
Safety issues of nanoparticles
 The small size of NPs corresponds to a large surface area. In fact, the ratio of the surface 
atoms to total atoms of the molecule increases with a decreasing molecule size. This prop-
erty  is important when NPs interact with biological systems: the large surface area in-
creases the reactivity of NPs as compared to normal molecules, representing an important 
property  for many  biomedical and industrial applications. The same properties which make 
NPs so attractive for nanomedicine and for specific industrial processes can also be delete-
rious when NPs interact with cells, causing  potential adverse effects or environmental con-
tamination. NPs biological activity can have a positive and desirable effect (e.g. drug de-
livery, penetration of cell barriers, interactions with cells and reactions), but  they can pro-
voke also negative effects (e.g., toxicity, induction of oxidative stress or of cellular dys-
function), or a mix of both (Holsapple et al., 2005).
 Industrial and academic researchers are more interested in discovering new NPs for 
biomedical and industrial applications rather than evaluating the potential risk that NPs can 
have on human health and environment. The exposure to NPs can occur for medicinal pur-
poses, or after unintentional exposure, during manufacture or processing for industrial ap-
plications. Many nanomaterials have been demonstrated to have adverse effect  to human 
health and cell cultures, resulting for example in increased reactive oxygen species produc-
tion, inflammatory  response, mitochondria perturbation, protein denaturation and degrada-
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tion, nuclear uptake, blood clotting and cell death (Oberdorster et al., 2005; Nel et al., 
2006). 
 The term “nanotoxicology” first showed up in 2004 and it is defined as the “science of 
engineered nanodevices and nanostructures that  deals with their effects in living organ-
isms” (Oberdorster et al., 2005).  Nanotoxicology research not only will provide data for 
safety  evaluation of engineered nanostructures but also will help to advance the field of 
nanomedicine by  providing informations about their undesirable properties and means to 
avoid them. United States Environmental Protection Agency  and the Food and Drug Ad-
ministration in U.S. and the Health and Consumer protection Directorate of the European 
Commission, have started dealing with the potential risks posed by nanoparticles, but still 
nanomaterials or materials containing nanoparticles, are not subjected to any  special regu-
lation regarding production, handling or labelling. 
 Most of the toxicity research on NPs in vivo has been carried out in mammalian sys-
tems. The exposure routes of NPs are: skin, respiratory tract and gastrointestinal tract (Fig. 
9). They need to be considered as potential portals of entry. Portal-of-entry-specific de-
fence mechanisms protect the mammalian organism from harmful materials. However, 
these defences may not always be as effective for NPs. In biomedicine, humans can be also 
exposed to NPs trough a systemic or subcutaneous  administration.
 The number of publications on the topic of nanomaterials has increased at an exponen-
tial rate since the 2000 to the 2011, reaching about 20 000 in the year 2011. The large 
number of publications on nanomaterials can be explained by the fact  that nanoscience and 
nanotechnology  are developing in a wide range of fields, including chemistry, physics, ma-
terials engineering, biology, medicine, and electronics. There is also a notable rise in the 
number of publications discussing the toxicity, of nanomaterials. The total number of pa-
pers on toxicity, however, remains low compared to the total number of publications on 
nanomaterials, with only around 500 publications in the year 2011.
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 The possible adverse health effects associated with inhalation, ingestion, and contact 
with nanoparticles depends on various factors, including size, aggregation, composition, 
crystallinity, surface functionalisation, etc (Harman, 2006). In addition, the toxicity of any 
nanoparticle to an organism depends on the individual’s genetic background (Buzea et al., 
2007).
 NPs have a similar size as viruses but even if they  do not replicate and do not take the 
control of cell cycle, they can interfere with the cell functions and cause diseases or in-
crease the gravity  or the chance to be affected by a disease. Multiple sclerosis, stroke, and 
Parkinson’s disease are all increased in people exposed to these pollution particles, espe-
cially  the ultrafine particles, that are the NPs with a size smaller than 100nm (Genc et al., 
2012). In fact, ultrafine nanoparticles cause much greater inflammation and microglial ac-
tivation than larger particles and the involvement of systemic inflammation even if it  re-
gards the body and not the brain, can lead to the inflammation of the brain and the subse-
quent degeneration (Genc et al., 2012). Nanoparticles in the gastrointestinal tract have been 
linked to Crohn’s disease and colon cancer. Nanoparticles that enter the circulatory  system 
are related to occurrence of arteriosclerosis, blood clots, arrhythmia, heart diseases, and 
ultimately  cardiac death. Translocation to other organs, such as liver, spleen, etc., may lead 
to diseases of these  organs as well. Exposure to some nanoparticles is associated with the 
occurrence of autoimmune diseases, such as systemic lupus erythematosus, scleroderma, 
and rheumatoid arthritis (Fig. 9) (Buzea et al., 2007). 
 The issue of QD toxicity is a serious obstacle to a full exploration of their in vivo usage 
in  biomedical imaging. The toxicity arises primarily  from two sources: 1. the semiconduc-
tor materials that commonly constitute the QDs core (and sometimes the overcoating shell) 
which can leach under certain circumstances (Derfus et al., 2004), and 2. the generation of 
reactive and free radical species during excitation (Bakalova et al., 2004a, 2004b). The tox-
icity of metals such as Cd and Se is well documented (Colvin, 2003; Hoet et al., 2004; 
Hardman, 2006; Nel et al., 2006). These heavy metals can cross the blood-brain barrier, 
can accumulate in adipose tissue with biological excretion half-lives greater than ten years. 
They  are primarily toxic to the liver and kidneys, and are considered possible teratogens 
and probable carcinogens (Colvin, 2003; Hoet et al., 2004; Hardman, 2006; Nel et al., 
2006). Today almost  all synthetic precursor materials used to make semiconductor QDs are 
toxic.
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Fig. 9. Schematic repre-
sentation of human body 
biodistribution of nanopar-
ticles after inhalation, in-
gestion or penetration 
trough the skin and the 
possible diseases they can 
induce (Buzea et al., 
2007).
  
However, before QDs can enter the market they will be subjected to some form of regula-
tory scrutiny, but which type of scrutiny  is still undetermined. In the world there isn’t  a 
jurisdiction that defines specific safety-related data for nanomaterials or declare when and 
if such requirements can be expected (Pelley and Saner, 2009).
This type of regulation should consider the toxicity and the biological fate of substances, 
including adsorption, distribution, metabolism and excretion (ADME) within a body and 
the transportation and transformation within the natural environment (Pelley et al., 2009).
Biodistribution and biological effect of different type of 
QDs
 The vast majority  of scientific papers reporting on the toxicity  of QDs have limited 
their investigation to cytotoxic effects observed in short-term, cell culture-based assay sys-
tems. Only  in the last few years the literature is exploring the in vivo effect, viability, re-
productive capacity and biological fate over long term period in rodents or other species. 
The number of studies on QDs toxicity  is increasing, but  the final interpretation of the cy-
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totoxic effects is further complicated because of the diversity of QDs being tested, as each 
individual type of QD possesses its own physicochemical properties, and due to the diver-
sity of test systems used. The dosage of QDs used and exposure times also vary widely in 
the literature. Furthermore, it is often unclear how the experimental dosages relate to con-
centrations associated with real-world commercial applications of QDs. Moreover, it is dif-
ficult to extrapolate the results of such studies in order to form any conclusions regarding 
the health and safety of QDs.
 In 2006 a review summarising the toxicology data of QDs concluded that the toxicity 
of QDs was dependent upon their physicochemical properties as well as environmental fac-
tors (Hardman, 2006). Three years later Pelley and collaborators adapted and extended 
Hardman’s table to summarise the studies that have been published.
Here we combine the data reported by both authors and we include all data from december 
2008 to january 2012 (refer to Appendix, Tab. X and XX).
Quantum Dots biodistribution in the body
 In his review of 2006, Hardman claimed that some studies, both in vitro and in vivo, 
did not find enough evidence to prove that QDs induce toxicity. 
The first studies with QDs, in vivo, after injection into mouse tail veins appeared around 
2003/2004 for in vivo imaging (Larson et al. 2003; Ballou et al. 2004). The CdSe QDs used 
by the authors immediately distribute in the circulatory  system, but  within an hour the par-
ticles are mainly cleared from the blood unless a large PEG polymer is used on the surface 
(Larson et al., 2003). CdSe/ZnS QDs capped with an amphiphilic polymer and mercaptoa-
cetic acid/peptides respectively show a decreased fluorescence during time in animal stud-
ies (Akerman et al., 2002; Gao et  al., 2004), suggesting a possible degradation of the sur-
face coatings in vivo, that causes surface defects and loss of fluorescence. The QDs that are 
coated with a high molecular weight polymer have greater in vivo stability  than those of a 
lower molecular weight (Gao et al., 2004). Moreover, the surface chemistry, the size and 
and the surface modifications determine the half life of the NPs in the blood, before enter-
ing in the organs and direct the fate of the nanoparticle in terms of excretion and accumula-
tion. The distribution, accumulation and clearance of CdSe/ZnS QDs in rats in a short term 
study (up to 10 days) with different coatings: MUA (MUA–QDs) or BSA (BSA–QDs), and 
hydrodynamic radii of 25 nm and 80 nm respectively, reveals that QDs accumulate in the 
liver rather than the spleen, although the uptake is from both organs (Fisher, 2006). In par-
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ticular, the main portion of the two types of QDs accumulates in liver at the edges of the 
liver sinusoid, in Kupffer cells and that there is a significant quantitative difference in tis-
sue distribution between both QDs in liver, spleen, lung and kidney (Fischer, 2006). After 
10 days there isn’t any sign of degradation of the inorganic core/shell part, or excretion of 
the QDs: the sequestered QDs remain in the RES cells (Fischer et al. 2006).
It has been reported that QDs accumulate also in lymphoid organs. QDs accumulate in 
cells of the red pulp  of the spleen, in cells within the subcapsular sinus in the lymph nodes 
and in the vascular sinus periphery in the bone marrow. MUA-QDs are found in higher 
quantities than BSA-QDs in both the lung and kidney.  
They  show a lack of cadmium ions in the faeces and urine, but other studies have con-
firmed the presence of fluorescence within the bladder and kidneys. A possible explanation 
is that these QDs are too large for excretion by the kidneys (Fischer et al. 2006).
An important aspect of the QDs toxicity is the need of excretion of administered NPs in a 
relatively short time.
 Longer term studies with commercial CdSe QDs coated with methoxy PEG-5000 
(emitting at  705 nm) show that, even if plasma half life of the NPs is short (18,5h), there is 
not excretion after 28 days from the systemic administration. The QDs continue to accu-
mulate in the spleen, liver and kidneys during the time of the investigation (Yang et al., 
2007). Similarly, another type of QDs, the CdSe/ZnS QDs coated with mPEG 5000 and 
emitting at 655 nm, immediately  after injection accumulate in various organs, including 
liver, spleen, lymph and bone marrow. Within five days, the fluorescence decreases in the 
liver, but it takes up to six months for the emission in the bone marrow to fade. The lymph 
nodes maintain the emission for up  to two years, and although the amount of material re-
tained within the animal varies, the locations does not. Interestingly, the QDs show a blue-
shifted signal (up to 40 nm) at two years from the injection as compared to the beginning. 
The phenomenon isn’t observed in the animals sacrificed soon after injection, or in tissue 
that had been sacrificed early and frozen for up to two years. The effect could be due to a 
slow breakdown of the QDs, resulting in the release of toxic heavy metal ions. However, 
no acute toxicity was observed and the particles remained fluorescent for up  to 2 years 
(Fitzpatrick et  al., 2009). Moreover, commercially available QTacker 705 nontargeted QDs 
(QD705) injected intravenously into mice accumulate primarily  within the liver, spleen, 
and kidney (Li et al., 2008). Also these type of PEGylated QDs don’t show any evidence of 
excretion or metabolism within 28 days following dosing. After 6 months these NPs cause 
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significative renal toxicity  in the treated but not control mice. Treated mice showed evi-
dence of proximal tubular degeneration, with pronounced changes in mitochondria in the 
proximal convoluted tubules. In contrast, other studies have demonstrated efficient excre-
tion of QDs in mice (Lin et al., 2008). In contrast to the results described above (Lin et al., 
2008) the biodistribution and excretion paths of water-soluble hydroxyl group-modified 
silica coated CdSeS QDs, intravenously  injected in mice is rapid via both faeces and urine, 
within 5 days following injection (Chen et al., 2008).
On the base of the data in literature it is possible to reach a generalisation regarding the 
preference of QDs for accumulation in certain target organs, like liver and spleen and in a 
minor quantity in kidneys, lungs, lymph nodes, bone marrow. In a very  small amount as 
compared to the injected dose QDs are detected also in the brain (Yang et al., 2007). The 
migration to the liver and spleen is due to the clearance of QDs by phagocytic cells of the 
reticuloendothelial (RE) system, which suggest that QDs residing in organs have already 
been internalised by cells (Kennel in 2008).
When QDs are injected either subcutaneously (Zimmer et al., 2006; Robe et al., 2008), in-
tradermally (Gopee et al., 2007) or directly  into animal tumour tissues (Ballou et al., 2007), 
the pattern of organ deposition is different. Also the size of QDs can determine the biologi-
cal fate: QDs with a size above a certain limit, have limited ability to migrate further into 
the lymphatic system or to extravasate from the vasculature (Zimmer in 2006).
Quantum Dots biodistribution in the brain
 ICP-MS studies reveal that QDs after both systemic or intraperitoneal administration 
can enter in the brain  (Akerman et  al., 2002; Yang et al., 2007, Kato et  al., 2010, Yeh et al., 
2011). The biodistribution of QDs 636 nm with a captopropil cap in the brain is investi-
gated by means of ICP-MS (Kato et al., 2010). 
The brain is a challenging organ for molecules to enter because of the blood brain barrier 
(BBB), functioning as a controller, avoiding the entrance of exogenous substances. Six 
hours after intraperitoneal administration, 15% of the Cd remain in various organs includ-
ing liver, spleen, kidney, brain and blood. In the brain, QDs are detected in the parenchyma 
and in the blood vessels. The relatively high concentration of Cd in the thalamus and brain-
stem  as compared to the other regions might reflect the anatomical lack of BBB character-
istic of these areas. Even if in a minor quantity, QDs accumulate also in olfactory bulbs, 
hippocampus and cortex . 
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 There are different strategies for the NPs to cross the BBB. Small size QDs may be 
transferred through a space of 20 nm that separate the capillary endothelium to the astro-
cytes or interact with the receptors located at the BBB (Sigh and Nalwa, 2007). Another 
suggested route of entry into the brain is the retrograde axonal transport, which has been 
reported for the pathogenic mechanism of prion disease (Sigh and Nalwa, 2007). 
When injected into the brain, QDs are taken up primarily  and with high efficiency by mi-
croglia, whereas a small fraction (0.5%) can be found in neurons. In particular the QDs ac-
cumulate in lysosomes in the microglia and don’t affect mitochondria. The presence of 
PEG coating decreases the activation of  glial cell marker GFAP as compared to CdTe QDs 
(Maysinger et al, 2007). A recent publication used mixed primary  cortical cultures to assess 
the internalisation pathway followed by QDs. The uptake of QDs by microglia cells is de-
creased by inhibitors of clathrin-dependent endocytosis, implicating the endosomal path-
way as the major route of entry for QDs into microglia (Minami et al., 2012). Furthermore, 
the inhibition of mannose receptors and macrophage scavenger receptors blocked the up-
take of QDs by microglia, indicating that QD uptake occurs also through microglia-
specific receptor endocytosis. Moreover, QDs conjugated to the toxin saporin depleted mi-
croglia in mixed primary cortical cultures, protect neurons in this culture against amyloid 
beta-induced neurotoxicity (Minami et al., 2012). 
Quantum Dots in the cell
 ASTI is an efficient peptide for delivering QDs in living mammalian cells and shows 
functional and sequence similarity  to G-protein-coupled galanin receptors in mammals. 
Functionalised QDs with ASTI mostly enter the cell by the enzyme phosphoinositide 3-
kinase (PI3K) which is involved in the formation of clathrin-coated vesicles. The clathrin-
mediated endocytosis is confirmed by colocalisation of QD560-labeled clathrin heavy-
chain antibody and QD605-AST1. For a 10% the endocytosis was also galanin receptor-
mediated (Anas et al., 2009).
QDs can induce acute and chronic toxicity  to cells and organisms. Most of the studies re-
late the toxicity to the presence in the tissue of free heavy metals, like Cadmium and Sele-
nium, that directly induce reactive oxygen species (ROS) production by  mitochondria 
(Turrens JF, 2003; Lovric et al., 2005a; Ipe et al., 2005; Lovric et  al., 2005b; Cho et al., 
2007). In fact QDs affect mitochondrial membrane properties Li et al., 2011) and mito-
chondrial network fragmentation and disruption of mitochondrial membrane potential (Yan 
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et al., 2011). Moreover QDs alteration of miRNAs in NIH/3T3 cells with apoptosis-like 
death and increased p53 protein levels and its post-translational modification by phospho-
rylation at Ser-15 (Li et al., 2011), DNA damage and generation of DNA adduct, after per 
os administration in mice (Khalil et al., 2011) and in human umbilical vein endothelial 
cells, in a dose-dependent manner (Zhang et al., 2010). 
Once they enter the cell via diffusion throughout plasma membrane or internalisation, they 
can interact with cellular structures,  homeostasis,  signal transduction, DNA repair, apop-
tosis and oxidative mechanism (Fig. 10). CdSe QDs induce a significant reduction in the 
rates of oocyte maturation, fertilisation, and in vitro embryo development (Hsieh et  al., 
2009). CdSe/CdS capped with 3-mercaptopropionic acid or polyethylene glycol or SiO2 
may be transferred from female mice to their foetuses across the placental barrier. The 
smaller QDs are more easily transferred across the placenta than larger QDs and the num-
ber of QDs transferred increases with increasing dosage (Chu et al., 2010).  At doses of 
3,600 and 720 pmol/mouse, QDs caused marked vascular thrombosis in the pulmonary  cir-
culation, most likely by activating the coagulation cascade via contact activation. Moreo-
ver, carboxyl-QDs and amine-QDs enhanced adenosine-5 ́-diphosphate–induced platelet 
aggregation (Geys et al., 2008).
Fig. 10. Various way for 
uptake of ENPs to mammal-
ian cells and the effect nano-
paticles can have on intracel-
lular processes (Simkò and 
Mattsson, 2010).
 
 The toxicity  of QDs and the capping materials is an issue that has to be considered be-
fore any  application in biomedicine. Several groups in capping materials such as mercap-
toacetic acid and tri-n-octylphosphine oxide (TOPO) are reactive to the cell and can pro-
duce toxicity to cells (Smith et al., 2008).
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At the moment all the data don’t show any Cadmium based QDs with a possible clinical 
application. New generation of fluorescent NPs without heavy metals and with coating 
adapted for the excretion can be the alternative. To reduce the cytotoxicity  of QDs, re-
placement of the cadmium by nontoxic or less-toxic metals such as Indium (In), or encap-
sulation of the core with a biocompatibile shell or designing them as small as possible, thus 
facilitating their clearance from the body(Smith et al., 2008) should be considered. In-
based semiconducting dots contain Arsenic, have an acceptably low cytotoxicity. 
Phagocytosis and uptake of nanoparticles 
 After systemic administration, or inhalation, NPs are sequestered by RE system by 
means of  phagocytic mechanism. The organs where NPs mostly  accumulate are liver, 
spleen and lung (refer to the follow paragraph) where the macrophages have different 
names according to the organs where they  are: alveolar macrophages (lung), splenic 
macrophages (spleen) and Kupfer cells (liver).
The phagocytosis of a molecule is a process where a molecule is internalised, by means of 
engulfment in vesicles, into a macrophage or a non professional phagocyte. The phagocy-
tosis mechanism involves the interaction between macrophages membrane receptors and 
specific  “presenting” ligands that recognise the NPs and, by a mechanism called opsonisa-
tion, they  label the exogenous molecule as non-self, facilitating the particles internalisation 
in the macrophages (Aderem and Underhill, 1999). The opsonisation molecules are anti-
bodies or complement molecules (e.g. complement protein 5a and IgM). Hydrophobic or 
charged molecules are quickly recognised by opsonisation molecules and internalised (Kelf 
et al., 2010), while the presence of hydrophilic coatings like PEG diminishing the opsoni-
sation process, decreasing the possibility of phagocytosis from macrophages and other non 
specialised cells (Palecanda and Kobzik, 2000, Kelf et al., 2010). 
 The opsonisation mechanism is initialised by different mechanisms involving the 
complement protein 5a that act as a chemotactic molecule (Oberdorster et al., 2005), the 
electric charge of the NPs (Kobzik, 1995) or the toll-like receptor that recognise non-self 
molecules and organisms (Inoue et al., 2006).  After the interaction between macrophages 
and opsonising ligands, the particle is internalised by the formation of a phagocyte vesicle 
or phagosome (Park, 2003), than successively, becomes a phagolysosomes, internalising 
digestive enzymes. The presence of PEG on the particle surface reduces the internalisation 
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(Kelf et al., 2010) while the absence of PEG and the charge on the surface promote the in-
ternalisation into the cells (Kelf et al., 2010).
 The inflammatory response is increased by the release of chemical messengers for the 
recruitment of other inflammatory cells by macrophages. The digestive process in the pha-
golysosomes involves proteases, nicotinamine adenine dinucleotide phospate (NADPH) 
oxidase that produces oxygen radicals (Park, 2003). After digestion the residues are re-
moved by exocytosis. The phagocytosis process, generally, lasts several hours. In the case 
of NPs, thanks to their small size and the presence of heavy  metals, it  is difficult for a 
macrophage to stop  and digest particles of few nanometers (Takenaka et al., 2001).  The 
efficiency of macrophages is higher with a cell size material (13-20um) than NPs, and the 
clearance is much quicker. In fact, the administration of high doses of NPs result in a better 
clearance from macrophages in the lungs and other organs than low doses. The reason is 
the final size: when the concentration is high, the NPs tend to form aggregates that results 
in a bigger size as compared to the single NP. Macrophages can stop easier aggregate of 
NP, while the single NP accumulates for longer period in organs and circulatory system. 
The NP that can not be digested results in a longer inflammatory response. When the pha-
golysosome can not digest  the NPs, the continuing production of ROS damage the phago-
some membranes, that  release the reactive species in the cytosol of the macrophage. The 
ROS lead to impairment of cell motility and functions, and subsequently, cell death. The 
death of the macrophage releases the reactive species outside, recruiting other macro-
phages that can’t digest the NPs as well. These inflammatory response create a source of 
reactive species and macrophages debris accumulation that can induce a long term inflam-
mation (Oberdorster et al., 1994). In the brain the increase of oxidative stress caused by 
this mechanism can be associated with diseases like neurodegerative deseases (Bondy, 
2011). 
 This can be the reason why in the brain it is difficult to see an immediate inflammatory 
response after systemic injection. The concentration is too low to be seen by microglia. 
Only after intracortical injection there is an immediate inflammatory response in terms of 
GFAP induction and microglia activation (Maysinger et al., 2007).  
Non stopped NPs that stay in the circulatory system are more likely to enter non phago-
cytic cells, like endothelial cells, epithelial cells (Hopwood et al., 1995), red blood cells, 
platelets (Nemmer et al., 2002) and nervous cells (Oberdorster et al., 2002).
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The entrance does not produce any  vesicle, and the NPs can accumulate both in the cyto-
plasm, or nucleus and interact with different structures of the cell. The uptake of the cell is 
assumed to be a passive uptake or adhesive interaction (Geiser et al., 2005). 
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RESULTS AND DISCUSSION
Qtracker®  800 QDs characterisation
 The QDs tested in our experiments are the Qtracker® 800 non targeted QDs from Invi-
trogen (QDs 800) (Cat. Q21071MP). Their core is made up  of a few hundred to a few 
thousand atoms of a semiconductor material (CaSeTe). The ICP-MS analysis of a QDs 800 
solution reveals that for 33 atoms of Cadmium (Cd) there are 11,43 atoms of Selenium (Se) 
and 1 atom of Tellurium (Te). The core is surrounded by a semiconductor shell of Zinc sul-
fide (ZnS) which stabilises the core, improving both the optical and physical properties of 
the material. An amphiphilic polymer encases the core and the shell, providing an hydro-
philic surface and a substrate for functionalisation with peptides and antibodies to create 
targeting QDs 800 nanocrystals.
 This amphiphilic inner coating is covalently modified with a polyethylene glycol (PEG) 
outer coating that, in our case, is not functionalised (Fig. 11 Bottom). The PEG surface im-
proves signal-to-noise ratios and provides a clearer resolution of cell populations and cellu-
lar morphology. Moreover, it reduces opsonisation, extending the circulation time of the 
NPs in the blood (Peracchia et al., 1999). PEG has been approved from FDA and has a lot 
of applications in the polymer based drug delivery (Knop et al., 2010).
 The composition of the core is important for the emission wavelength. They  are the big-
gest type of QDs produced by Invitrogen, with NIR emission wavelength, 750-800nm. 
Non targeted QDs 800 are designed for in vivo imaging, for studying vascular structure af-
ter injection. These nanocrystals exhibit intense fluorescence, red-shifted emission that 
permits to increase tissue penetration, and the PEG surface coating minimises any immune 
response by the tissue, and the cell uptake. The PEG surface coating is not modified with 
reactive functional groups, permitting the QDs 800 to be retained in circulation for at least 
3 h and to be imaged for up to 3 months without additional injections (Invitrogen data 
sheet).
We analyse the particle size and morphology by TEM. The particle size in water suspen-
sion is 8,27 ± 1,27 nm. 
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The hydrodynamic size, measured with Malvern Nano Zs instrument with a 633 nm laser 
diode, is 36nm (Rampazzo et al., 2011). The morphology of the NPs is shown in Fig. 11 
Top.
Fig. 11. Top: Characteristics of QDs® 800: the two graphs on the left indicate the absorption and emission 
spectra of different type of QDs. We excited the QDs® 800 at 405nm and the emission wavelength was col-
lected at 750-850nm. On the right hand side a TEM image of QDs® 800 morphology and the measure of the 
electron dense part of the NPs (nm). Bottom: Schematic representation of non target QDs® 800.
Comparative body retentions and tissue distributions of 
QTracker® 800 QDs in mice 
 The biodistribution analysis of QDs 800 in mice, after i.v. injection, is performed using 
different imaging techniques (e.g. optical imaging, electron microscopy, confocal micros-
copy etc). The systemic administration mimics the human route of exposure. 
The optical imager allows to detect NIR fluorescence in in vivo and ex vivo systems. The 
QDs 800 excitation and emission wavelengths can penetrate in the tissue within 1 cm 
depth, giving higher fluorescence intensity  and more specific QDs localisation in small 
animals. The instrument is equipped with different  filters which discriminate the NIR 
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emission. At 800 nm there are no interference from water or haemoglobin of the tissue, 
maximising the signal/background in the experimental animals (Weissleder, 2001). 
 Firstly we follow the kinetic of biodistribution of QDs 800 in vivo for 3h after the injec-
tion. In vivo images just after the injection reveal a significative increase of signal as com-
pared to background, measured in the pre-injection images. Region Of Interest (ROI) are 
traced manually on the planar images where fluorescence builds up: in the anatomical re-
gions of lung, liver and spleen and brain (Fig. 14A). The average efficiency (fraction of 
fluorescent photons relative to the number of incident excitation photons) of the ROIs is 
represented with the standard error mean (SEM) in Fig. 12. 
Measurements of the total flux (p/s) emitted from the extracted organs after perfusion with 
PBS with SEM  are reported in Fig. 13. Using Cy5.5 filter, QDs 800 show a significantly 
higher (p<0,05, paired Student’s t-test) fluorescent signal as compared to controls in all 
organs analysed at 3 h. The fluorescence is particularly high in the liver. 
The data are confirmed with ICP-MS analysis that quantifies the amount of heavy metals 
(Cd, Se and Te) in the organs and tissues and electron microscopy that discriminates the 
cells and structures of accumulation. 
Cd is the major core material of QDs and is not detectable in physiological conditions 
keeping the background noise virtually  to zero. We estimate QDs quantity on the basis of 
the amount of Cd measured in the organs.
The QDs800 biodistribution is investigated at 24h after the i.v. injection, where the acute 
response occurs, and at longer time points, 1, 2 and 3 weeks.
Fig. 12. Kinetic of bio-
distribution of fluores-
cence during 3 h after 
the injection. The aver-
age efficiency for ROIs 
is measured in different 
regions before and after 
the injection. The black 
triangles, circles and 
squares are the pre and 
post treatment of con-
trols animals while the 
coloured triangles ,  cir-
cles and squares are 
respectively the pre and 
post treatment of QDs 
800 animals. 
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Fig. 13. Quantification of 
the fluorescence signal (in 
photon counts/second) from 
QDs in various extracted 
organs of animals treated 
with QDs and saline and 
imaged with Cy5.5 filter. 
The bars represent averages 
± SEM (N = 3).
The serum clearance, assessed with ICP-MS at 1, 2 and 3 weeks reveals Cd concentrations 
(± SEM) of 0,2435 ± 0,068; 0,0075 ± 0,0005 and 0,013 ± 0,0019 µg/ml at 1, 2, 3 weeks 
respectively. Cd concentration decreases after 1 week, as reported also for other type of 
QDs (Yang et al., 2007; Lin et al., 2008), but doesn’t reach the control levels at longer time 
points. The Cd concentrations in treated animals are statistically different at all time points 
as compared to controls (p<0,001, two ways ANOVA test). Non specific binding of QDs to 
cellular blood components (e.g. erythrocytes) is detected with TEM analysis. 
Red blood cell do not have phagocytic ability, and the uptake of QDs depends only  on the 
small size of the NPs (Peters et al., 2006). The charge, instead, determines the uptake by 
platelets. NPs influence the formation of blood clot  (Nemmar et al., 2002): QDs 800 inter-
act with plasmic proteins and in particular with fibrinogen (Pozzi-Mucelli et al., 2009).
44
 
Fig. 14. A) In vivo average efficiency at 3h after injection in treated and control animals. B=brain; Li=liver; 
Lu=lungs; S=spleen. B) ex vivo images after PBS perfusion,  imaged with Cy5.5 filter. Li=liver; Br=brain; 
Sp=spleen; Ki=kidneys; Lu=lungs. 
 The levels of Cd in all organs are significantly higher than controls, at all time points 
analysed (p<0,001 two ways ANOVA test) (Tab. 4). 
Fig. 15. Amount of Cd in different organs expressed as percentage of the injected dose at 3h, 24 h, 1, 2 and 3 
weeks after the iv injection.
Tab. 4. Concentration of Cd in each organ (ng of Cd / mg organ wet weight).  Data represent QDs treated 
animal organs before (baseline) and after i.v. injection. Average ± St.Dev.
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Already  at 3 h, part of the QDs leave the bloodstream and accumulate respectively 6% of 
the injected dose in the spleen, and 5% in the liver. The 0,1% is found in the lung, the 0,7% 
in the kidneys while only the 0,01% of the injected dose is found in the brain (Fig. 15). No 
changes in organ weights are revealed during the 3 weeks of exposure (p>0,05 two ways 
ANOVA test). The Cd levels detected in tissues from control mice are negligible, below 
0,001 ng Cd/mg wet tissue. This is expected, as Cd has no known biological function, and 
laboratory mice are not  exposed to typical sources of Cd. We compare the QDs treated 
animals to saline animals because the vehicle controls, which consisted of suspension 
buffer with the QDs removed, yielded insignificant levels of Cd and behave similarly to 
saline group.
Fig. 16. Fluorescence images of QDs at 3 weeks after injection with simultaneously analysed emission spec-
tra profile in liver A) and A’) and spleen B) and B’) (20x magnification lens). In the images, ROI are placed 
on the particles (red and green arrows in A’ and red arrow in B’) and on the background (blu arrow in A’  and 
green arrow in B’). 
 The organ with the highest Cd concentration is the spleen (and therefore the maximum 
QDs accumulation). In terms of percentage of the injected dose, principally  QDs accumu-
late in the liver, since it is a bigger organ. The spleen is the most probable cause of the 
presence of Cd in the blood after 2 and 3 weeks. We believe that the spleen behaves like a 
“sponge”, absorbing blood full of QDs immediately after the injection and continuing to 
release the NPs in time, e.g. by inflammatory cells, red blood cells and platelets as carriers. 
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It is also possible that inflammatory cells transport QDs from the spleen to the brain, in-
creasing the Cd concentration in the brain over time. The amount of NPs accumulated in 
each organ reflects the different absorption properties. Heavy metals concentration is high 
in all organs throughout all time points, suggesting a biological half-life in the scale of 
weeks or months for QDs in rodents and possibly humans.
 The fluorescence microscopy is used as an additional method for detecting QDs. It 
confirms the presence of fluorescence at  3 weeks in liver and spleen. A closer analysis of 
the fluorescence images shows localisation of QDs at the edges of the liver sinusoid. 
Lambda scan reveals the typical peak of emission of QDs, which differs from the back-
ground (Fig. 16).  
Fig. 17. TEM images. A and B) QDs in Kupffer cell (K) at the boundary of the hepatic sinusoid (S) and se-
questration in phagolysosome. C) QDs are sequestrated in vesicles in endothelial cells (E). D) and E) QDs in 
a histiocytes and sequestration in lysosomes in the red pulp.
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Fig. 18. QDs at the different time points. A) QDs on a grid before being injected, from B) to E) at 24h, 1 
week, 2 weeks and 3 weeks.  
 The electron microscopy images show that at all time points spleen and liver macro-
phages (histiocytes and Kupffer cells) and endothelial cells take up the QDs. The QDs 
seem to enter the cells via phagocytic process and endocytosis. In fact they are entrapped 
in phagolysosomes in both Kupffer cells and histiocytes (Fig. 17). The Kupffer cell can be 
identified by  its active phagocytic morphology, with many phagolysosomes in the cytosol, 
and location within the sinusoid. No QDs are found in the hepatocytes. In the spleen, QDs 
are mostly sequestered in phagosomes in the macrophages of the red pulp (Fig. 17 D and 
E). The morphology of QDs changes depending on the accumulation site: in the lysosomes 
they  are smaller and less defined as compared to the vesicles in the endothelial cells. The 
digestive chemicals of phagocytic cells, hydrochloride acid and hydrogen peroxide, can 
cause considerable QDs degradation after 1week of incubation, and zinc leaches early in 
the phagocytic degradation process since it is located in the external shell of the QDs 
(Mancini et al., 2008).
This hypothesis is confirmed by the fact that the diameter of the QDs, measured with TEM, 
becomes smaller over the time: 8,2 ± 1,87 nm (mean ± SEM, on the grid), 7,96 ± 2,17 nm 
(mean ± SEM, after 24 h), 6,71 ± 1,39 (mean ± SEM, after 1 week).
 An increasing amount of Cd in the kidneys after 2 and 3 weeks is detected with ICP-
MS (Tab. 4). The liver is detoxifying the body, digesting and biotransforming QDs in order 
to excrete them thought the kidneys. As reported in literature, QDs, are not likely to be di-
gested and excreted by kidneys: after 6 months they are still accumulated in the kidneys 
causing proximal tubular degeneration with changes in mitochondria in many convoluted 
tubules (Lin et al., 2008, with QDs similar to the QDs 800 used in our experiments). We 
can expect a similar renal toxicity. Choi and colleagues in 2007 demonstrated that QDs 
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can’t be renally  cleared unless they are less than 5.5 nm in diameter. The QDs used in these 
experiments have an organic coating that increases hydrodynamic diameter to 36 nm, pos-
sibly preventing renal excretion. Further experiments are needed to elucidate the effect  and 
accumulation of QDs over longer time on kidneys. 
The ratios between the elements Cd, Se and Te over time compared to the ratios in the in-
jected solution is different (data not shown). One possible explanation for the difference in 
heavy  metal ratios is the leaching of Cd, Se, Te and Zn ions from the NPs, an evidence al-
ready  reported in literature (Lovric et al., 2004; Kirchner et al., 2005; Maysinger et al., 
2007). 
PEGylated QDs, BSA coated QDs and polymer QDs behave quite similarly  (Hauck et al., 
2010). 
 PEG immunohistochemistry reveals the persistence of the external coating on the QDs 
over time. The Fig. 19 shows the amount of PEG staining in liver and spleen over time. 
Considering the difference in staining amount over the background, it  seems that there is a 
reduction of PEG at 2 and 3 weeks as compared to 24h in both liver and spleen. The stain-
ing quantification with light microscopy is still on going.
and location within the sinusoid. No QDs are found in the hepatocytes.
Fig. 19. PEG staining. Top: Liver at different time points and acquisition with a 20x magnification. Bottom: 
Spleen with 20x and 10x  magnification lenses at all time points. The arrows indicate the unspecific signal 
given by mast cells in the spleen. 
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 Referring to the brain, the contents of Cd, illustrated in Tab. 4, is significative higher 
as compared to controls (p < 0,01, two ways ANOVA test) at all time points
The electron microscopy  reveals the presence of the nanoparticles in the somatosensory 
cortex in epithelial cells, neurons and glia, accumulated both in cytosol and nucleus. The 
NPs are not sequestrated by specific structures, but they form small aggregates that interact 
with cell structures like mitochondria, myelin sheath, synapses, chromatin etc. (Fig. 20). In 
hippocampus and thalamus no QDs aggregates are found, probably  due to the lower con-
centration of QDs in these specific regions and to the technique, the electron microscopy, 
which allows to look only at a very small area. 
Fig. 20.  TEM images of cerebral cortex slices at 1 week. A) QDs in the nucleus (N) and cytosol (C) of a 
neuron. B) QDs in a synaptic bouton.  C) QDs are sequestered by endothelial cells (E) and are localised in the 
nucleus and in the cytosol.  An aggregate is localised outside the endothelial cell probably in the cytosol of an 
astrocyte (A), BL=basal lamina. D) QDs in a mitochondria (M).  E) QDs are crossing BBB, BV=blood vessel. 
F) Enlargement of image C). G) QDs in the cytosol of a microglial cell, indicated by the circle. Lysosomes 
(P) containing ingested materials and some QDs. H) QDs on myelin sheath. I) QDs in an epithelial cell.  Ar-
rows indicates the aggregates of QDs.
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Fig. 21. Confocal images of central (A) and lateral (B) ventricles at 3 weeks after treatment with QDs.  The 
red dots indicated by the arrows are the 800nm emitting QDs. Acquisition with 20x magnification lens.
 
 At 3 weeks after the treatment the nanoparticles are only found in the ventricles (Fig. 
21). At the same time point the PEG is detected around blood vessels and in the paren-
chyma, in the anatomical structures around the ventricles (Fig. 22).
Fig. 22. PEG staining 
of different brain ar-
eas. A) Hippocampal 
section from a treated 
animal sacrificed after 
2 weeks from injec-
tion.  The staining is on 
and around dentate 
gyrus cellular layer 
(4x magni f ica t ion 
lens). B) Hippocampal 
section from a control 
animal sacrificed after 
2 weeks (4x magnifi-
cation lens). C) Sec-
tion of somatosensory 
cortex of a treated 
animal after 2 weeks 
from the injection (60x 
magnification lens). 
D) Section of cortex of 
a control animal (20x 
magnification lens). E) 
Cortex of a treated 
animal at 1 week (60x 
magnification lens). F) 
Cortex of treated ani-
mal at 3 weeks (60x 
magnification lens).
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Discussion
 Our observations have the following implications: a) the visualisation of red fluores-
cence (Fig. 16 and 21) suggests aggregation of a large number of QDs nanocrystals in situ 
because fluorescence from only a few particles would be undetectable; b) a major mecha-
nism of distribution of QDs involves mononuclear phagocytic system in many organs; c) at 
low concentration QDs enter the brain, and after 1 week they are not stooped and seques-
tered by microglia. An early inflammatory response is elicited only after intracortical injec-
tion (Maysinger et al., 2007). 
The lack of an immediate inflammatory response in the brain is probably due to: 
a) after systemic injection, a lower amount of nanoparticles reaches the brain as compared 
to the amount after an intracortical injection, and they are not immediately seen by the im-
mune system, or b) the PEG coating decreases the opsonisation process and minimises the 
recognition by the mononuclear phagocytic system in the brain (Akerman et al., 2002), or 
c) the size of the QDs is too small to be phagocytized in the first instance by microglia 
(Oberdorster et al., 1994). 
 Our results of biodistribution are confirmed by  literature (Yang et al., 2007; Lin et al., 
2008, Tiwari et al., 2011, Sui et al., 2011, Yeh et al., 2011). 
Even if the amount in the single organs is different, which may reflect  differences in the 
type of QDs used and in the dose and the analysed time course, we confirm that the highest 
Cd concentration is in the spleen, followed by the liver and the kidneys. The reticuloendo-
thelial system in liver and spleen is the major cleanup site of nanoparticles via uptake by 
mononuclear phagocytes, Kupffer cells in liver and histiocytes in the spleen. Macrophages 
are diffused in the connective tissue and in liver (Kupffer cells), spleen and lymph nodes 
(sinus histiocytes), lungs (alveolar macrophages), and central nervous system (microglia). 
In the spleen macrophages remove senescent erythrocytes, leukocytes, and megakaryo-
cytes by phagocytosis and digestion. It is possible that QDs accumulate in a significant 
amount in lymph node as well, since they represent the organ of the immune system. All 
these data haven’t been confirmed yet.
 Commercial QDs 705 from Invitrogen show a plasma clearance in about a week with a 
return to background level at  longer time points (Yang et al., 2007). QDs 800 behave dif-
ferently, decreasing after one week but still continuing to circulate in the blood stream at 2 
and 3 weeks after the injection. These two types of QDs are very similar, and the difference 
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is only in emission wavelength and core composition. Among the possibilities, a different 
sensitivity of the ICP-MS instruments, can be the explanation of the different results.
 About 0.1% of the QDs in the body, accumulate in the brain, after both i.v. and i.p. ad-
ministration (Yang et al., 2007; Kato et al., 2010). The blood brain barrier (BBB) plays an 
important role in the homeostasis and as a defencing mechanism. The endothelial cells and 
the tight junctions form a physical barrier for exogenous compounds.
There are many hypothesis of how QDs and in general NPs cross the BBB. QDs can cross 
BBB through the 20nm gap  between astrocytic foot processes and the capillary endothe-
lium, or through receptors located at the BBB (Kato et al., 2010). Another possibility is 
that QDs induce inflammatory  response which increases the permeability of the BBB fa-
cilitating their entrance. ROS production is another well known effect after QDs treatment 
(Tang et al., 2010; Kim et al., 2011; Liu et al., 2011; Yan et al., 2011). 
 We find QDs 800 at 3 weeks from the injection in the ependymal cells of the choroid 
plexus. Other PEGylated NPs after 24h from systemic injection are found in choroid 
plexus and in the epithelial cell of the pial surface (Calvo et al., 2001) and the authors at-
tribute the retention of the particles by the choroid plexuses as “the logical consequence of 
the function of this tissue as a producer of cerebrospinal fluid”. The possible mechanisms 
of entrance of NPs in the CSF crossing blood-CSF barrier, are diffusion and active trans-
port (Bhaskar et al., 2010). 
 Colloidal polymer particles, coated with polysorbate 80, are found in the brain paren-
chyma as well, supporting the view that many type of NPs can cross BBB (Kreuter et al., 
1995).
The presence of Cd and Se in the brain can induce directly  ROS production that increases 
BBB permeability. It  seems that also mitochondria are the major sources of ROS produc-
tion in most mammalian cells (Turrens et al., 2003), and their ROS production increases in 
many pathological conditions and is associated with mitochondrial dysfunction 
(Newsholme et al., 2007; Swerdlow, 2007). A mitochondrial toxin, the 3-nitropropionic 
acid (3-NP), disrupts the mitochondrial electron transport chain, causing an elevation of 
ROS generation, thereby triggering events such as MMP-9 induction that eventually leads 
to BBB opening (Kim et al., 2003). Another study shows QDs toxicity  on mitochondria in 
human umbilical vein endothelial cells: CdTe QDs elicited significant oxidative stress, mi-
tochondrial network fragmentation, as well as disruption of mitochondrial membrane po-
tential. The effect is reversed with ROS scavenger (Yan et al., 2011). Also Vieira and col-
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leagues in 2011 report mitochondria toxicity  in a T. Cruzi protozoa model. The mitochon-
dria impairment can affect BBB permeability by ROS production as well as cell energy 
production. 
 An increase in oxidative stress leads to elevated oxidative damage to biomolecules such 
as proteins and lipids. A decrease of Na+/K+ ATPase is closely correlated to the induction 
of oxidative stress, suggesting that elevated ROS levels damage the ATPase, thereby lead-
ing to BBB dysfunction by allowing excessive and inappropriate influx of Ca2+ into cells 
(Huang et al., 2008). Future experiments regarding the energy production and the BBB 
permeability  after QDs treatment are necessary.
 The tight junctions are also present in other organs; e.g in the liver. In healthy liver the 
endothelium is fenestrated with pores up  to 100nm, while, in the presence of inflammation, 
the permeability is increased.
 All the studies reported in literature are performed in healthy animals. It is important to 
understand that not only  the chemistry of QDs but also the the tissue/organ conditions 
strongly determine their uptake and toxicity. The impact of NPs in pathophysiological con-
ditions is still unknown. The QDs effect  has been investigated only on the vasculature and 
on the inflammatory reactions in postischemic skeletal and heart muscle (Reheberg et al., 
2012). Amine-modified QDs are strongly associated with the vessel walls of postcapillary 
venules and they amplify ischemia-reperfusion-elicited leukocyte transmigration (Rehe-
berg et al., 2012). Moreover, the postischemic myocardium shows a strong association of 
amine-QDs with microvessel walls.
An increasing number of studies report biodistribution of QDs at long time points, but still 
there is a little knowledge about the effect of NPs on organs such liver, spleen, kidneys, 
brain etc. As long as they accumulate for long term period, potentially, they  can induce ad-
verse effects and cytotoxicity. 
The majority of the published papers regarding QDs toxicity shows no relevant effects on 
cell viability  at  the concentration used for imaging applications. In vivo experiments, on 
the other hand, show many possible adverse effects. Literature lack of in vivo toxicological 
studies, for long term periods and with a deep analysis of the effects on single organs. In 
vitro models, with cell viability  assays, represents only a good screening and point of start 
for a toxicological evaluation.
The Fig. 22 is a schematic summary of QDs biodistribution in the body, based on our re-
sults and literature.
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Fig. 22. Schematic 
representation of the 
QDs biodistribution 
fate after systemic 
administration.
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CHAPTER 3
Learning and Memory abilities after 
Quantum Dots administration
INTRODUCTION
Nanoparticles and blood-brain-barrier
Anatomy of the blood brain barrier
 Nanoparticles have the potential to revolutionise medicine because they  can reach and 
affect target organs and tissues at the molecular and cellular levels. 
It has been reported that neuronal cells can uptake NPs via the olfactory  nerves, in the case 
they  have been inhaled (Driscoll et al., 1996, Oberdorster et al., 2009 ) or via the blood-
brain barrier (Peters et al., 2206). 
 The blood-brain barrier (BBB) protects the central nervous system (CNS) from poten-
tially  harmful xenobiotics and endogenous molecules (Bhaskar et al., 2010), but it repre-
sents also an insurmountable obstacle for a large number of drugs, like antibiotics, antineo-
plastic agents etc.
The BBB is composed by a monolayer of specialised endothelial cells linked by tight junc-
tions (TJ), which restrict the movement of small polar molecules and macromolecules be-
tween the blood and the brain parenchyma. TJ possess transmembrane proteins (e.g. junc-
tional adhesion molecule-1, occludin, claudins) and cytoplasmic proteins (e.g. zonula 
occludens-1 and -2, cingulin etc.) which act as physiological barrier (Fig. 23). The endo-
thelial barrier is supplemented with capillary pericytes. The basement membrane (or basal 
lamina) is interposed between endothelial cells and astrocytic end-feet. The astrocytic end-
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feet are linked by gap junctions and express a variety of receptors, ion channels, and water-
transporting proteins, that transport substances across the BBB. 
Hydrophobic molecules (e.g. O2, CO2, hormones, etc) enter the brain trough the transcel-
lular lipophilic pathway, while hydrophilic molecules use the paracellular aqueous path-
way, the transport proteins, the receptor-mediated transcytosis, and the adsorptive-
mediated transcytosis (Abbott et al., 2006). The diffusion of drugs from the blood into the 
brain depends upon the ability  of the molecule to traverse the lipid membranes (Roney et 
al., 2005). Some drugs are structurally  modified to mimic endogenous molecules to take 
advantage of transport proteins on the membranes. 
In addition to BBB, the Blood-CerebroSpinal Fluid barrier (BCSF) is formed by epithelial 
cells of the choroid plexus and controls the exchange of molecules between blood and CSF 
(Fig. 23). 
Fig. 23. BBB and 
BCSF representa-
tion.  CSF = cerebro-
spinal fluid. (from 
Bhaskar et al., 2010)
Surface modifications and functionalisation for crossing the blood brain barrier 
 The uptake and the dynamic of the NPs in the CNS are very complex. 
Surface modifications of NPs are intensely studied for medical applications like diagnosis 
and therapy aiming to influence the behaviour of the NPs and to improve the brain perme-
ability. 
Coating the NPs means absorbing specific proteins or polymers onto their surface. The 
coatings prolong their circulation in the blood, increase the interactions with endothelial 
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transport receptors and augment the possibility  of crossing the barrier. In fact, the longer 
blood circulation of NPs influences endothelial cell membrane permeability (Chen et al., 
2008), and induce vesicular transport to gain access into the CNS. Moreover, the solid 
polymeric matrix, which covers the NPs, protects the incorporated drugs against degrada-
tion (Garcia et al., 2005). 
Several molecules like lectin and polysorbate-80 (Gao et al., 2006), apolipoprotein E 
(Kreuter et  al., 2002), transferrin (Mishra et al., 2006), and peptides (Krauzewicz et al., 
2000) have been used for targeting brain endothelial cell membranes and can facilitate the 
transport across BBB.
It has been reported that circulating NPs cause the generation of free radicals that can dis-
rupt or increase the permeability of the BBB, augmenting the NPs adsorption in the brain. 
 An important factor for crossing BBB is electrostatic charge of NPs. Since BBB is 
negatively charged, cationic charged molecules are more likely to interact  with the endo-
thelium (Nagy et al., 1983) and increase cell permeability (Hardebo and Kahstrom, 1985). 
An in vitro study reveals that cationised NPs translocate more readily to the brain than ani-
onic or neutral NPs (Fenart et  al., 1999). However, neutral NPs and low concentrations 
anionic NPs do not affect BBB integrity, while high concentrations of anionic NPs or cati-
onic NPs disrupt  the BBB structure. Cationic NPs, in particular, have a greater toxic effect 
and immediately open the BBB (Lockman et al., 2004). An example is polysorbate 80-
coated polybutylcyanoacrylate (P80-PBCA) (Kreuter et al., 2002; Calvo et al., 2011). 
Poloxamine 908-coated NPs, on the other hand, do not cross BBB efficiently because of 
their incapacity to interact with the endothelial cells of the BBB (Calvo et al., 2001).
So far, for medical applications of drug delivery, low concentration of neutral and nega-
tively charged NPs should preferentially be used (Koziara et al., 2006). 
 PEGylated nanoparticles are neutral and have shown good stability  in the blood stream 
and to efficiently avoid mononuclear phagocyte system (Kelf et al., 2010). PEG also in-
creases the possibility of receptor-mediated transport  through the brain capillary endothe-
lium (Oliver, 2005). Moreover, while other NPs coatings (e.g. poloxamine 908) are easily 
lost after in vivo administration, the PEG chain is covalently  attached to the NPs hydopho-
bic core and its release over time takes much longer (Calvo et al., 2001). PEGylated NPs 
are much more effective carrier to improve nanoparticle brain concentration as compared 
to uncoated NPs, especially  for the deeper regions of the brain like striatum, hippocampus, 
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hypothalamus and thalamus, without any BBB permeability modification. PEGylated NPs 
are found in choroid plexus after 24h from i.v. injection (Calvo et al., 2001).  
 Other in vivo studies have shown that the NPs coated with both PEG and the 
poly(hexadecylcyanoacrylate) PHDCA-hydrophobic chain are able to penetrate the healthy 
rat brain and brain glioma (Brigger et al., 2001; Calvo et al., 2002).
NPs coated with PLA, PLGA or PEG surface modifications, or the combinations of all, 
seem to be promising for drug delivery to the brain. They are neutral, biocompatible and 
they  can pass the BBB. Nevertheless, the safety profile of most PEGylated NPs is still un-
clear (Plard and Didier, 1999; Olivier, 2005). 
Not only the charge but also the size of the NP is important for drug delivery: small size 
and lipophilicity allow molecules to passively diffuse and cross BBB (Sahagun et al., 1990; 
Fischer et al., 1998).
 Another possible route for the uptake of NPs is the endocytosis by endothelial cells of 
the BBB via low-density  lipoprotein receptor (LDLR) family. NPs functionalised with 
Apoliprotein E (ApoE) and B (ApoB) can act as Trojan Horse lipoprotein-like particles 
(Kreuter et al., 2002). ApoE protein mimics low density lipoprotein (LDL) causing the par-
ticles to be transported across the blood brain barrier via the LDL receptors. The cellular 
uptake of PEG-PHDCA NPs by endothelial cells, in an in vitro model, is via endocytosis, 
with an intracellular endo/lysosmal localisation (Kim et al., 2007). The clathrin is the me-
diator of the small invaginations in the cell membrane. The formation of clathrin mediated 
vesicles is generally  linked to the action of proteins from the LDLR gene family (Kim et 
al., 2007).
 Nanoparticles functionalised with a thiamine surface ligand (Lockman et al., 2003), 
with an average diameter of 67 nm, are able to associate with the blood brain barrier thia-
mine transporters and thereby  increase the unidirectional transfer coefficient for the parti-
cles into the brain.
QDs are sequestered by microglia through clathrin-dependant endocytosis (Anas et al., 
2009). Carboxyl-QDs naturally  incapsulate in vesicles in a Ca2+- and clathrin-dependent 
manner  (Zhang and Tsien, 200) and are used to study the synaptic vesicles release.
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Nanoparticles effects in the brain
 The study  of the effects of NPs in the brain is becoming an increasingly hot topic in 
literature. The number of publications regarding NPs biodistribution in the brain (Kato et 
al., 2010) and their effect on neuronal cells, both in vivo and ex vivo, are steadily increasing 
(Maysinger et al., 2007, Tang et al., 2009). 
While the reticuloendothelial system is the major cleanup sites of nanoparticles in liver and 
spleen, via uptake by  mononuclear phagocytes, unrecognised NPs may have a long circula-
tion half-life and relocate to other target organs, like the brain (De Jong and Borm, 2008). 
Once NPs accumulate in the brain, they can induce oxidative stress (Tang et al., 2009). Due 
to their surface coatings, NPs can be internalized by macrophages, which in turn induces 
oxidative stress by generating free radicals. Both in vivo and ex vivo studies show that dif-
ferent type of NPs (e.g. fullerenes, QDs, nanotubes etc.) induce reactive oxygen species 
(ROS) (Oberdorster et al., 2005), leading to damage of cell functions, DNA, cell mem-
branes, proteins etc (Brown et al., 2004). ROS are generated directly  by the NPs, by  the 
heavy  metals that constitute the NPs core (Risom et  al., 2005), by mitochondria dysfunc-
tion (Sioutas et al., 2005), or by inflammatory  cells like neutrophils and macrophages 
(Long et al., 2004).
 Some type of non-PEGylated and PEGylated QDs induce inflammatory response and 
possibly gliosis after injection in the brain (Maysinger et al., 2007). This inflammatory 
state can lead to dysfunctions, depending on the duration of this oxidative stress within the 
CNS and on the sensibility of the brain area to the inflammatory changes. 
For example, injection of CdSe QDs and streptavidin-QDs in the hippocampus affect syn-
aptic transmission and plasticity. Pair-pulse relation and long-term potentiation are signifi-
cantly decreased after treatments, and oxidative stress is induced: SOD activity, GSH con-
tent and MDA levels are all increased in the animals treated with QDs. The authors attrib-
ute the cause of toxic effects to Cd, which is released from the NPs (Tang et al., 2009). 
Moreover, an in vitro study shows that unmodified CdSe QDs induce intracellular Ca2+ 
concentration involving both extracellular and intracellular Ca2+. Cytoplasmic Ca2+ is in-
volved in many cellular pathways and in the development of ROS (Trump and Berezesky, 
1995). Extracellular Ca2+ in-fluxes mainly through sodium channels, and partially through 
N-type Ca2+ channels. The intracellular component involves Ca2+ release from mitochon-
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dria through mitochondrial Na+– Ca2+ exchangers (MNCX), that further induced more Ca2+ 
release from endoplasmic reticulum  through ryanodine receptors (Tang et al., 2007).
 Recently, it  has been shown that CdSe QDs can activate voltage gated ion channels in 
cortical neurons cell culture. When stimulated, QDs can produce a photo-generated dipole 
that perturbs the cell membrane potential, hyperpolarizing and depolarizing both K+ and 
Na2+ channels and generating action potentials. This is a new application of QDs that  can 
represent a new frontier for treatment of neurodegenerative diseases (Lugo et al., 2012).
The heavy  metals, that compose the QDs core, can be deleterious to the brain functions. 
Neuro-2A cells exposed to Zn-O NPs change morphology, increasing the size and display-
ing cellular shrinkage, and increase in apoptosis. Moreover, Zn-O NPs increase the ampli-
tude of sodium currents (INa), enhancing Na+ influx and accumulating intracellular Ca2+, 
and increase the excitability  of neurons in hippocampal cornus ammonis (CA) pyramidal 
neurons. This effect results on in vivo enhanced Long Term Potentiation (LTP), barely in-
fluencing depotentiation in the Dentate Gyrus (DG) region of the hippocampus while the 
escape latency in Morris Water Maze is prolonged (Han et al., 2011).
Exposure to Cd in utero and in infancy is associated with risk of impaired cognitive devel-
opment (Hu, 2000). In vivo and in vitro studies have revealed that exposure to Cd induce 
oxidative stress in astrocytes and accumulates ROS that induce astrocytic death (Yang et 
al., 2008). Se and Te are also well know to be toxic to humans, causing hepatic, renal and 
neurologic toxicity. All these toxic effects are mediated by  the direct interaction of heavy 
metals with neuronal cells as well as by the activation of the glial cells that change the en-
vironment and physiological condition of the neuron.
Immune cells in the brain
 The brain functions depend on an integrated system of interactions between neurons, 
glial cells, epithelial cells and white blood cells. In the classical view, the inflammation is 
an accumulation of mobile innate and/or adaptive immune cells in the tissue, recruited via 
the bloodstream or proliferating locally  (Jenkins et al., 2011). The innate immune system in 
the CNS includes microglia and perivascular macrophages (termed also ‘‘perivascular 
cells’’) that serve as the first line of defence of  the CNS. 
 All these cells maintain the homeostasis of the brain’s microenvironment. Conse-
quently, an alterations of the communication between neurons, glial cells, epithelial cells 
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and white blood cells can lead to dysfunctions and diseases (e.g. multiple sclerosis and 
neurodegenerative diseases).
 Glial cells are very  active even in the absence of pathological insults and their proc-
esses periodically contact dendritic spines and axon terminals in vivo (Nimmerjahn et al., 
2005; Davalos et al., 2005). Recently, MHC class I antigens have been implicated in synap-
tic plasticity  and memory function (Shatz, 2009). Moreover, microglia regulate perisynap-
tic extracellular spaces, remodel dendritic spines, and phagocyte axon terminals and den-
dritic spines (Tremblay and Majewska, 2011). Fourgeaud and Boulang described a role for 
immune molecules in the establishment and plasticity of glutamatergic synapses (Four-
geaud and Boulang, 2010).
Astrocytes also have different roles in physiological conditions: they control synaptogene-
sis (Christopherson et al., 2005) and synaptic transmission (Newman, 2003) while micro-
glia has been demonstrated to be important in neurogenesis in the DG (Ziv et al., 2006) and 
in neuroprotection (Streit, 2002).
 At this point the classical concept of “neuroinflammation” has to be revisited, since 
inflammation is not the only role that all these components exert in the brain (Graeber et 
al., 2011). 
A change in the “inflammatory  state” after an insult involves a change in the role and activ-
ity  of these cell types (microglia, astrocytes, immunity-related blood cells, endothelial 
cells) as well as of the  pro-inflammatory  mediators, like cytokines and chemokines, that 
are released by immune cells and can interfere with normal innate immunity functions. Tis-
sue damage and classic inflammation can lead to changes in synaptic plasticity  and mem-
ory function via dysregulation of MHC class I expression (Shatz, 2009), as well as a pe-
ripheral inflammatory  challenge (like lipopolysaccharide) results in the parallel activation 
of microglia and alterations in dendritic spine dynamics (Kondo et al., 2011). 
 Cytokines and chemokines are small molecules released by immune cells, with pro- 
and anti-inflammatory roles (Lok et al., 2007). In physiological condition they regulate the 
communication between the cells of neurovascular unit, contributing to the maintenance of 
the brain structure and functions, and modulate neuronal excitability and energy demands 
imposed by  neuronal activity (Abbott et al., 2006; Rostene et al., 2007; Willis and Davis, 
2008). Cytokines are synthesised de novo in the CNS by  neurons (Merz et al., 1998) and 
glia (Garden and Moller, 2006).
63
The immune system also modulates sleep and wakefulness and some cytokines are in-
volved in sleep regulation under physiological conditions (Imeri and Opp, 2009). 
 During an inflammatory response chemokines and cytokines induce chemotaxis in 
nearby  responsive cells. The inflammatory reaction in the brain must be highly regulated to 
minimise neuronal damage because neurons have a high sensitivity  to inflammatory stim-
uli (Northrup et al., 2011).
For these reasons, prolonged imbalances in the chemokines and cytokines levels and in the 
innate immune system can lead to neuronal dysfunction.
The presence of free heavy metals released by QDs in the brain parenchyma or in neuronal 
cells, can directly induce ROS production and inflammatory response. The inability  of the 
immune system to detect and phagocyte NPs in the brain can have potentially dangerous 
consequences, since it can lead to a long term inflammatory state.
 Moreover, activated microglia induces the expression of pro-inflammatory mediators 
like TNF-α and Egr-1 and the increased ROS levels contribute to BBB dysfunction and 
may alter its integrity  (Lynch et al., 2004; Shiu et al., 2007). Microglia also express induci-
ble nitric oxide synthase (iNOS), that generates significant and possibly damaging levels of 
nitric oxide (NO) (Marques et al., 2008).
Neuronal plasticity and inflammation
 In the last years it has been established that  microglia can express ‘‘immune mole-
cules’’, which can have CNS-specific roles independent of their roles in the immune or in-
flammatory response (Graeber, 2010). An example is MHC class I antigens that have been 
implicated in synaptic plasticity and memory  function (Shatz, 2009) and, consequently, 
tissue damage and classic inflammation can change synaptic plasticity and memory func-
tion via dysregulation of MHC class I expression (Shatz, 2009).  Ullian and colleagues 
(2001) demonstrated that glia cells induce the formation of new functional synapses and 
they  release cytokines, like TNF-α, which has an important role in synaptic strength (Ul-
lian et al., 2001; Beattie et al., 2002). 
Moreover, glial cells not only modify neuronal plasticity, but they are themselves also plas-
tic and can change in response to neuronal activity (Oliet et al., 2001; Piet et al., 2004).
 The consequence that an inflammatory reaction can lead in the brain are dangerous and 
they  must be very highly regulated to minimise neuronal damage. If an insult changes glial 
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structure for long period, it alters both the immediate synaptic environment as well as the 
surrounding extracellular space. These changes could have profound effects on synaptic 
function and plasticity. In fact a peripheral inflammatory challenge (lipopolysaccharide in-
jection) results in the parallel activation of microglia and alterations in dendritic spine dy-
namics (Kondo et al., 2011). The change in inflammatory state can induce alterations in the 
electrical activity of neurons as well as in the expression and/or functions of all major 
categories of ion channels like sodium, chloride, calcium, potassium channels (Eisenhut 
and Wallace, 2010). 
 One of the most utilised animals model for studying learning and memory functions, 
that identifies the changes in plasticity in synaptic connections, is LTP.
Even if it  is not yet clear whether the changes that underlie LTP also underlie memory con-
solidation, it shares many features with memory and learning mechanisms.
The first description of LTP was done by Bliss and Lomo in 1973 where they reported that 
trains of high-frequency stimulation to the rabbit perforant path caused a sustained increase 
in efficiency of synaptic transmission in the granule cells of the DG (Bliss and Lomo, 
1973).
 LTP underlies some aspect of plasticity and memory storage:
a. consolidation of memory requires some forms of synaptic remodelling, that is at 
the basis of LTP formation; 
b. LTP shares many features with long-term memory  like cooperactivity, associativ-
ity, input specificity and durability (Abraham et al., 1995); 
c. Similar cellular/molecular mechanisms are responsible for some type of learning 
(like spatial learning); 
d. the rhythmic bursts of activity  that induce LTP mimic the occurring theta rhythm 
that takes place in the hippocampus during exploratory behaviour (Diamond et al., 
1988); 
e. some forms of memory are inhibited by agents that also inhibits LTP (Lynch, 
2004).
However, it has be considered that LTP recording are made from specific populations of 
cells in response to a specific inputs from a specific collection of fibers, while the consoli-
dation of memory involves activation of numerous pathways and several brain areas. 
 LTP is most easily demonstrable in the hippocampus, which is a fundamental area in 
memory acquisition (Cooke and Bliss, 2006), but several other pathways support LTP (e.g. 
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entorinhal cortex to DG (Lomo and Bliss in 1973), Schaffer collateral to CA1, Hippicam-
pus (CA1) to subiculum, hippocampus (CA1) to prefrontal cortex, thalamus to layer IV 
cortex, cortex to cortical pathways, cortex to striatum, auditory thalamus to amygdala etc).
 During LTP two neurons, one pre synaptic and the other post synaptic communicate 
across a synapse. This communication is predominantly carried out by improving the post-
synaptic cell's sensitivity  to excitatory neurotransmitter (glutamate) received from the pre-
synaptic cell, by increasing the the number of neurotransmitter receptors (NMDA recep-
tors) on the postsynaptic cell surface. The binding of glutamate or D-serine (released by 
astrocytes) to NMDA receptors facilitate the diffusion of Ca2+ ions across plasma mem-
brane of the synapse and act as intracellular messenger if the same postsynaptic cell has 
been simultaneously depolarised by  other synapses. The influx of Ca2+ activates the en-
zyme Ca2+-calmodulin-dependent kinase II (CaMKII) that phosphorilates another gluta-
mate receptor, the AMPA receptor, which increases the permeability of Na+, depolarising 
the cell and making it more sensible to incoming impulse. 
The change is about 50% increase in the amplitude of the response and can last for at least 
ten hours in an anaesthetised animal or up to 16 weeks in the unanaesthetised animals, fol-
lowing a series of tetanic stimuli. 
 A negative correlation exists between LTP and oxidative stress (Lynch, 2002) and be-
tween LTP and inflammation. ROS have a negative effect on synaptic plasticity, and they 
impair LTP in CA1 in vitro (Pellmar and Lepinski, 1993) and DG in vivo (Lynch, 2002).
The injection of LPS in hippocampus, that increases the concentration of IL-1β, a pro-
inflammatory cytokine, decreases the LTP (Nolan et al., 2002).
IL-1β impairs LTP through the augmentation of the enzyme superoxide dismutase (SOD) 
that decreases the level of ROS (Vereker et  al., 2001). The augmentation of IL-1β is corre-
lated to inflammation, ageing (Murphy and Segal, 1997) and stress (Murray and Lynch, 
1998). On the other hand, chronic treatment of aged rats with aspirin, which combats in-
flammation, improves the performance in spatial learning task in aged rats (Smith et al., 
2002), restoring the normal LTP signal. 
Novel object recognition test for cognitive abilities
 QDs have been proposed for diagnosis and imaging but before any clinical applica-
tions, an investigation on the potential undesirable effects on physiological functions is re-
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quired (Guideline for Safety Pharmacology Studies). To study  potential adverse effects of 
QDs on the CNS, an important function to take in consideration is learning and memory. 
The potential impact of any new chemical entity on memory  function has to be evaluated 
because the major users of drugs are old people, who are increasingly  affected by  neurode-
generative disorders like Parkinson’s and Alzheimer diseases, as compared to young peo-
ple. 
 The NOR, novel object recognition test (or one trial object recognition) is a well 
documented task that provides the basis for the study of a wide range of cognitive abilities 
in rats and mice. NOR test is used to assess recognition memory that is part of the declara-
tive memory. Declarative memory is defined as the conscious memory for facts and events 
and is divided in episodic memory (memory for personal events) and semantic memory 
(memory for general information) (Winters et al., 2008). In contrast to non-declarative 
memory, such as procedural memory (in habits or skills), which often requires an extensive 
acquisition phase, declarative memory is associated with shorter learning phase. 
 NOR test, initially described in rodents by Ennaceur and Delacour in 1988, is based on 
the natural exploratory ability of rats and mice. The difference in exploration between a 
previously  seen object  called familiar object and a novel object is taken as an index of 
memory performance. An healthy animal in NOR test recognises the familiar object as al-
ready  seen and spends more time exploring the novel object. The test is not stressful, is re-
peatable and, with the appropriate set up, it can be performed in the animal home cage, 
thus decreasing anxiety related behaviour (that can mask or interfere with the result). 
 Some scholars consider the object recognition test a model of short-term episodic 
memory (Mathiansen and DiCamillo, 2010).  Since short term memory, or primary  mem-
ory, has a limited duration, from a few seconds to a maximum of a minute, we prefer to 
define the NOR test as a model of long term memory that by  contrast, has a greater capac-
ity  and duration. The difference is based on the duration of retention, i.e. the capacity of 
storing information, and on different anatomical circuits and neural mechanisms underly-
ing each storage system. 
 Different anatomical regions of the brain are implicated in NOR task. Lesions in the 
perirhinal cortex (PRh) disrupt object recognition (Buckley and Gaffan, 1998; Gaffan et 
al., 2000; Gutierraz et al., 2004; Winters ate al., 2010). The PRh is part of the parahippo-
campal region and is located dorsally to the hippocampal formation. Inactivation of PRh 
cortex show normal one-trial object  recognition at short delays up to 10 minutes (Norman 
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and Eacott, 2005) and impairment at longer delays (Ennaceur et al., 1996, 1997; Mumby et 
al., 2002; Hannesson et al., 2005; Norman and Eacott, 2005) suggesting an involvement of 
this structure in the maintenance of object memory during time. PRh and postrhinal corte-
ces are important for processing complex visual stimuli. The PRh cortex has both direct 
and indirect connections with the hippocampus via the entorhinal cortex (Ent) (Witter et 
al., 1986). Both structures are part  of the medial temporal lobe system (Buffalo et al., 
2000). 
 The hippocampus is another region involved in NOR task. It is anatomically  connected 
with the PRh and prefrontal cortices (Jay and Witter, 1991; Burwell et al., 1995). The role 
of the hippocampus in recognition memory is controversial. While a number of studies 
show that hippocampal or fornix lesions produce no effect in object recognition (Bussey et 
al., 2000; Mumby et al., 2002; Winters et al., 2004; Forwood et al., 2005; Good et al., 
2007; Langston and Wood, 2010), other studies report significant impairments (Clark et al., 
2000, 2001). The informations we can obtain from these works are: the rodent hippocam-
pus is not required for the encoding or retrieval of object information after short retention 
intervals (up  to 5 min), but becomes important when object information has to be main-
tained over longer delays (from 15 min to 24 hours). Moreover, deficits are only evident 
after near complete hippocampus lesions: only the lesion of the 75–100% of total hippo-
campal tissue impairs NOR task, while damages of only 50–75% of the hippocampal don’t 
impair the one-trial object recognition after a 3 h retention delay (Broadbent et al., 2004).  
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RESULTS AND DISCUSSION
Behavioural changes induced by administration of 
QTracker® 800 Quantum Dots 
QTracker® 800 Quantum Dots impair Novel Object Recognition test
 All details of the experiments are described in Materials and Methods. 
Our data indicate that one single administration of QDs can elicit  biological and behav-
ioural effects. The Fig. 24 illustrates the discrimination difference of NOR test. The dis-
crimination difference is a parameter indicating the amount of time spent investigating the 
novel object relative to total object-investigation time, during the test trial (Gaskin et al., 
2003). The object recognition is reflected by a discrimination ratio above 50%. At 3 weeks 
after treatment, the discrimination difference of treated animals is 53%, meaning that ani-
mals spend a similar amount of time exploring novel and familiar objects as compared to 
controls and indicating the evidence of an impairment in NOR test (p<0,02, two ways 
ANOVA for repeated measures). The position of novel and familiar objects are counterbal-
anced between groups and time points. All objects are tested for intrinsic preference before 
the test. 
The training trials show no preference for object position at all time points (data not 
shown). 
The impairment in object recognition after 1h delay  time, is probably  caused by alteration 
of different regions of the brain. It is still difficult to understand what are exactly  the ana-
tomical regions coding for recognition memory in NOR test, and the results in literature 
are confusing (Dere et al., 2007). Moreover, QDs are not localised in a specific brain area.
In order to exclude that the decreased novel object exploration is due to an impairment of 
locomotory functions, immediately  after NOR test the animals are tested with rotarod, grip 
strength meter tests and we measure the distance moved during NOR test.
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Fig. 24. Novel object recognition test results.  The graph represents the discrimination ratio of QDs=treated 
animals (red bars) vs CTR=control animals (blu bars) at all time point. Data represent average ±SEM.
 Grip strength meter is a measure of the forelimb grip force in grams,  while rotarod 
measures the duration of riding time (seconds) of the animals on a rotating cylinder sus-
pended above a cage floor. Rodents naturally  try  to stay  on the rotating cylinder (rotarod), 
and avoid falling to the ground. We measured the length of time that a given animal stays 
on this rotating rod as a measure of their balance, coordination, physical condition, and 
motor-planning, during the time points. 
Fig. 25. Locomotor activity tests. Left: Rotarod. Right: Grip Strength Meter. QDs=treated animals (red bars) 
CTR=control animals (blu bars) at all time points. Data represent average ±SEM.
No statistical differences are found between controls (CTR) and treated mice (QDs) 
(p>0,05 two-way ANOVA for repeated measures) in all the three tests (Fig. 25 and 26).
The survival and mean body weights of treated mice are similar to controls for all the 3 
weeks of the study.
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Fig. 26. Distance moved during test trial in the 
NOR test. No differences between the two 
groups.  QDs=treated animals (red bars) vs 
CTR=control animals (blu bars) at all time 
points. Data represent average ±SEM.
Discussion
Balb-c mice are associated with a higher level of anxiety as compared to others strains 
(Brooks et al., 2005). Animal anxiety may cause inhibition of exploration of a novel object 
(Tang and Sanford, 2005). During the past 30 years NOR test has been performed in a 
novel environment, giving to the animal a period of environment habituation before run-
ning the test.
 A decrease in object interaction during training and test trials may be due to a too short 
habituation period (Lukaszewska and Radulska, 1994), influencing novelty  approach 
(Sheldon, 1968). The use of the home cage as testing environment has been proposed to 
meet some of the concerns of interpretation and reproducibility  of behavioural data (Gerlai, 
2002; Wurber, 2002 Kas & Van Ree, 2004; Tecott & Nestler, 2004; Spuijt & DeVisser, 
2006).
In our experiments, the animals perform the tasks in their home cage, showing a higher 
object exploration as compared to other studies in literature (Dellu et al. in 2000; Sik et al., 
2003; Brooks et al., 2005).
 The exposure to NPs induces less novel exploration during time, with an impairment 
at 3 weeks, which can be caused by  the presence of exogenous compound, the presence of 
heavy metals, the increased inflammatory response or the combination of the three. 
 One feature of the one-trial object recognition paradigm is that the effects of lesions or 
drugs on attention, sensory–motor functions or the motivation to explore novel objects can 
potentially affect the results (Dere et al., 2007). On the other hand, NOR test is less stress-
ful than the other cognitive tasks, short in time, and optimal for repeated measures.
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In our experiment we exclude the impairment in motor performance as verified by locomo-
tory tests.  
NOR test is performed during dark period, with the use of red light. Mice have neither red 
nor infrared vision so they  can be considered blind under the infrared illumination. Objects 
are cleaned with ethanol and water in order to eliminate odours as much as possible. In 
these conditions we don’t  exclude a contribution of somatosensory cortex for the explora-
tion and recognition of objects. Somatosensory cortex is an area where inputs from the 
thalamus, carrying information from whiskers, terminate. Rodents, in fact, explore their 
local environment by  actively  whisking their mystacial vibrissae to localise objects and 
identify them, based on their shape, texture etc. (Moreno et al., 2010). 
Thus, as compared to other cognitive tasks, NOR test can be affected by  a strong cortical 
components, that is required to explore and encode objects. This cortical component can be 
affected by the presence of QDs as well. Moreover, NPs in most cases, reach the blood 
flow. The cortices are areas in the brain with a high level of vascularisation, and, poten-
tially, could be one of the main accumulation areas. For these reasons, future experiments 
will explore somatosensory cortex functions. 
 QDs toxicology studies mostly  lack of the behavioural studies component. Some pa-
pers report behavioural alteration induced by aluminium, TiO2 , Zinc oxide, diesel, Man-
ganese, gold NPs.
 The behavioural tests that have been used in literature, such as Morris water maze 
(Win-Shwe et al., 2008), passive avoidance (Chen et al., 2010) and Y-maze (Hu et al., 
2010) are referred to hippocampal spatial memory functions.
It has also been shown that, even if NPs do not cross BBB, they  can induce behavioural 
impairments.
The effect that NPs exposure can have on the behaviour of animals and of the human popu-
lation is an important point to take in consideration and to analyse further.
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Inflammatory response induced by QTracker® 800 
Quantum Dots administration
Microglia and astrocytes response 
 The inflammation in the brain leads to microglia and astrocyte activation. Microglia and 
astrocytes are sensitive to the changes in the microenvironment of the CNS and rapidly  ac-
tivate in all conditions that affect normal neuronal functions. 
 The presence of QDs in the brain elicit an inflammatory response, that changes the mor-
phology and the number of glial cells. Different areas of the brain react differently to the 
inflammatory response and the presence of pro-inflammatory cytokines. Herrera and col-
leagues in 2000, for example, reported that substantia nigra is far more sensitive than the 
striatum to the inflammatory stimulus.
In our experiments the level of inflammation at 3 weeks after exposure to QDs is evaluated 
in terms of astrocytes (GFAP expression) and microglia (Iba-1 expression) response. GFAP 
is an established marker of astrocyte maturation and reactivity  (Gomes et al., 1999). Iba-1, 
ionized calcium-binding adaptor molecule 1, is located in the cytosol of all microglia and 
infiltrating monocytes, regardless of activation state, although its expression increases with 
activation. 
 In the treated samples there is no evidence of colocalisation of QDs and astrocytes at 3 
weeks after treatment. This is in line to the fact that QDs fluorescence, at this time point, is 
observed only in ventricles. 
Interestingly, we find traces of PEG staining in the hippocampus, localised in the pyrami-
dal cell layers in CA1, CA2 and CA3, in the stratum radiatum and in the stratum 
lacunosum-molecolare. In the DG, PEG is localised in the granular cell layer, in the hilus 
and in the enclosed blade of the DG. The double staining with GFAP and PEG antibodies 
reveals no specific colocalisation of PEG and astrocytes in hippocampus at 3 weeks. In lit-
erature it is shown that different type of PEGylated QDs are sequestered in microglia lyso-
somes within 7 days, after intracortical injection (Maysinger et al., 2007). 
In our case, the systemic injection provides a lower amount of QDs that reach the brain as 
compared to an intracortical injection and possibly the amount of QDs is not enough to in-
duce an immediate inflammatory response. 
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 The density of GFAP staining and the number of Iba-1+ cells and their morphology in 
different regions of the brain are evaluated to assess the inflammatory state. 
Fig. 27. Immunofluorescence of astrocytes (green) and PEG (red) in the hippocampus. From the left to the right: 
dentate gyrus (DG), CA1 area and CA2/CA3 area. The pictures represents controls animals (top), and QDs ani-
mals (bottom). Images are acquired with 20x magnification lens. 
A single injection of QDs 800 induce an increase in a astrocytes activation in the hippo-
campus (Fig. 27). The quantification of GFAP is performed with a western blot which 
shows a significative increase in astrocytes expression in the hippocampus after 3 weeks 
from the treatment (P<0,05 Student’s t test) (Fig. 28). A quantification with light micros-
copy is still on going. 
Fig. 28. Western blot of GFAP in the hippocampus. Data show average ±SEM.
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 Hippocampus, PRh and LEnt are involved in novel recognition test (Dere et al. 2007). 
In particular the PRh-to-LEnt-to-hippocampal formation pathway conveys non-spatial in-
formation about external stimuli (Naber et al., 1997). 
All these areas show an increased microglia response at  3 weeks after QDs treatment 
(p<0.02 Student’t test), while somatosensory cortex (S1Tr) shows no differences (p>0.05) 
(Fig. 30). 
Microglia are activated in response to brain injuries and immunological stimuli (Streit et 
al., 1999; Liu and Hong, 2003) to undergo dramatic alterations in morphology, changing 
from resting, ramified microglia into activated, amoeboid microglia (Kreutzberg, 1996). 
The ameboid microglia is thought to favour phagocytosis and mobility.
Photomicrographs in Fig. 29 show the distribution and appearance of microglia in the hip-
pocampus, PRh and LEnt. Qualitative examination reveals that most of the Iba-1+ cells ex-
hibits a ramified morphology with larger-diameter processes, characteristic of moderately 
activated microglia (Ladeby et al., 2005) and that large, macrophage-like cells are rare. 
The quantitative evaluation is described in Materials and Methods section. 
Fig. 29. Microglia (Iba-1) immunohistochemistry of CA1 area (a, b); DG (e, f); Perirhinal cortex (PRh) and 
Entorhinal cortex (LEnt) (c, d) and primary somatosensory cortex (S1Tr) (g, h). The pictures represent con-
trol animals (left) and QDs animals (right). Images are acquired with 40x magnification lens.
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Fig. 30.  The graphs represent the number of Iba-1+ cells in the analysed areas. A significative difference is 
detected in CA1, DG and PPr areas between treated and controls (p<0,05, Student’s t-test). PRH=perirhinal 
cortex, LEnt=lateral entorhinal cortex, S1Tr=primary somatosensory cortex trunk region. Data represent av-
erage ± SEM.
Discussion
 Our data demonstrate that QDs800 induce an inflammatory response characterised by an 
augmentation of glial cells in different part of the brain at 3 weeks after QDs.
The brain is more sensitive to immune reactions and takes longer to return to basal level as 
compared to other organs (Streit, 2006; Frank et al., 2010). 
The activation of microglia generally leads to an augmentation of cytokines like interleuk-
ins IL-1, IL-6 and IL-8, which results in a cytotoxic effect. In fact, when their production is 
prolonged in the time, they recruit and activate macrophages that produce high concentra-
tion of ROS (Bondy, 2011).
As demonstrated by immunohistochemistry results, the presence of QDs within and around 
neurons activate glial mechanism for at least 3 weeks. TEM analysis reveals an unspecific 
localisation of QDs within neurons and glial cells in the brain after 1 week, while in liver 
and spleen they are immediately recognised as non self and sequestered in in vesicles and 
lysosomes for digestion and excretion. It seems that the brain fails in the first instance in 
phagocyting activity, delaying the response as compared to liver and spleen.
Many neurodegenerative diseases are associated with the extended presence of structures 
(like amyloid plaques, Lewy bodies etc.), that are not readily  guided into degradation by  a 
proteolytic processes (Salminen et al., 2009). The prolonged phagocytic activity  leads to 
their identification as non-self, and causes prolonged activation of inflammatory system 
(Golde and Miller, 2009) that results in an increased production of nitric oxide (Sugama et 
al., 2009).
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QDs effect in the brain seems to be in part similar to neurodegenerative diseases inflamma-
tory component.  If the stimulus remains unsolved the inflammatory  response, that has a 
beneficial value in the short term, can have deleterious consequences (Bondy, 2011). 
Longer exposure times are needed to evaluate the duration of inflammatory response and 
the consequent effects.
Example of mineral or nanoparticles (e.g. titanium dioxide, silver, iron oxide, manganese 
oxide) that cause prolonged immune response are shown in literature (Mohor et al., 1991; 
Wang et al., 2008; Antonini et al., 2009; Shin et al., 2010). 
Moreover, the exposure of NPs on a pathological state, like LPS-induced inflammatory 
state, increases the inflammatory response (Wang et al., 2008). An inflammatory state in-
duced near cerebral blood vessels can increase the permeability  of capillary endothelium 
and disrupt normal function of the BBB (Trickler et al., 2010).
Chemokines and cytokines quantification 
 The activated microglia may release some cytotoxic factors, such as cytokines, that 
might cause neurotoxicity. Cytokines and chemokines control, with positive and negative 
feed-back mechanisms, the inflammatory response in the brain.
We find that the exposure to QDs 800 does not significantly increase the levels of pro-
inflammatory cytokines in brain and serum. Only  IL12p40, TNF-α and IL-1β levels show 
an increasing trend in the brain at 1 week after treatment (p>0,05 two way ANOVA) (Fig. 
31). All other measured cytokines are not detectable. 
The cytokine amounts are associated with high variability  per animal: for this reason a 
number of 3 animals per group is not enough to have a robust data, but it should be in-
creased to 6 animals per group. The data are used in a pilot study as an indication of cyto-
kines behaviour during time.  
Fig. 31. Cytokines quantification in the brain (N=3). The data represent the average ±SEM.
IL12p40, TNF-α and IL-1β are pro-inflammatory cytokines that stimulate leukocyte prolif-
eration, cytotoxicity, release of proteolytic enzymes, synthesis of prostaglandins and others 
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cytokines (Cannon, 2000; Bao et al., 2002). Cytokine measurements after treatment show 
that QDs cause negligible or limited cytokines reaction in vitro (Nguyen et al., 2012), but 
they  increase TNF-α and IL-6 levels in the liver at 16 weeks after exposure (Lin et al., 
2011). Intratracheal instillation of PEGylated QDs705-COOH results in acute neutrophils 
infiltration in the lung, followed by interstitial lymphocyte infiltration and a granulomatous 
reaction on days 17 and 90. The NPs also induce gene expression of cytokines, chemokines 
and metalloproteinase 12 in lung tissues (Ho et al., 2011).
Neuronal plasticity after QTracker® 800 Quantum Dots 
administration 
 Consistent with the classical view, CA1 synaptic plasticity is related to learning and 
memory (Neves et al., 2008). 
The QDs 800 induce an inflammatory response with an increase of microglia and astrocyte 
expression in the CNS simultaneously with an impairment in NOR test at 3 weeks after 
injection. As verified in the previous paragraph, the inflammatory response is particularly 
evident in the anatomical regions associated with recognition memory: Ent, DG, areas 
CA1-CA3, PRh of the limbic system. 
Rodent learning and memory performance has been linked to NMDA-receptor-dependent 
forms of synaptic plasticity.
NMDA-receptor-mediated LTP. The genetic inactivation of the critical NR1 subunit of the 
NMDA-receptor, selectively in pyramidal cells of the CA1 region, impairs one-trial object 
recognition in mice at delays ranging from 30 min to 24 h (Rampon et al., 2000). 
To explore if QDs treatment could impair long-term synaptic plasticity in CA1 area, LTP is 
induced by a high frequency stimulus (HFS). 
 Our results show no difference in LTP at 1 and 3 weeks after treatment between QDs 
and controls animals (p>0.05 Student’s t test) (Fig. 32). At 3 weeks controls and treated 
animals behave very similarly, while at 1 week after treatment there is a decreasing trend 
of QDs animals as compared to controls after the HFS. More animals are needed in order 
to confirm the data.
The NMDA receptors activation initiates a cascade of cellular reactions that is thought to 
lead to maintenance of LTP, via the increase of intracellular Ca2+ concentration.
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Studies show that acute application of CdSe QDs is capable of elevating intracellular Ca2+ 
concentrations in the primary cultures of hippocampal neurons (Tang et al., 2008a; Tang et 
al., 2008b). The increased intracellular Ca2+ levels could enhance certain presynaptic neu-
rotransmitter release and boost postsynaptic response (Berridge, 1998; Augustine et al., 
2003).
Fig. 32.  Effect of QDs 800 on LTP of fEPSP in CA1 area. The data show the LTP signals after 60minutes 
after the high frequency stimulus (HFS) is applied. The graph on the right represents the averages of the time-
course ± SEM.
 Acute exposure to either streptavidin-CdSe/ZnS QDs or unmodified CdSe QDs signifi-
cantly increases the Input/Output functions (a measure that reflects the level of presynaptic 
neurotransmitter release and the postsynaptic receptor response), indicating that QDs en-
hance the basal synaptic transmission and plasticity in DG area, and increase the baseline 
of both fEPSP slope and population spike (PS) amplitude, suggesting that QDs enhanced 
synaptic efficiency in this area. It  has also reported that LTP of both fEPSP slope and popu-
lation spike amplitude are significantly depressed under QDs insult (Tang et al., 2009). 
Considering the complexity  of mechanisms underlying the LTP, it is very hard to figure out 
how QDs impair the LTP. The authors attribute the responsibility to the increase of free 
Cd2+ (QD core degradation), free radical formation and interaction of QDs with intracellu-
lar components at 20minutes after hippocampal injection.
Moreover, QDs administration can significantly increase the malondialdehyde (MDA) 
concentration which is considered as index of lipid peroxidation (Tang et al., 2009).
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 The lipid peroxidation, caused by ROS, results in a decreased membrane concentration 
of polyunsatured fatty acids and alteration of membrane composition and fluidity (Murray 
et al., 1997; Lynch, 2002). A change in membrane composition and fluidity impacts on re-
ceptor functions: an example is the age related decrease in NMDA receptor caused by ROS 
production and lipid peroxidation increase, that lead to binding and signalling changes 
(Tamaru et al., 1991). 
Astrocytes play an important role in LTP (McCall et al., 1996), with a direct participation 
of GFAP in the change in arborization of astrocytic process during LTP (Wenzel et  al., 
1991). It is reasonable that an impairment in GFAP expression interfere in the necessary 
signalling between astrocytes and neurons or synapses.
 It has been shown that a metal mixture of As, Cd and Pb, affects neurobehavioral pa-
rameters and reduces the expression of GFAP, an important protein component  of BBB 
(McCall et al., 1996), accompanied by increased apoptotic and morphologically changed 
GFAP-expressing astrocytes. The apoptotic effect on astrocytes involves the increase in 
intracellular Ca2+ release and ROS generation (Rai et al., 2010).
The fact that there is no alteration of LTP function at 3 weeks while we observe an impair-
ment in recognition memory (novel object recognition test data), is probably caused by a 
stronger correlation between spatial memory and LTP rather that recognition memory and 
LTP.
A possible impairment in hippocampal function caused by the presence of QDs can occur 
earlier. At 3 weeks in fact, we don’t find any QDs in the brain parenchyma, while at one 
week after injection electron microscopy reveals their presence in different cell types in the 
somatosensory cortex.
 The impairment in LTP and NMDA receptors, associated with an impairment in recog-
nition memory  and with an increase in inflammatory  markers like GFAP astrocytes, has 
been found in other animals models like the genetic rat model of depression, the Flinders 
Sensitive Line (Gómez-Galán et al., 2012). 
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CHAPTER 4 
Sleep/wake period and QDs 800
INTRODUCTION
The sickness behaviour hypothesis
 Some studies establish that systemic administration of cytokines leads to a wide variety  
of side effects, developing a condition known as the systemic inflammatory response syn-
drome (SIRS). 
Pro-inflammatory cytokines act in the brain to induce fever and profound psychological 
and behavioural changes, like decreased locomotory activity, decreased social investiga-
tion, sleep changes, decreased food intake (D’Mello and Swain, 2011). These changes are 
generally called ‘‘sickness behaviour’’ (Kent et al.1992). 
The sickness behaviour syndrome serves as an adaptive purpose during systemic infections 
and consequently inflammation, and one of its consequences is an impairment in sleep-
wakefulness cycle. Cytokines, like TNF-α and IL-1β play a role in the physiological con-
trol of sleep-wake cycle and contribute to daytime sleepiness observed in patients with pe-
ripheral disease (Vgontzas et al., 1997; Imeri and Opp, 2009).
The presence of cytokines and inflammatory  response in the brain has been associated with 
a communication between brain and other organs like liver, after a peripheral inflammation 
stress. The liver communicates with the brain through TNF-α, IL-1β and IL-6 and the re-
sult is the increase in pro-inflammatory cytokines and glia activation also in the brain, even 
if the insult is not related to brain. Circulating TNF-α and IL-1β, released by Kupffer cells, 
communicate with brain via many pathways, as described by  D’Mello and Swain, 2011.
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TNF-α has been linked with sleep  abnormalities, fatigue, and mood disorders (Aouizerat et 
al., 2009). The correlation between inflammation and sleep abnormalities has been studied 
both in humans and animals models.
Sickness behaviour is associated with many behavioural alterations that can be screened 
using different behavioural tests like plus maze, light dark box, elevated T maze, open field 
and ultrasound vocalisation (Bassi et al., 2011). Locomotor activity measurements have 
been used for many years to evaluate chemical-induced changes in the CNS (Reiter, 1978). 
Measures of activity has been established as an indicator of internal state or motivation 
level (Maestripieri et al., 1992). 
For specific research questions all these behavioural tests are the appropriate assays. How-
ever, automated home cage observations offer the possibility  to study long-term behaviour 
with a high temporal and spatial resolution in undisturbed mice under both novelty-induced 
and baseline conditions. The automated home cage can represent a potential good model of 
behavioural screening for NPs exposure effect, thanks to the long time period assessment 
without stress for the animal.
Automated home cage activity has been proposed as a good tool for the characterisation of 
inbred mice (De Visser et al., 2006). It represents a quantitative characterisation of behav-
ioural organisation in freely  acting mice and provides a powerful approach for assessing 
the impact of chemical exposure, nervous system alteration and environmental manipula-
tions on whole animal physiology  and behaviour (e.g. energy  balance, thermal status, 
osmotic/volume status, sleep). It can en-light differences in locomotor activity, circadian 
rhythmicity and activity between different strains and experimental conditions. Animal be-
haviour can be divided into two major discrete states: active and inactive (Goulding et al., 
2008). During the active states, animals forage and control the external environment, trav-
ersing the home range. During inactive states the animals return to a refuge (nest  or the 
home base) and rest or sleep (Adam and Davis, 1967). Motor activity has been suggested 
for the routine preliminary assessment (screening) of the neurotoxic potential of chemicals 
for its noninvasive nature, ease of testing, availability of automated test equipment, and 
objectivity of the data (Mac Phail et al., 1989). The automatic home cage has been used for 
example, for discriminating the effect of gene mutation (Wade et al., 2008). 
Ganea and colleagues used the home cage locomotor activity  to find changes in circadian 
rhythm, novelty-induced locomotor activity  as well as alterations in locomotion due to 
pharmacological interventions (Ganea et al., 2007). Tang and colleagues described signifi-
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cant correlations of home cage activity with the activity in other behavioural tests (open 
field, emergence and novelty object) conducted in an open field (Tang and Sanford, 2005). 
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RESULTS AND DISCUSSION
Basal activity  
 In our experiment the animals are housed in Phenotyper® cages (Noldus) for all the pe-
riod of the study and their activity is automatically recorded with video-tracking software, 
EthoVision XT® (Noldus), that permits to score the basal activity  (e.g. distance moved and 
velocity) during 24h. We hypothesise that the inflammatory response induced by  the long 
term presence of QDs 800 in the brain, leads to a sickness behaviour syndrome, affecting 
sleep-wake cycle. 
Fig. 33. Animal basal activity in the home cage during 24h.  Data represent average ±SEM.
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Different parameters can be used for the description of basal or novelty-induced behaviour 
in rodents: “duration of movement” and “distance moved” are considered as indexes of the 
level of activity, that is an indication of how animals interact with the surrounding envi-
ronment. Other parameters like “velocity”, “number of stops” and “time spent in the shel-
ter” are more likely evaluated as anxiety-related behaviours. In fact these parameters corre-
late with anxiety-related behaviour on the elevated plus maze (De Visser et al., 2006).
In our case the velocity is calculated by the software as the total “distance moved” over 
time, so we can not consider it as an indicator of stress related behaviour. In order to have 
behavioural informations, velocity  should be calculated only in ‘movement’ episodes, thus 
excluding periods of non-movement. Other parameters are necessary  in order to com-
pletely establish the basal animal behaviour. 
No differences in locomotory activity (distance moved and velocity) are detected between 
QDs treated animals and controls at all the time points analysed (p>0,05 two ways 
ANOVA for repeated measures)(Fig. 33). 
The animals show predominantly activity during the dark phase as compared with the light 
phase, with peaks of activity at the change of the light.
In literature only a few papers reported behavioural tests after nanoparticle exposure and 
none of them has been done after QDs treatment. 
Sleep/wake period analysis
 A pilot experiment shows that  after 1 week after QDs 800 systemic exposure, there are 
no difference between treated and controls in the sleep/wake period (Fig. 34) (p>0,05 one 
way ANOVA). The data are obtained with Neuroscore® EEG analysis. At the same time the 
behaviour of the animals is recorded in PhenoTyper® cages with video synchronisation in 
order to confirm the EEG data. The software automatically assigns a vigilance stage to 
each epoch. The stages are  Sleep and Slow Wave Sleep, Wake, and Active Wake. The fre-
quency  content of the EEG combined with animal activity  and movement are used as the 
basis of the scoring criteria.
The trend of increase of sleep period of treated animals compared to controls can be con-
sidered a feature of sickness behaviour. Further experiments are required for en-lighting 
the data on sleep/wakefulness cycle.
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Fig. 34.  Sleep/wake period  assessed with Neuroscore® EEG analysis after 1 week after QDs800 treatment. 
Data represent average ±SEM.
The alteration of sleep/wake period has been reported in a few papers after NPs administra-
tion, and still very  little is known. Gold NPs alter some genes, both in liver and spleen, that 
are related to the circadian rhythm, including D site albumin promoter binding protein, Pe-
riod homolog 2 (Drosophila), Basic helix-loop- helix domain containing, class B3 and 
Neuronal PAS domain protein 2 (predicted), that is the liver homolog of CLOCK gene, ex-
pressed in the suprachiamatic nucleus in the brain. The gene encodes proteins regulating 
circadian rhythm (Balasubramanian et al., 2010). 
The immune system also modulates sleep and wakefulness and some cytokines are in-
volved in sleep regulation under physiological conditions (Imeri and Opp, 2009). Other 
type of PEGylated gold NPs increase the acute inflammatory  response in the liver inducing 
the expression of adhesion molecules, chemokines and cytokines (IL1β, IL-6, IL-10, IL-
12β, TNF-α) in the first 24h (Cho et al., 2009).
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CONCLUSIONS
 Our studies revealed that QDs nanoparticles accumulate in different organs for at  least 
3 weeks after a single i.v. injection. The reticuloendothelial system in liver and spleen is 
the major cleanup  site of QDs nanoparticles via uptake by mononuclear phagocytes: Kupf-
fer cells in liver and histiocytes in the spleen.
 At lower concentration QDs enter the brain already  after 24h from the injection. Inter-
estingly, they are not stopped by microglia and sequestered in lysosomes, but they interact 
with different cellular structures (e.g. mitochondria, myelin sheath, chromatin, synapses). 
Their presence is evident around blood vessels in different brain areas, in epithelial cells, 
neurons and glial cells.  It seems that the brain fails in the first instance in phagocyting ac-
tivity, delaying the response as compared to liver and spleen. At 3 weeks the retention of 
QDs is only in the ependymal cells of the choroid plexus as a logical consequence of the 
function of the tissue.
 At 3 weeks QDs impair object recognition test. This effect is probably caused by  an 
alteration of hippocampal and cortical functions, which in turn can be due to the prolonged 
inflammatory response. As a matter of fact, we find an increasing expression of astrocytes 
and microglia cells in enthorinal and perirhinal cortices, dentate gyrus, areas CA1-CA3 of 
the limbic system after the treatment.
 LTP, on the other hand, which is considered a model of learning and memory, fails to 
reproduce an impairment of hippocampal plasticity at 1 and 3 weeks after treatment.
 We also assess if the prolonged exposure to QDs leads to a sickness behaviour syn-
drome, but no differences in circadian rhythm and basal activity  are found between treated 
and controls animals.
 Some nanomaterials have been studied in clinical trials or have already been approved 
by the U.S. Food and Drug Administration (FDA) for use in humans (McCarthy et  al., 
2005) and many proof-of-concept studies of nanomaterials in cell-culture and small-animal 
models for medical applications are under way (Resch-Genger et al., 2008). QDs are be-
tween them and  recently they have been proposed for clinical use (Tab. 5). The Cornell 
Dots, for example, are nanoparticles similar to QDs, that in 2011 have been approved, by 
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the FDA for the first phase I clinical trial on five melanoma patients at Memorial Sloan-
K e t t e r i n g C a n c e r C e n t e r ( M S K C C ) i n N e w W o r k C i t y 
(http://www.sciencedaily.com/releases/2011/02/110205162831.htm).
Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 363;25 nejm.org december 16, 20102438
sia, adenoma, and more specifically, primary lung 
cancer, in which a decrease in the function of the 
reticuloendothelial system affects the amount of 
nonspecific phagocytic uptake.
Na nom ater i a l s for in V i tro 
Di agnosis
The second key application of nanomaterials is 
as a label for measuring molecules of interest in 
biologic samples. Nanomaterials are used to ei-
ther simplify the readout or amplify the detection 
threshold of the diagnostic device. Nanoparticles 
are used in lateral-flow in vitro diagnostic assays 
(LFA) (as described below), such as the urine preg-
nancy test for detecting protein markers (e.g., hu-
man chorionic gonadotropin [hCG]).20 The hCG 
molecule is introduced into a membrane strip, 
which moves through the membrane by capillary 
force and initially interacts with anti-hCG anti-
body–coated gold nanoparticles. On successful 
binding, this complex moves through the mem-
brane until it recognizes a region that is also 
coated with anti-hCG antibody. The complex be-
comes tethered to the membrane surface as a 
result of the antigen–antibody interaction. The 
Table 1. Examples of Nanomaterials in Clinical Use.*
Nanomaterial Trade Name Application Target Adverse Effects Manufacturer Current Status
Metallic
Iron oxide Feridex MRI contrast Liver Back pain, vaso-
dilatation
Bayer Schering FDA approved
Resovist MRI contrast Liver None Bayer Schering FDA approved
Combidex MRI contrast Lymph nodes None Advanced Magnetics In phase 3 clin-
ical trials
NanoTherm Cancer therapy Various forms Acute urinary  
retention
MagForce In phase 3 clin-
ical trials
Gold Verigene In vitro diag-
nostics
Genetic Not applicable Nanosphere FDA approved
Aurimmune Cancer therapy Various forms Fever CytImmune Sciences In phase 2 clin-
ical trials
Nanoshells Auroshell Cancer therapy Head and neck Under investigation Nanospectra 
Biosciences
In phase 1 clin-
ical trials
Semiconductor
Quantum dot Qdots, EviTags, 
semiconductor 
nanocrystals
Fluorescent con-
trast, in vitro 
diag nostics
Tumors, cells, 
 tissues, and 
molecular 
sensing 
 structures
Not applicable Life Technologies, 
eBioscience, 
Nanoco, 
CrystalPlex, 
Cytodiagnostics
Research  
use only
Organic
Protein Abraxane Cancer therapy Breast Cytopenia Abraxis Bioscience FDA approved
Liposome Doxil/Caelyx Cancer therapy Various forms Hand–foot syndrome, 
stomatitis
Ortho Biotech FDA approved
Polymer Oncaspar Cancer therapy Acute lymphoblas-
tic leukemia
Urticaria, rash Rhône-Poulenc Rorer FDA approved
CALAA-01 Cancer therapy Various forms Mild renal toxicity Calando In phase 2 clin-
ical trials
Dendrimer VivaGel Microbicide Cervicovaginal Abdominal pain,  
dysuria
Starpharma In phase 2 clin-
ical trials
Micelle Genexol-PM Cancer therapy Various forms Peripheral sensory 
neuropathy, 
 neutropenia
Samyang For phase 4 
clinical  
trials
* MRI denotes magnetic resonance imaging.
The New England Journal of Medicine 
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Tab. 5. Nanomaterials in clinical use (Kim et al., 2010).
 The results of this thesis indicate that the issue of QD toxicity is a serious obstacle to a 
full exploration of their in vivo usage in biomedical imaging.
New generation of fluorescent NPs without heavy metals and with coatings adapted for the 
excretion could be the alternative.
90
MATERIALS AND METHODS
Animals and treatment
Male Balb-c mice (6 weeks old) from Harlan-Nossan (Udine, Italy) are maintained on a 
12h light/dark inverted schedule, 23 ± 1°C, with access to food and water ad libitum, and 
are habituated to the experimenters for two weeks prior to the procedures employed in the 
present study. Animals receive surgeries for implantation of subcutaneous transmitters for 
ECoG recording. The experiments receives authorisation from the Italian Ministry of 
Health, and are conducted following the principles of the NIH Guide for the Use and Care 
of Laboratory Animals, and the European Community Council (86/609/ EEC) directive. 
Mice are housed and used according to current European Community rules.
Experiments on mice are approved by the research committees from the University  of Ve-
rona and Italian National Institute of Health.
At the start of the experiments the mice are approximately 12 weeks old. At 13 weeks old 
they  receive one single treatment, via tail vein, of 10µl/g of 40pM QTracker® 800 QDs so-
lution.
Serial sacrifices under (zolazepam and tiletamine anaesthesia) take place at baseline, 3h, 
24h, 1 week, 2 weeks and 3 weeks after treatment. After anaesthesia animals are perfused 
for 5min with PBS at 4°C. Immediately organ samples are collected included brain, liver, 
lungs, spleen, kidneys.
At each time points we measure body weights and organ weights of each animals.
Tissue distribution analysis with Optical Imaging 
 Fluorescence of QDs both in vivo and ex vivo is investigated by using an exciting ra-
diation in the 500–550 nm interval (DsRed/DsRed filters), and in the 810–875 nm range by 
using an exciting radiation in the 710–760 nm region (ICG/ ICG filters).
Visible and NIR fluorescence images of small living animals are acquired using an optical 
imager (IVIS 200, Caliper, Alameda, USA) equipped with a CCD camera cooled at 90° C. 
Images are acquired with: exposure time 1⁄4 1 s, binning 1⁄4 8 and aperture stop f 1⁄4 2. 
Anesthetized (Isofluorane 2%) mice are put in prone position on the heated stage of the 
instrument. Animal treatments are approved by the Institutional Ethical Committee (CIR-
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SAL) according to the regulations of the Italian Ministry of Health and to the European 
Communities Council (86/609/EEC) directive. Images are acquired before and after (con-
tinuously  for 3 h) tail vein injection. Three hours after injection the animals are perfused 
with PBS. The extracted organs for each group are acquired with the following parameters: 
exposure time 1⁄4 1 s, binning 1⁄4 8 and f/1.
Tissue distribution study with ICP-MS 
 After PBS perfusion, organs are collected and weighted.  Selenium (82Se), tellurium 
(125Te), Zinc (66Zn) and cadmium (114Cd) concentration are measured in each organ with 
ICP-MS XSERIES 2 system (ThermoFisher Scientific). 40-100mg of tissue are mineral-
ised by Microwave mineralisator MARS XPRESS (CEM) with 1,5 mL nitric acid 13% and 
a thermal program of 5min 100°C, 5min 120°C and 5 min 180°C. The mineralised samples 
are diluted with milliQ water and analysed with ICP-MS instrument.
Tissue distribution study with confocal microscopy
 At 3 weeks after i.v. injection of QDs, mice (n=5) are transcardially perfused with PBS 
and 4% paraformaldehyde. Brain, liver, spleen are immediately dissected and 60 µm-thick 
frozen sections are prepared. 120 µm-thick sections are prepared vibrating slicer 
(VT1200S, Leica) for confocal microscopy. Immunofluorescence images are captured and 
the spectral profiles of QDs on tissue sections are measured using a Zeiss LSM  710 Confo-
cal Laser Scanning Microscope (CLSM) (Carl Zeiss, Germany). The NPs are excited by a 
laser at 405 nm and visualised with 20x objective lens (water immersed, confocal aperture 
1) in the range 700-760 nm. Z-stacks and lambda scan of each sample are recorded using 
the ZEN 2010 software (Carl Zeiss, Germany). The images are analysed using Image J 
(v1.41, NIH). 
Tissue distribution study with transmission electron microscopy 
 Samples are fixed in 2% glutaraldehyde in Sorensen buffer ph7,4 for 2h, post-fixed 
in1% osmium tetraoxide (OsO4) in aqueous solution for 2h, dehydrated in graded concen-
trations of acetone and embedded in Epon-Araldite mixture (Electron microscopy  Sci-
ences, Fort Washington, PA, USA). The semi-thin section (1µm thickness) are examined by 
light microscopy and stained with toluidine blue. The ultra-thin sections are cut at 70nm 
thickness and placed on Cu/Rh grids with Ultracut E (Reichert, Wien, Austria), and ob-
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served using an electron microscope Morgagni 268D Philips (Zeiss, Oberkocken, Ger-
many).
Immunohistochemistry and Immunofluorescence
 Immunohistochemistry and immunofluorescence stainings are performed on 4% para-
formaldehyde fixed tissues, on frozen sections (60 µm-thick), n=4, four consecutive sec-
tions per area of interest, per animal. 
Immunohistochemistry is performed on sections which are incubated for 10min in 10% 
methanol with 3% H2O2. After blocking with 5% normal horse serum and 0.25% Triton-X 
in 10 mM PBS for 60 min at room temperature, sections are incubated with anti-Iba-1 anti-
body (rabbit polyclonal, 1:1000, Wako Chem, Japan) at  4◦C 48h and then incubated with 
donkey anti-rabbit biotinylated secondary (1:400; Jackson, USA) at room temperature for 
2h. The immunoreaction is detected using a Vectastain Elite ABC kit  (Vector, Burlingame, 
CA, USA) and then visualized with 3.3′-diaminobenzidine tetrahydrocloride  (DAKO) 
with Nickel sulphate for 5–10 min. Finally, sections are dehydrated with ethanol and 
mounted with Entellan® Mounting Medium (Merk Chemicals, Germany). 
For immunofluorescence we use the mouse anti-PEG (AGP4) antibody, (dilution 1:200), a 
gift from dr Steve Roffler. PEG staining is performed  on 60 µm-thick sections. The stain-
ing is performed using the methodology indicated on the KIT VECTOR M.O.M. (Vector, 
Burlingame, CA, USA) which permits to detect  mouse primary antibodies on mouse tissue. 
Sections are incubated for 1h with mouse anti mouse PEG (AGP4) antibody, (dilution 
1:200) a gift from Steve Roffler (Institute of Biomedical Sciences, Academia Sinica, Tai-
wan). The visualisation of the positivity is obtained by the use a secondary  biotin goat anti 
mouse Cy5 (Invitrogen). For immunohistochemistry  the visualisation is obtained with 3.3′-
diaminobenzidine tetrahydrocloride (DAKO).
GFAP staining is performed before PEG staining. Sections are incubated for 48h at 4°C 
with rabbit anti GFAP (Abcam, Cambridge, UK) diluted 1:1000 in TBS. Secondary goat 
anti rabbit Alex 488 (Invitrogen) is incubated for 45min at room temperature (1:1000). 
Sections are mounted with Fluoromount™ Acqueous Mounting Medium (Sigma-Aldrich, 
US) and observed with confocal laser scanning microscope (510 Meta CLSM, Carl Zeiss, 
Jena, Germany).
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Cell counting
 The number of Iba-1+ cells are counted in 4 sections per animal (4 animals per group) 
using regions of interest (ROI), in both hemispheres beginning at bregma −1.28mm. The 
ROI is delimited by a squared frame placed in the analysed areas. Two ROI at 20x magni-
fication are placed in the somatosensory  cortex (S1Tr), two at 40x magnification on the 
hippocampus and CA1 area, while one ROI at 20x magnification is placed on LEnt and 
PRh area. In the somatosensory cortex the ROI are placed in the II-VI layers.  
The Fig. 35 shows the ROI in CA1, DG, PPr, LEnt and S1Tr that are counted.
Fig. 35. Representative coronal section. The 
squares show the areas where the counting is 
performed
Western Blot
 Hippocampal samples are homogenised on ice in 100µL RIPA buffer (50 mM  Tris, 
150mM NaCl, 1 mM EDTA, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, pH 
7.4) with 10% protease inhibitor (Sigma P8340) using a Kontes Pellet Pestle, incubated on 
ice for 1 hour, centrifuged for 20 min at 4°C at  14000 rpm, and supernatant recovered. Pro-
tein concentrations are determined using BCA protein assay (Thermo Scientific) and a Bio-
Rad xMark microplate spectrophotometer .
For Western blot, 10µg protein is separated by SDS-PAGE, and transferred to Immobilon-
FL 0.45µm PVDF membrane (Millipore) using a Bio-Rad Trans-Blot SD semi-dry  transfer 
cell. Membranes are blocked for 1 hour and incubated in primary antibody  overnight at 
4°C for anti-GFAP or for 1 hour at room temperature for anti-β-actin. Membranes are 
washed before being incubated in HRP-conjugated secondary for 1 hour at room tempera-
ture, washed again and HRP signal detected using Amersham ECL Plus Western Blotting 
Detection Reagent (GE Healthcare) and developed using Amersham Hyperfilm ECL 
chemiluminescent film (GE Healthcare). After developing, membranes are washed, and 
CA1
DG
S1Tr
PPr/LEnt
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stripped by incubating in stripping buffer (62.5 mM Tris, 2% SDS, 100 mM β-
mercaptoethanol, pH 6.8) for 20 minutes at 37°C with agitation, washed again and either 
re-probed or air dried. Membrane washes are performed in Tris-buffered saline with 0.05% 
Tween-20 (TBST), and blocking steps and antibody  dilutions and incubations are per-
formed in 2% skim milk powder in TBST. Rabbit anti-GFAP polyclonal antibody  (Abcam) 
was used at 1/10000 dilution, with donkey anti-rabbit secondary (Millipore) also at 1/
10000. Mouse Anti-β-actin monoclonal antibody (Abcam) was used at 1/1000 dilution, 
with goat anti-rabbit secondary (Millipore) also at 1/1000.
Western blot images are scanned using an Epson Perfection U700 Photo scanner, and quan-
tified using Image J software.
Citokines and chemokines quantification
 Blood samples are collected after anaesthesia and before perfusion from the ophthal-
mic artery. The blood is allowed to clot  at  room temperature for 30 minutes before cen-
trifugation at 1,800 g at 4°C for 10 minutes. Proteases inhibitor cocktail (SigmaAldrich) is 
add in order to preserve the proteins in the serum. 
Brain samples are collected by dislocation and rapid collection of the brain. Brains are ho-
mogenised with TrisHCl 0,1M, NaCl 0,75M, Tween20 0,05% and protease inhibitor. The 
samples are centrifuged at 11000rpm for 20min at 4°C and stored at -20°C.
Citokines and chemokines are quantified by Luminex technology (Bio-Rad). All kits and 
reagents are obtained from Millipore (Billerica, MA, US). The cytokines evaluated are: 
interferon-gamma (IFN-γ), tumour necrosis factor-alpha (TNF-α), interleukin-1beta (IL-
1β), T helper 17 (Th17), interleukin 12 p70 (IL12p70) and interleukin 12 p40 (IL12p40). 
Quantification is performed at CRIBI, Padova University. 
Novel Object Recognition test
 Ten different objects (in triplets) made of plastic, wood or glass that differ in terms of 
height, colour, shape and surface texture are used. The objects are fixed to the floor of the 
arena with tape to ensure that  the mice can not displace them. The objects have no known 
ethological significance for the mice, and have never been paired with a reinforcer. Pilot 
studies ensured that mice of the Balb-c genetic background strain could discriminate be-
tween the objects, and there is no per se preference for one of these objects.
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Novel object recognition test consists in one training trial of 10 minutes where the animals 
are exposed to two identical objects, followed by a test trial. In the test  trial the animals are 
exposed two objects: one identical to the previous ones (familiar object) and one new ob-
ject (novel object). The presentations of the objects in both training and test trials is per-
formed as follows. The animal is confined in  the end of the cage by  the use of a mobile 
separator made of paper. The separator allowed to place the objects in the correct position 
in the cage without be seen by the animal. The objects are placed in a symmetrical position 
in the cage at the same distance from the walls and 7 cm from the other. Once the training 
trial is finished  the objects are removed from the cage and the animals is left undisturbed 
for the delay time (1 h). Successively, the test trial of 5 minutes occurs. The position of 
novel object was randomly changed between animals. The test is performed between 9 am 
and 4 pm, during the dark phase. By the use of Ethovision XT by Noldus, a computerised 
tracking system, we measure the exploratory behaviour. The test is performed in the Phe-
notyper® cages used as animal home cages 22,5(l)x31(w)x45(h)cm. Each mouse is tested 
repeatedly at  all time points. Each animal received only one object recognition test per day 
with at least 3 days rest between tests.
Fig. 36. Schematic representa-
tion of novel object recognition 
test.
Novel Object Recognition test
introduced by Ennanceur and Delacour in 1988
Delay
Familiar trial Novel trial
Novel objectFamiliar object
Anatomical region for declarative memory is
medial temporal lobe system:
hippocampal formation (enthorinal cortex, 
dentate gyrus, areas CA1–CA4 and subiculum), 
amygdala and parahippocampal cortices (Buffalo et 
al., 1999; Squire et al., 2004)
martedì 24 gennaio 2012
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Fig. 37. An example of NOR 
analysis with EthoVision XT 
software. The software can di-
scriminate the nose (blue dot) and 
the centre (red dot) of the animal 
and can record the duration and 
frequency of nose entrance in the 
object area, previously identified. 
In this example the object areas 
are the pink and the celestas 
drawn areas around the right and 
left objects
For each mouse, the time 
spent exploring the objects 
(in seconds) during the test 
trial is scored off-line from 
videotapes. Exploration of an object is assumed when the mouse approaches an object, and 
has physical contact  with it, either with its whiskers, snout or forepaws. Vicinity to an ob-
ject, at a distance less than 2 cm, is not considered as exploratory behaviour. For each re-
tention delay, the proportion of time exploring the novel object, relative to the total time 
spent exploring both objects, is taken as a measure of object recognition (known as dis-
crimination ratio, tnovel/(tnovel+tfamiliar)). Discrimination ratio values higher than 0.5 suggest a 
preference for the novel object, values close to=0.5 would suggest no recognition, while 
values well below 0.5 suggest a preference for the familiar object.
The animals are thus tested for the motor coordination by Rota-Rod (Ugo Basile, Varese, 
Italy), while motor strength is assessed by the Grip Strength Meter (Ugo Basile).
Rotarod test
 Locomotor coordination and balance are measured by placing mice on an accelerating, 
3-cm-diameter, rotating drum (Ugo Basile, Comerio, Italy) for two trials with a minimum 2 
min interval between trials. The rotarod started at 4 rpm and increased to 40 rpm over a 5 
min period. Pre-training is performed the day before baseline and consisted in two rides for 
1 minute each at a constant velocity.
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Fig. 38. Rotarod
Grip Strength Meter test
 In a separate assessment of forelimb strength, a mouse is suspended by the tail and 
lowered until it grasped the loop of a mouse grip-strength meter (Ugo Basile). The mouse 
is then gently  pulled away from the loop and the maximum grip force exerted by the mouse 
before losing its grip is recorded. 
Ten trials are made per animal per time point and the average of these readings represents 
the animal’s forelimb grip force at that particular time.
Fig. 39. Grip Strenght Meter system
Basal activity
 Animals activity is automatically recorded with video-tracking in specially designed 
cages (PhenoTyper®, Noldus Information Technology, Wageningen, The Netherlands). The 
cages are divided into two rooms with a white plastic sheet to a final arena of 45x21x60cm 
per animal. Each cage contains a top-unit with built-in hardware for video-tracking, i.e. a 
digital infrared-sensitive video camera and infrared lights. These provides constant and 
even illumination of the cage. An infrared filter placed in front of the camera prevent the 
interference with room illumination. This method allows behavioural recording in both 
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dark and light periods. EthoVision XT (Noldus Information Technology, Wageningen, The 
Netherlands) is used as video-tracking software (Fig. 40).
Four home cages are connected to a single PC. The video images of these cages are con-
verted into a single video image by a Quad unit. Nine home cages in total, each divided 
into two rooms are used in this experiment.
The cages are made of transparent Perspex walls with an white plastic floor covered with 
sawdust. Each cage contained a single animal. All cages were provided with bedding mate-
rial (sawdust) and paper shreds (Enviro Dri®, TecniLab) as environmental enrichment A 
feeding station and a water bottle are attached to the outside of the cage wall. 
Observations of home cage behaviour activity are recorded for 4 consecutive weeks (one 
week of baseline and 3 weeks after treatment). Video tracking is performed at a rate of 
25000sample/sec. All parameters are calculated in 1-h bins and subsequently lumped into 
12-h fragments to distinguish between dark and light  periods. For circadian rhythmicity no 
lumping is performed, instead hourly  values at each time point (baseline, 24h, 1, 2, 3 
weeks) are used.
‘Distance moved’ total (distance travelled by the animal in the cage in one hour) is used as 
parameters for the analysis. 
Fig. 40. Phenotypers cages for animal activity recording and analysis. On the right an example of Ethovision 
XT analysis.
Surgeries 
 After 1 week from animals arrival the surgeries are started. Mice were implanted with 
the telemetry transmitters TA11ETA-F10 (Data Science International, DSI PhysioTel 
transmitters, Arden Hills, MN, U.S.A).
Radio-telemetry is a technique that allows us to monitor and analyse electroencephalo-
grams, locomotor activity and temperature in conscious and freely  moving animals: these 
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devices continuously sense, process and transmit information from the animal to a data 
storing system.
Prior to the surgery  all animals received Medetomidine (Domitor 0.05 mg/kg s.c) as seda-
tive 5 min before the anesthetic Tiletamina+Zolazepam (Zoletil 20 mg/kg i.p); after anaes-
thesia (before the beginning of the surgery) the analgesic Carprofen (Rimadyl 5 mg/kg s.c), 
and prophylactic antibiotic Amoxicilina (Clamoxyl 150 mg/kg s.c) were done. 
During the surgery  the animal is shaved laterally  and on the head. Incision is made on the 
lateral of the abdomen where the transmitter will be placed. Catheters containing two elec-
trodes are passed subcutaneously from the abdomen up to an incision made over the skull, 
passing close to the scapula. The electrodes are then placed in the cortical zone and fixed 
with tissue glue and dental cement. Once the suture closed, the animal was awakened from 
anaesthesia with Atipamezole (Antisedan 5 mg/kg s.c.). Four weeks of recovery follow the 
surgeries.
Electrocorticogram recording
 The electrocorticogram (ECoG) recording has been done using telemetric technology  
(Dataquest® A.R.T. Data Acquisition 3.0 for telemetry systems, Data Sciences Interna-
tional, Arden Hills, MN, USA). We use probes implanted subcutaneously on the back, with 
subcutaneous electrodes leading to the sub-dura mater above the parietal cortex. ECoG are 
recorded 24h/day from baseline to week three. All data are analysed with NeuroScore® 
(Data Sciences International) data system.
Long term potential (LTP) recording
LTP recordings are performed similar to Selig et al. (1995).
The hippocampal slice preparation
To obtain hippocampal slices, a mouse is anaesthetised with isofluorane (4%) and decapi-
tated. Its brain is quickly removed from skull and placed in ice-cold artificial cerebrospinal 
fluid (ACSF) containing NaCl 126 mM, KCl 2.5 mM, CaCl2 2.4 mM, MgCl2 1.2 mM, 
NaH2PO4 1.2 mM, NaHCO3 24 mM and glucose 11 mM, bubbled with 95% O2 and 5% 
CO2. The brain is hemisected, cut into 400 µm horizontal slices containing the hippocam-
pus on a vibrating slicer (VT1200S, Leica) and then transferred to a holding chamber to be 
equilibrated at 33ºC for at least 2 h.
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Experimental set up
A pair of bipolar tungsten stimulating electrode is positioned in the stratum radiatum of the 
CA1 area (Schaffer collateral), approximately 300-400 µm from the recording site and 
~200 µm from the CA1 pyramidal cell layer, at  a depth of 100-200 µm. To record field ex-
citatory  postsynaptic potentials (fEPSP), the recording electrode, filled with ACSF, is posi-
tioned in the stratum radiatum at a similar distance from the pyramidal cell layer in the 
CA1 (Fig. 41).  After establishing a stimulus-response profile of fEPSP by applying an in-
creasing stimulus voltage every 15s (5V, 10V, 20V, 35V, 50V) until the maximum response 
is reached, a stable baseline fEPSP is then recorded for 30 mins (stimulated every 60 s) at a 
constant stimulus intensity  that yielded a half-maximal fEPSP amplitude.  To induce LTP, 
tetanic stimulations are delivered using the same stimulation intensity as for baseline.  In 
the 3-week group, two tetanic stimulations are applied with a frequency of 100 Hz for 1 s, 
separated by 10 s interval, while in the 1-week group 4 tetanic stimulations of 1 s with an 
interval of 20 s are performed. Then the normal baseline recording settings resumed for a 
further 90 mins post-LTP induction.  The fEPSPs are quantified by measuring the peak 
amplitudes for each episode and plotted against time.
 
Fig. 41. Schematic representation of LTP recording. 
Statistical analysis
 Two ways ANOVA for repeated measures analysis of variance is used to examine no-
vel object recognition test  (N=8), rotarod (N=8), grip  strengh meter test (N=8), distance 
moved during NOR test (N=8) and home cage activity (N=8).
Student’s t-test is used to compare microglia cell counting (N=4, 4 sections per animal), 
Western Blot (N=5) and LTP (N=5).
Paired Student’s t-test is used to compare Optical imaging data (N=3).
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BERGMANN GLIA6,18. So, the ability of neurotransmitters to
mobilize Ca2+ levels in astrocytes is not just a property of
cell culture,but is present in acutely isolated brain-slice
preparations, indicating that it might be a physiologically
relevant signalling pathway.
It is now clear that astrocytes respond to a variety of
synaptically released transmitters in addition to gluta-
mate. For example, noradrenaline18,19, histamine20,
acetylcholine20, ATP21–23 and GABA (!-aminobutyric
acid)24 can induce elevations of astrocytic Ca2+. Indeed,
the list of transmitters that can mobilize astrocytic Ca2+
is almost as long as the list ofmolecules that activate
neuronal receptors25–27.
Long-range Ca2+ signalling between astrocytes
The initial observations of Cornell Bell et al.10 not only
revealed glutamate-induced Ca2+ elevations in astrocytes
but also pointed to the possibility that Ca2+ sig als could
spread between astrocytes in the form of Ca2+ waves.
This possibility was sup orted by studies in w ich
mechanical stimuli were delivered to single astrocytes in
cell culture. Mechanical stimulation of an astrocyte
caused a local elevation of astrocytic Ca2+ that subse-
quently spread to its neighbours in the form of a wave of
is thought to be siphoned away by astrocytes that
express a high density of K+ channels.More recently,
oligodendrocyte precursors have been shown to receive
direct synaptic inputs from glutamate-releasing neurons8.
The breakthrough discoveries that showed that
astrocytes are dynamic and can respond to neuronal
inputs came as the result of a series of technical
advances. The development of ion-sensitive fluorescent
indicators, such as fura-2 (REF. 9), together with the
development of quantitative imaging techniques,patch-
clamp recording from brain slices and confocal
microscopy,provided the necessary tools to re-examine
astrocyte responses. Studies in cell culture first, and later
in brain slices, showed that transmitters that are released
from neurons induce transient elevations of internal
Ca2+ levels in astrocytes. For example, addition of gluta-
mate to cultures of astrocytes10–13 evoked sustained or
oscillating elevations of their internal Ca2+ level.
Similarly, stimulation of premyelinated axons causes a
Ca2+ elevation in cultured Schwann cells due to ATP that
is released from the neuron14. Furthermore, glutamate-
stimulated Ca2+ elevations spread from one astrocyte to
another, indicating that Ca2+ signalling between astro-
cytes might form the basis of a long-range signalling
pathway in the nervous system10.
Several studies done using brain slices have now
shown that this Ca2+-signalling pathway is present in
nervous tissue,not just in cell culture. Initially, studies
on organotypic hippocampal slices and later in acutely
isolated hippocampus showed that axonal stimulation
causes a glutamate-receptor-dependent increase in
astrocytic Ca2+ (REFS 15,16) (FIG. 2), which might be medi-
ated by the glutamate-receptor-dependent production
of PROSTAGLANDINS17. Additionally, activation of axons in
the cerebellum leads to elevations of the Ca2+ levels of
a
b
c
d
a b
c d
1 µm
2 µm
Figure 1 | Glial cells make intimate contact with synaptic terminals. A three-dimensional
reconstruction of a portion of the arbour of a Bergmann glial cell is shown (left). Electron
micrographs of four sections are shown on the right. The processes of the glial cell are black as a
result of the photoconversion of injected dye. a | Glial process makes direct contact with a
synapse. b | Glial compartment with no synaptic contact. c | Bulging glial structure containing a
mitochondrion. d | The stalk of the glial appendage. (Modified with permission from REF. 6 
© (1999) Macmillan Magazines Ltd.)
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Figure 2 | Neuronal stimulation causes a neurotransmitter-
dep ndent elevation of astrocytic Ca2+. a | Representation
of the hippocampus. A stimulating electrode was placed in the
SCHAFFER COLLATERAL pathway (SC) to stimulate action
potentials. b | Fluorescence imaging of the Ca2+ levels of
astrocytes in area CA1 of the hippocampus revealed that SC
stimulation (red stars) evoked Ca2+ elevations in individual
astrocytes that were suppressed by the metabotropic
glutamate receptor antagonist "-methyl-4-carboxy-
phenylglycine (MCPG). (Modified with permission from REF. 15
© (1996) Society for Neuroscience.) 
PROSTAGLANDINS
Biologically active metabolites of
arachidonic acid and other
lipids.Prostaglandins have many
functions; for example, they are
involved in vasodilation,
bronchodilation, inflamatory
reactions and the regulation of
cell proliferation.
BERGMANN GLIA
The main glial cell type present
in the cerebellum.
SCHAFFER COLLATERALS
Axons of the CA3 pyramidal
cells of the hippocampus that
form synapses with the apical
dendrites of CA1 neurons.
© 2001 Macmillan Magazines Ltd
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Two ways ANOVA is used to compare cytokines quantification (Ncontrol=2; NQDs=3) and 
ICP-MS data.
One way ANOVA is used to compare sleep/wake period scoring (N=3),
Statistical significance is assessed using an alpha level of 0,05. Statistical analyses are 
conducted using GraphPad Prism 5 for Mac (La Jolla, CA, USA).
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APPENDIX - QDs Biodistribution and effects 
QDs 
composition
[QD] used Cells, tissue, 
organ, 
animals 
used
Exposure 
time
Biological fate Observed toxicity References
InP/ZnS Dendron 
coated 
Emission 
wavelength: 
710nm Dose: 1 
nmol/animal
Intravenous 
injection in 
BALB-c mice
30, 60, 120 
minutes
- Near-infrared emission, high stability in 
biological media, suitable size
- QD710-Dendron lacks significant toxicity at 
the doses tested
Gao et al., 2012
- One day following administration, 
approximately 60% of QD710-Dendron 
was eliminated from the body based on the 
ICP-MS results. Organ/tissue 
accumulation was found to be highest in 
the liver, spleen, and kidney. Renal and 
hepatobiliary clearance.
CdSe/ZnS Amino 
(PEG) anti-
HER2ab 
(imaging of 
breast cancer) 
(Invitrogen) and 
CdSe/ZnS
Emission 
wavelength 
525nm. Dose: 
500nM
Wistar rats 
injected 
intravenously 
twice in the tail 
vein, once on 
day 0 and once 
on day 15
8 weeks - Both QDs accumulated in the liver, 
kidney and spleen.
- The biochemistry panel assay showed 
nonsignificant changes in the anti-HER2ab-
QDs treated group but these changes were 
significant in QDs treated group. No tissue 
damage, inflammation, lesions, and QDs 
deposition were found in histology and TEM 
images of the anti-HER2ab-QDs treated group. 
Apoptosis in liver and kidney was not found in 
the anti-HER2ab-QDs treated group. Animals 
treated with nonconjugated QDs showed comet 
formation and apoptosis. Cadmium deposition 
was confirmed in the QDs treated group 
compared with the anti-HER2ab-QDs treated 
group
Tiwari et al., 
2011
aqueous 
synthesised QDs 
(aqQDs)
Injected in mice - aqQDs are initially accumulated in liver 
after short-time (0.5-4 h) post-injection, 
and then are increasingly absorbed by 
kidney during long-time (15-80 days) 
blood circulation. Moreover, obviously 
size-dependent biodistribution is observed: 
aqQDs with larger sizes are more quickly 
accumulated in the spleen
- Histological and biochemical analysis, and 
body weight measurement demonstrate that 
there is no overt toxicity of aqQDs in mice 
even at long-time exposure time
Sui et al., 2011
CdTe/CdSe/ZnS 
carboxylated 
(COOH) and 
amino (NH₂) 
polyethylene 
glycol (PEG)-
(Invitrogen)
250 µl of QDs 
(40 nM)
J774.A1 'murine 
macrophage-like' 
cells
10, 30, 60 
and 120 min
- COOH and NH₂ (PEG) QDs, as well as 
20 nm and 200 nm polystyrene beads were 
located within lysosomes and the 
mitochondria of macrophages after 2 h. 
Elemental transmission electron 
microscopy confirmed both COOH and 
NH₂ (PEG) QDs to be located within 
membrane-bound compartments at this 
time point.
- Toxicity was not assessed in this study. Clift et al., 2011
CdSe/ZnS COOH 
(negative charge) 
18 nm. Emission 
wavelength 
655nm
Monocytes 
CD14+ isolated 
from porcine 
blood and 
differentiated 
into dendritic 
cells (DCs) with 
GM-CSF and 
IL-4
24h - Monocytes showed cellular uptake of 
QDs, while lymphocytes did not. 
Monocyte differentiation into DCs 
increased the cellular uptake by sixfold 
when dosed with 2 nM of QDs. 
- Viability assays, including 96AQ, CCK-8, 
alamar blue and ApoTox, exhibited minimal 
toxicity in DCs dosed with QDs at 24 h.  
Glutathione levels showed a significant 
decrease with 10 nM of QDS. QDs exposure 
was associated with a decrease in CD80/CD86 
expression after LPS stimulation, suggesting 
suppression with DC maturation.
Zang et al., 
2011
- Transmission electron microscopy 
depicted QDs in the cytoplasmic vacuoles 
of DCs. Twelve endocytic inhibitors 
demonstrated QDs endocytosis in DCs, 
which was recognised by clathrin and 
scavenger receptors and regulated by F-
actin and phospholipase C. 
- DC maturation with lipopolysaccharide 
(LPS) caused an increase in QDs uptake 
compared with DCs without LPS 
stimulation. 
QDs(705) and 
CdCl2
705nm Intravenous 
injection in mice
- QD705 were detected in the brain during 
early exposure.Liver and spleen 
demonstrated a constant Cd concentration 
for 28 days after QD705 injection that the 
authors attributed to intact QD705 stored 
in mononuclear phagocytes. The kidneys 
showed a time-dependent accumulation of 
Cd in the QD705-exposed animals. By day 
28, Cd in the kidneys from QD705 was 3-
fold that of CdCl2. QD705 have a longer 
kinetics in distribution and metabolism 
than CdCl2.
QD705 showed a longer plasma and body 
retention than CdCl2 
Yeh et al., 2011
CdTe/CdSe 
encapsulated in 
poly(lactic-co-
glycolic acid) 
(PLGA)
Size: 
135.0-162.3 nm 
Dose: 20 µM
I n t r a v e n o u s 
injection in mice
1 h, 24 h, 48 
h and 72 h
- QDs-loaded PLGA nanoparticles 
showed stability, high cellular uptake and 
long circulation time in vivo
- Cytotoxicity (MTT assay) of QDs-loaded 
PLGA nanospheres was comparable with that 
of empty PLGA nanospheres at least for 48 h 
treatment
Kim et al., 2011
5, 40, 100 and 
160 µM
KB cells 48h
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QDs 
composition
[QD] used Cells, tissue, 
organ, 
animals 
used
Exposure 
time
Biological fate Observed toxicity Referenc
es
CdSe QDs 20 nM CdCl2, 5 
nM, 10 nM and 
20 nM QDs
murine hepatoma 
cells, Hepa 1–6, 
and monocyte-
macrophage, 
J774A.1 cells
24 h and 48 
h
- QDs distributed into various organs upon 
the in vivo administration. Liver appeared to 
be the predominant site for the QD 
accumulation. 
- QDs promoted oxidative stress in vivo and in 
vitro
Liu et al., 
2011
Acute exposure: 
200 nM CdCl2 
(292.8 ng/kg 
body weight), 20 
nM (30.6 ng/kg 
body weight) and 
200 nM (305.6 
ng/kg body 
weight) CdSe 
QDs. Chronic 
exposure: 20 nM 
CdCl2 (29.3 ng/kg 
body weight), 5 
nM (7.6 ng/kg 
body weight) and 
10 nM (15.3 ng/
kg body weight) 
QDs for 6 wks,
Intraperitoneal 
injection in mice
24 hrs after 
the final 
injection
- QDs induced dramatic hepatic toxicity in vivo 
and in vitro, which was much greater than that 
induced by cadmium ions at a similar or even a 
higher dose.
CdTeSe/CdZnS 
QDs
20pmol Female balb/c 
mice injected 
subcutaneously 
in the distal part 
of the right 
anterior paw
5, 15, 30, 
and 60 min; 
4, 24, 48, 
96 h and 
10 days
QDs remain trapped in these LNs during 
several days. Liver is the organ of the 
reticuloendothelial system with the higher 
QD concentrations after s.c. injection. This 
accumulation is much lower than that 
observed after QD i.v. injection. During 
10 days of observation, QDs were not 
cleared from the body neither by urine nor 
faeces (data not shown), suggesting that 
QDs are sequestered in vivo
- Increased inflammation Pic et al., 
2010
CdSe/ZnSe 
Mercaptopropion
ic acid (MPA) 
and Gum arabic 
(GA)/tri-n-
octylphosphine 
oxide (TOPO) 
1 nM MPA-coated 
QDs, 0.373 nM 
GA/TOPO-QDs, 
0.746 nM GA/
T O P O - Q D s , 
10 µM CdCl2, and 
50 µM CdCl2 
BALB/3T3 
fibroblast cells
24h - MPA-coated QDs were distributed inside 
the cytoplasmic region of cells. In contrast, 
GA/TOPO-coated QDs were not found 
inside cells. 
- MPA-coated QDs were highly cyto-
compatible, whereas GA/TOPO-coated QDs 
were toxic to the cells. Cells treated with GA/
TOPO-coated QDs showed altered morphology, 
decreased viability, significant concentrations of 
intracellular free cadmium, detectable reactive 
oxygen species (ROS) formation, 
depolymerised cytoskeleton, and irregular-
shaped nuclei.
Mahto et 
al., 2010
CdTe/CdS  3-
mercaptopropion
ic acid (MPA) or 
polyethylene 
glycol (PEG) or 
SiO2
MPA-coated QDs
(532), QDs(599), 
and QDs(656). 
TEM measured 
sizes: 1.67 ± 0.29 
nm, 2.59 ± 0.43 
and 3.21 ± 0.32 
nm respectively. 
After coating with 
PEG or SiO2 
shells, the QDs
(656) increased in 
size to 4.20 ± 
0.86 and 4.09 
± 1.02 nm, 
respectively. 
Doses: 350ul 
containing 20, 50, 
86, or 125 mg Cd. 
 
Intravenous 
injection in Kun 
Ming pregnant 
mice. The 
pregnant mice 
gave birth 1–5 
days post- 
injection.
24h QDs may be transferred from female mice 
to their foetuses across the placental barrier. 
Smaller QDs are more easily transferred 
than larger QDs and the number of QDs 
transferred increases with increasing 
dosage. Capping with an inorganic silica 
shell or organic polyethylene glycol reduces 
QD transfer but does not eliminate it
Toxicity was not assessed in this study. Chu et al., 
2010
CdTeSe/ZnS 
NH2 PEG 
(Initrogen)
40 nM J774.A1 murine 
'macrophage-
like' cell
2h - Elemental co-localization analysis of two 
elements present in the QDs (sulfur and 
cadmium) was performed on putative 
intracellular QDs with electron 
spectroscopic imaging (ESI). Both elements 
were shown on a single particle level and 
QDs were confirmed to be located inside 
intracellular vesicles. ESI analysis showed 
that not all nano-sized structures, initially 
identified as QDs, were confirmed.
Toxicity was not assessed in this study. Brandenber
ger et al., 
2010
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CdSe/ZnS - 
captopropil
13.5 (636nm) Intraperitoneally 
in male ICR mice
6h - QD-cap were delivered through systemic 
blood circulation. Mass balance studies of 
organs revealed: liver (2,25%), spleen 
(1,57%), kidney (0,718%) and brain 
(0,101%)
Toxicity was not assessed in this study. Kato et al., 
2010
- Although QD-cap were predominantly 
located inside the blood vessels in liver, 
kidney and brain, a few were distributed in 
the brain parenchyma.
- The mass balance studies in the brain 
areas: brainstem (29,4%), thalamus 
(38,76%), Basal ganglia (2,64%), 
Hippocampus (1,98%), Cortex (21,36%), 
Olfactory bulbs (3,2%), Cerebellum 
(2,66%)
CdTe QDs 1mmol/L, 10ul nasal; once in 
ICR mice
30m Located in the olfactory bulbs Toxicity was not assessed in this study. Yin et al., 2010
CdSeTe non 
targeted 
(Invitrogen) 
QDs705
40pmol Intravenous 
injection in ICR 
mice
1 day, 1, 2, 4, 
16  weeks
- After 4 weeks QDs accumulated in liver, 
kidney in a minor quantity in the spleen. No 
Cd was detected in urine and plasma, while 
CdCl2 mostly accumulated in in kidney, 
spleen and urine.
- The molar ratio of Cd/Te and the 
Metallothionein-1 (MT-1) expression 
demonstrated that the Cd/Se/Te complex is 
not stable or biologically inert. The increased 
MT protein was induced in the PCT 
epithelial cells of the kidneys indicating that 
QD705 was broken down in the kidneys with 
the release of free Cd which induced MT 
production in the renal epithelial cell.
Lin et al., 2009
CdCl2 - After 16 weeks Cd concentration was still 
high in the liver but increased the amount in 
the kidney
Methoxy-
PEG-5000 CdTe 
QDs
40pmol i.v.; once in male 
ICR mice
- Persisted in the spleen, liver, and kidneys 
for at least 28 days. Partially eliminated 
after 6 months
- Mitochondrial alterations in renal tubular 
epithelial cells
Lin et al., 2008
CdSe QDs 
coated with 
silica
5nmol/mouse i.v.; once in ICR 
male mice
- Mainly in the liver, kidneys, spleen and 
lungs. 33.3% and 23.8% of QDs in feaces 
and urine.
Toxicity was not assessed in this study. Chen et al., 
2008
AFP-Ab (Aplha 
fetoprotein 
monoclonal 
antibody CdsSe 
QDs 
1,44-3600pmol/
mouse
i.v.; once in Balb-
c male mice
- At the time point of 24 h, the QD–AFP- 
Ab probes were mainly distributed in the 
liver, spleen, and kidneys
- No animal died in the test group and no 
difference in body weight
Chen et al., 
2008
QDs 
composition
[QD] used Cells, tissue, 
organ, 
animals 
used
Exposure 
time
Biological fate Observed toxicity References
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QDs 
composition
[QD] used Cells, tissue, 
organ, 
animals 
used
Exposure 
time
Biological fate Observed toxicity References
Carboxyl- and 
amine- CdSe 
QDs
i.v.; once in male 
Balb-c mice
- QDs were mainly found in the lungs, 
liver, and blood.
- Marked vascular thrombosis for carboxyl-
QDs at high dose
Geys et al., 
2008
fat- CdSe QDs orally; Wistar 
rats
- QDs were degraded in the digestive tract. 
QDs with fat were more stable and 
degraded more slowly than bare ones.
Toxicity was not assessed in this study. Karabanovas et 
al., 2008
Carboxylic acid 
group CdSeQDs
40pmol s.c.; one in 
female fox mice
- Located in axillary lymph nods. Most of 
the injected QDs remained at the injec- 
tion site.
Toxicity was not assessed in this study. Robe et al., 
2008
Commercial 
PEGylated QD 
545, QD 655, 
QD 705
QD-PEG CdSe/
ZnS  core 
diameter 
(3-8nm); particle 
diameter 
(20-50m)
PC12 cells and 
primary cortical 
cultures. 30nM
24h - PEGylated QD gave stronger signal 
compared to non PEGylated QD. In 
primary neuronal culture the uptake was 
higher in glia cell than neurons (<0,5% 
neurons relative to glia)
The biocompatibility as assessed by Alman 
Blue and cell counting was not significantly 
different from naive control PC12 cells, except 
when the cells were treated with non 
PEGylated  QD 595. 
Maysinger et 
al., 2007
Non commercial 
non PEGylated 
CdTe QDs and 
cerium oxide
 -From cortical culture: no detection of QD 
in the mitochondria. Detection of QDs in 
lysosomes.
Commercial 
PEGylated QD 
545, QD 655, 
QD 705
QD-PEG CdSe/
ZnS  core 
diameter 
(3-8nm); particle 
diameter 
(20-50m)
Subcutaneously 
in mice
1 h, 24 h, 72 
h, 7 days
- The majority of the injected QDs 
accumulated within the Iba-1 positive 
microglia cells.
The astrocytes density was higher at 24h after 
administration in animals receiving QD705 as 
compared to control, receiving saline. There 
was no marked difference after 7 days. No 
detectable damage to either neurons or glia.
Non commercial 
non PEGylated 
CdTe QDs and 
cerium oxide
 - Fluorescent activated cell sorting and 
confocal microscopy showed that 
internalisation of QDs do not cause marked 
cell damage within one week.
InAs/ZnSe-
DHLA-PEG
8.7 nm Injected both 
subcutaneously 
and 
intravenously (in 
both mice and 
rats)
Approximate
ly 5 min
- QD were specifically engineered to have 
small diameters.
Toxicity was not assessed in this study. Zimmer et al., 
2006
- When injected subcutaneously, QD 
migrated to sentinel lymph nodes, as 
observed previously with larger QD, but 
also migrated further into the lymphatic 
system.
- QD injected intravenously were shown to 
extravasate from the vasculature (first 
demonstration of this point in the 
literature).
CdSe/ZnS-
MAA-targeting 
peptides PEG 
(maximal 
emission spectra 
at both 550 and 
625 nm).    In 
absence of 
peptide: 3.5 nm 
(green) or 5.5 nm 
(red). Diameter 
with peptide not 
reported, but size 
was approx. 190 
kDa.
Intravenous 
injection into the 
tail vein (mice)
5–20 min - QD were specifically targeted to the 
circulatory systems of normal lungs and 
tumours using peptides.
Toxicity was not assessed in this study. Akerman et 
al., 2002
- QD also accumulated in the liver and 
spleen, regardless of the peptide used for 
targeting.
- Adding PEG to the QD was shown to 
partially inhibit the nonspecific uptake of 
QD into the liver and spleen (suggesting the 
involvement of RE cells).
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QDs 
composition
[QD] used Cell, tissue, 
organ, 
animal tested
Exposure 
time
Observed toxicity References
Carboxyl-QDs 
and amine-QDs
data not shown in 
the abstract
data not shown in 
the abstract
data not shown in 
the abstract
- Amine-modified QDs, but not carboxyl-QDs, were strongly associated with the 
vessel wall of postcapillary venules and amplified ischemia-reperfusion-elicited 
leukocyte transmigration. Strong association of amine-QDs with microvessel walls 
was also present in the postischemic myocardium.
Rehberg et al., 
2012
-  Electron microscopy and FACS analyses revealed that amine-modified QDs, but 
not carboxyl-QDs, were associated with endogenous microparticles. At microvessel 
walls, these aggregates were attached to endothelial cells.
CdSe invertebrate 
freshwater model, 
Hydra vulgaris
- Sub-lethal doses of QDs caused time and dose dependent morphological damages 
more severe than Cd(2+) ions at the same concentrations, impaired both reproductive 
and regenerative capability, activated biochemical and molecular responses. Low QD 
doses, apparently in the absence of morphological damages, caused early changes in 
the expression of general stress responsive and apoptotic genes
Ambrosone et 
al., 2012
CdS/Cd(OH)(2) (0.52mgCd/m(3)) Wistar rats head-
nose exposed
6h/day on 5 days - CdS/Cd(OH)(2) QD caused local neutrophil inflammation in the lungs that partially 
regressed after the 3-week recovery period. There was no evidence that QD were 
translocated to the central nervous system nor that a systemic acute phase response 
occurred
Ma-Hock et al., 
2012
CdTe mitochondria 
isolated from rat 
livers
- QDs affected the mitochondrial membrane properties, bioenergetics and induced 
mitochondrial permeability transition (MPT)
Li et al., 2011
CdSe/ZnS 
octylamine-poly
(acrylic acid) 
(OPA) modified 
545nm and 
605nm
human skin cells 24h - QD545 and QD605 show low cytotoxic response in HaCaT keratinocyte cells with 
TC50 values of 818.2 nM and 162.0 nM, respectively. Pretreatment with silibinin, an 
antioxidant molecule with membrane stabilising properties,  significantly reduced 
QD-induced cell death in A375 and A375-S2 cells.
Zeng et al. 
2011
Aqueous 
synthesised QDs 
(aqQDs): CdTe, 
CdTe/CdS core-
shell structured 
and CdTe/CdS/
ZnS core-shell-
shell structured 
aqQDs and CdCl2
37nM - 600nM HEK293 cells 10h - CdTe/CdS/ZnS core-shell-shell structured QDs are nearly nontoxic to cells further 
confirmed the role of released cadmium ions on cytotoxicity, and the effective 
protection of the ZnS shell. However, intracellular level of Cd2+ ions cannot be the 
only reason since the comparison with CdCl2-treated cells suggests there are other 
factors contributed to the cytotoxicity of aqQDs. The studies on genome-wide gene 
expression profiling and subcellular localisation of aqQDs with synchrotron-based 
scanning transmission X-ray microscopy (STXM) suggested that the cytotoxicity of 
CdTe QDs not only comes from the release of Cd2+ ions but also intracellular 
distribution of QD nanoparticles in cells and the associated nanoscale effects
Chen et al., 
2011
CdSe 
mercaptoacetic 
acid (MAA) - and 
CdSe doped with 
1% cobalt ions of 
similar size
QDs Size: 5.0 ± 
0.2 nm. Doses: 
500, 1000, and 
2000 mg/kg
per os in mice 2 and 7 days of 
treatment
- After two days of treatment, the high dose of doped MAA-QDs was significantly 
able to induce DNA damage, formation of micronuclei (MNs), and generation of 
DNA adduct (8-hydroxy-2-deoxyguanosine, 8-OHdG). However, increasing DNA 
damage and the frequency of MNs formation as well as the generation of DNA 
adducts were observed with both the undoped MAA-QDs (2000 mg/kg) and doped 
MAA-QDs (1000 and 2000 mg/kg) after seven days of treatment
Khalil et al., 
2011
CdSe short-chain 
thioglycolic acid 
(TGA) 
15 µg/ml, 30 µg/
ml and 45 µg/ml
NIH/3T3 cells 12 and 24 h - The expression patterns of miRNAs were altered by CdTe QDs in cells with 
apoptosis-like death with time- and dose-dependent tendencies. The differential 
expression of miRNAs are induced by CdTe QDs at the processing of miRNA 
biogenesis, which is an adaptive process of cells to external stimuli.
Li et al., 2011
- As a regulator in miRNA biogenesis, p53 is involved in the transcription and 
processing of pri-miRNA. With no significant changes in the mRNA levels of p53, 
the increase in overall p53 protein levels and its post-translational modification by 
phosphorylation at Ser-15 are induced by CdTe QD treatment.
CdTe 
mercaptosuccinic 
acid (MSA)
0.1-100µg/mL human umbilical 
vein endothelial 
cells (HUVECs)
- Dose-dependently decreased the cell viability of HUVECs, indicating CdTe QDs 
induced significant endothelial toxicity
Yan et al., 2011
- 10µg/mL CdTe QDs elicited significant oxidative stress, mitochondrial network 
fragmentation as well as disruption of mitochondrial membrane potential (!"(m)); 
whereas ROS scavenger could protect HUVECs from QDs-induced mitochondrial 
dysfunction. Moreover, upon 24h exposure to 10µg/mL CdTe QDs, the apoptotic 
HUVECs dramatically increased by 402.01%, accompanied with alternative 
expression of apoptosis proteins, which were upregulation of Bax, downregulation of 
Bcl-2, release of mitochondrial cytochrome c and cleavage of caspase-9/caspase-3. 
ZnS and CdS 
QDs
1 and 10microM human 
endothelial cells 
(EA hy926) 
3, 4 and 6 days The ZnS QDs with all four distinct types of surface conditions were nontoxic at all 
concentrations for at least 6 days. The CdS QDs with (3-mercaptopropyl)
trimethoxysilane (MPS)-replacement plus silica capping were less cytotoxic than 
those with 3-mercaptopropionic acid (MPA) capping and those with MPS-
replacement capping.
Li et al., 2011
The CdS QDs were nontoxic only at 1 microM, and showed significant cytotoxicity 
at 10 microM after 3 days. Comparing the results of ZnS and CdS QDs with the 
same particle size, surface condition and concentration, it is indicated that the 
cytotoxicity of CdS QDs and the lack of it in ZnS QDs
CdTe QDs 2 and 200 µM living T. cruzi 
protozoa
72 h and 7 days after 72 h, a 200 µM cadmium telluride (CdTe) QD solution induced important 
morphological alterations in T. cruzi, such as DNA damage, plasma membrane 
blebbing and mitochondrial swelling. No damage to the plasma membrane when 
incubated with 200 µM CdTe QDs for up to 72 h, giving no evidence of classical 
necrosis. Parasites incubated with 2 µM CdTe QDs still proliferated after seven days.
Vieira et al., 
2011
A low concentration of CdTe QDs (2 µM) is optimal for bioimaging, whereas a high 
concentration (200 µM CdTe) could be toxic to cells
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CdTe gelatinised 
and non-
gelatinised 
Thioglycolic acid 
(TGA)
pheochromocyto
ma 12 (PC12) 
cells
72h - Cell viability, DNA quantification and proliferation were affected by the presence 
of the QDs at various concentrations and incubation times. Cell response was found 
to not only be concentration dependant but also influenced by the surface 
environment of the QDs. Gelatine capping on the surface acts as a barrier towards the 
leaking of toxic atoms, thus reducing the negative impact of the QDs
CdTe, CdTe/SiO
(2) and Mn-doped 
ZnSe
in vitro study - CdTe/SiO(2) NPs led to much less DNA damage when compared with CdTe QDs, 
as a silica overcoating layer could isolate the QDs from the external environment. 
Mn:ZnSe d-dots as a new class of non-cadmium doped QDs demonstrated almost no 
damage for DNA molecules
Wang et al., 
2010
CdSe QDs 2-3nm diameter Intrahippocampal 
injection in DG in 
Wistar rats of 
0,5nM and 10nM 
solutions
120 minutes after 
injection
- QDs, no matter whether they are modified or not, could enhance basal synaptic 
transmission and impair short- and long-term synaptic plasticity in rat hippocampal 
DG area, including I/O functions, PPF and LTP.
Tang et al., 
2009
CdSe/ZnS 
streptavidin 
(Molecular probe)
15-20nm (565nm 
emission peak)
CdTe QDs 137,5ug i.t.; once in 
female ApoE-/- 
female mice
inflammation, genotoxicity Jacobsen et 
al., 2009
CdSe 0–500 nM oocyte 24h - CdSe-core QDs have cytotoxic effects on mouse blastocysts and are associated with 
defects in subsequent development
Hsieh et al., 
2009
CdSe/ZnS oocytes - CdSe-core QDs induced a significant reduction in the rates of oocyte maturation, 
fertilisation, and in vitro embryo development, but not ZnS-coated CdSe QDs. 
Treatment of oocytes with 500 nM CdSe-core QDs during in vitro maturation (IVM) 
led to increased resorption of postimplantation embryos and decreased placental and 
foetal weights.
CdSe/ZnS 
Carboxyl and 
CdSe/ZnS Amine
9 nmol/mL Intravenous 
injection in male 
Balb-c High dose 
(720-3,600 pmol/
mouse) and low 
dose 
(1,44-144pml/
mouse)
1h, 4h, 24h  At doses of 3,600 and 720 pmol/mouse, QDs caused marked vascular thrombosis in 
the pulmonary circulation, especially with carboxyl-QDs, most likely by activating 
the coagulation cascade via contact activation. They saw an effect of surface charge 
for all the parameters tested. QDs were mainly found in lung, liver, and blood. 
Thrombotic complications were abolished, and P-selectin was not affected by 
pretreatment of the animals with heparin. In vitro, carboxyl-QDs and amine-QDs 
enhanced adenosine-5 !-diphosphate–induced platelet aggregation.
Geys et al., 
2008
Human and 
murine platelet-
rich plasma (PRP)
- Death after injection of high dose of carboxyl-QDs, no death with amino-QDs 
CdTe QDs 2ug/kg i.v.; once; male 
rats
- Few signs of functional toxicity or clinical changes Zhang et al., 
2007
CdSe/ZnS  and 
CdSe 
mercaptopropioni
c acid
2 - 10nM MDA-MB-435S 
Breast Cancer 
Cells
18h - Poisoning of NRK cells due to the release of Cd2+ ions starts at concentrations of 
0.65 ± 0.12 µM and 5.9 ± 1.3 µM of surface Cd atoms for mercaptopropionic acid 
coated CdSe and CdSe/ZnS particles, respectively. 
Kirchner et 
al., 2005
NRK fibroblast 2 days
Two cell lines 
(RBL and CHO)
2 days - No morphological changes of the cells were identified, although uptake of the 
nanocrystals by the cells was clearly verified by fluorescence microscopy. Patch-
clamp recordings revealed no changes of ion channel function and characteristic 
electrophysiological properties of the cells between QDs incubated cells and controls.
CdSe/ZnS PEG, 
BSA, polymer 
(negative 
charged)
Size: 2-6nm. 
Doses: 15, 5, 2,5 
nmol.
Systemic 
administration in 
Sprague Dawley 
rats.
1, 3, 10, 23, 84 
days and surface 
chemistry study : 
1, 3, 5, 7, 15, 30
Even at high doses (15 nmol), QDs do not cause significant toxicity in Sprague–
Dawley rats over the course of this long- term study. Chronically dosed rats, which 
received a total of 60 nmol of QDs over 4 weeks, did not experience QD toxicity.
Hauck et al., 
2010
CdSe QDs 1, 10, 50 microg/
ml
Human umbilical 
vein endothelial 
cells
12h - Formation of yH2AX foci, indicative of DNA damage, in a dose-dependent manner. 
Moreover, QD treatment clearly induced the generation of reactive oxygen species 
(ROS). Pre-treatment with N-acetyl-cysteine (NAC), a ROS scavenger, could inhibit 
the induction of ROS by QDs, as well as the formation of yH2AX foci.
Zhang et al., 
2010
CdTe QDs Emission 
wavelength: 
Green-QDs 
535nm (size: 2.04 
nm); Red-QDs 
654 nm (size: 
3.79nm)
- It is a study on toxic interaction of CdTe  QDs with human serum albumin (HSA). 
The size of the nanoparticles affected the affinity for HSA and the increasing size of 
QDs enhanced the affinity for HSA.
Xiao et al., 
2010
QDs 
composition
[QD] used Cell, tissue, 
organ, 
animal tested
Exposure 
time
Observed toxicity References
CdSe/ZnS- NH2 
(positive), -
COOH 
(negative), -PEG 
(neutral)
QDs (565) and 
QDs (655). 
QD565 was 
spherical, with an 
outside diameter 
of 4.6 nm, and 
QD655 was 
ellipsoid (6 nm 
"12 nm). In vitro 
doses: 5, 10, and 
20 nM
Bovine cornea 24 h and 48h - QDs penetrated and were retained within the cornea for a relatively long period 
while the epithelium is injured. QDs affected corneal stromal cell viability up to a 
significant magnitude of 50%, under a relatively low concentration (20 nM) and short 
duration (48 h).
Kuo et al., 
2011
1mM Injection into the 
eyes of mice
26 days - QDs were proven to accumulate within the cornea in vivo for a much longer 
duration than that (26 days)
Table XX. Biological fate and effects of QDs
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